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ABSTRACT  
The topoisomerase I (TopoI) poisons (e.g. camptothecin, CPT) cause stabilisation of the 
TopoI-DNA cleavable complex resulting in DNA single strand breaks (SSBs). DNA 
breakage and cytotoxicity are related to TopoI activity and TopoI poisons are thought to 
be primarily cytotoxic in S phase due to conversion of SSB to double strand breaks 
(DSB) through replication fork collision. DNA SSB are repaired by the base excision 
repair/SSB repair (BER/SSBR) pathway and DSB are predominantly repaired by 
homologous recombination repair (HRR) or non-homologous end joining (NHEJ). Poly 
(ADP-ribose) polymerase-1 (PARP-1) recognises SSB and DSB and promotes their 
repair. Previous studies in this laboratory demonstrate that PARP inhibitors enhance 
TopoI poison-induced cytotoxicity by a mechanism that involves elevation of DNA 
breaks level or retarding the repair of TopoI poison-induced DNA strand breaks. The 
role of BER/SSBR in this process was verified previously however, there is no data 
linking sensitisation of TopoI poison-induced cytotoxicity by PARP inhibitors to a 
specific cell cycle phase. The aim of this project was to test the hypothesis that a) PARP 
inhibition inhibits the repair of CPT-induced SSB, resulting in more replication-
associated DSB in S phase cells, b) PARP inhibition further retards DSB repair and c) 
consequently the greatest sensitisation is seen in S phase cells. To elucidate the 
mechanisms DNA breakage, and cytotoxicity were determined in asynchronous cells 
and those separated into G1, S and G2/M phases by centrifugal elutriation, in cells 
exposed to the clinically active PARP-1 inhibitor, AG014699, and CPT.  Cell cycle-
specific variations in TopoI and PARP expression and activity were also investigated as 
possible contributors to ultimate cytotoxicity.  
Survival of asynchronous Lovo colorectal cancer cells exposed to CPT was 
substantially reduced by co-incubation with AG014699. CPT cytotoxicity was greater in 
a 60% pure S phase population than in 90% pure G1 population. AG014699 increased 
the cytotoxicity of CPT in the S phase cells but not cells in G1.  K562 leukaemia cells 
were used to confirm findings obtained with Lovo cells.  Highly purified (>90% pure) 
cell cycle specific fraction of K562 cells were used to demonstrate that CPT was most 
cytotoxic to S phase cells  and that potentiation of CPT-induced cytotoxicity by 
AG014699 is predominantly related to S phase cells whose survival was reduced by 2-
fold. TopoI activity was greatest in S phase cells, corresponding to the greater 
cytotoxicity of CPT in this phase. However, the magnitude of the effect of AG014699 
on survival did not correspond with the level of PARP-1 activity, which was highest in 
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G2 cells. The potentiation of CPT-induced cytotoxicity by AG014699 in S phase was 
shown to correlate with the level of SSB and DSB, which was highest in S phase. 
Repair of CPT-induced SSB and DSB was most rapid during S phase and AG014699 
hindered the repair of both SSB and DSB to the greatest extent in S phase compared 
with other phases of the cell cycle. This suggests that collision with the replication fork 
is a major mechanism for the induction of DSB and resultant cytotoxicity. and that 
PARP is involved in the repair of CPT-induced DSB as well as SSB.  
BER/SSBR requires XRCC1 as well as PARP, furthermore, PARP-1 is proposed to act 
in a backup NHEJ pathway that also involves XRCC1. To test these hypotheses the 
effect of AG014699 on the DNA repair and cytotoxicity of CPT, temozolomide (a DNA 
methylating agent that induces SSB) and neocarzinostatin (an inducer of DSB) was 
investigated in XRCC1 wild type (AA8) and mutant (EM9) cells. AG014699  enhanced 
the cytotoxicity of these agents in parallel with increasing the number of DSB and 
inhibition of their repair in EM9 as well as AA8 cells. Therefore PARP has an 
additional role in the protection of cells from DNA SSB and DSB  independent of 
XRCC1.  
Currently there are 9 PARP inhibitors undergoing clinical evaluation, including 
combinations with TopoI poisons. The data presented here demonstrate that PARP 
inhibitors reduce the repair of TopoI poison-induced DNA DSB as well as SSB and 
consequent cell survival primarily in S phase. Furthermore, we demonstrate that the 
activity of PARP inhibition is independent of XRCC1 indicating that tumours 
associated with XRCC1 polymorphisms will be similarly sensitive. These findings may 
have implications for the rational design of clinical trials involving PARP inhibitor – 
TopoI poison combinations. 
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Chapter 1. Introduction 
  Cancer overview  1.1.
Cancer is caused by genetic, epigenetic or translational changes that force the 
progressive transformation of normal cells into malignant derivatives (Baylin and Jones, 
2011).  Cancer cells are generally characterized by defects in the regulation of cell 
proliferation and homeostasis, destruction of adjacent tissues and eventually capability 
to spread (metastasis) to other locations in the body. The most life-threatening and 
difficult-to-cure stage of cancer occurs when the original tumour undergoes metastasis. 
The presence of cancer can be suspected based on symptoms (e.g. a lump you can find 
anywhere in the body), or findings from radiology. However, definitive diagnosis of 
cancer occurrence requires the microscopic examination of a biopsy specimen. It is 
difficult to estimate the reliable number of people susceptible to cancer, however 
according to statistics available from Cancer Research UK in United Kingdom in 2002 
there were 41,720 women diagnosed with breast cancer and in the same year 22,504 
men were diagnosed with lung cancer (www.cancerresearchuk.org). 
Different types of cancer are classified based on the type of cell/tissue from which 
tumours originate. The major cancers types listed include Carcinoma (derived from 
epithelial cells. including breast, prostate, lung and colon.); Sarcoma: (derived from 
connective tissue, or mesenchymal cells); Lymphoma and leukaemia: (derived from 
hematopoietic blood-forming cells); Germ cell tumour (derived from pluripotent cells) 
and Blastoma (derived from immature or embryonic tissue).  
A process that leads to cancer is complex therefore, difficult and far from being 
completely understood. However, the results of decades of research allow us to identify 
six features/capabilities that can be acquired by the cells during the transformation into 
cancer cells. These features were reviewed in detail by Hanahan and Weinberg, who 
refer to them as “Hallmarks of cancer” (Figure 1. 1) and involve, self-sufficiency in 
growth signals, insensitivity to antigrowth signals, evading apoptosis, limitless 
replicative potential, sustained angiogenesis, tissue invasion and metastasis (Hanahan 
and Weinberg, 2000). Genomic instability is an “enabling characteristic” and may be 
caused by defects or imbalances in DNA damage signalling or repair (Hanahan and 
Weinberg, 2011). 
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Figure 1. 1. “Acquired Capabilities” - functional capabilities acquired by cells  during 
their transformation into cancer cells (Hanahan and Weinberg, 2000). 
The main goal in the treatment of cancer is the complete removal of tumour tissue 
without damaging the rest of the body. The early diagnosis, location of the tumour, 
stage of the illness, and general condition of patient have a major impact on the choice 
of therapy, therapy limitation and survival prognosis. 
Probably the most effective method used to treat cancer is surgery. Radiation therapy is 
another common method employed in cancer treatment. Ionizing radiation focused on 
tumour tissue kills cancer cells via induction of plethora of single and double strand 
breaks (Purdy, 2008). If tumour cannot be surgically removed  it is necessary to apply 
radiation therapy and/or some form of chemotherapy that improve radiation 
effectiveness (Verheij et al.). 
Examples of major classes of chemotherapeutics drugs include: DNA reactive drugs 
(Monofunctional or Bifunctional alkylating agents, Platinum compounds e.g. 
Temozolomide or Chlorambucil, Cisplatin); Topoisomerase I/II inhibitors (Topotecan 
Etoposide); alkylating agents (e.g. Temozolomide), Antimetabolites (Pyrimidine or 
Purine analogues e.g. 5-fluorouraci or 6-thioguanine); Tubulin binders (e.g. Paclitaxel, 
Vincristine). The general mechanism of action of these conventional chemotherapeutics 
is to stop the proliferation of cancer cells, mainly by DNA damage induction (Chabner 
and Roberts, 2005, DeVita and Chu, 2008). 
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Development of new anticancer drugs is currently focused to targeting specific proteins 
or metabolic pathways involving DNA damage repair proteins, cell cycle control 
regulators, growth factors and their receptors, apoptosis (Goldblatt and Lee, 2010). 
 Cell cycle control in cancer.  1.2.
The cell cycle is a sequence of events occurring in living cells, covering the period 
between cell divisions (interphase) and the period in which cell divides into two 
daughter cells (mitosis). Based on the sequence of molecular events occurring in the 
interphase, this period is divided into four phases/Gaps referred to as G0, G1, S and G2. 
A family of serine/threonine kinases referred to as cyclin dependent kinases (Cdk) 
regulates the progression of cell through subsequent phase of the cell cycle. These 
kinases are formed by a catalytic kinase subunit (Cdk) and a regulatory subunit – a 
cyclin.  
Several different cyclins control cell cycle phase progression. Cyclins also determine 
Cdk subcellular localization and the level of cyclins depends on the position of cell 
cycle. Cells begin cell cycle by entering the interphase. At the beginning of the cell 
cycle the level of G1 cyclins rises and they bind to their Cdk partner. This gives the cell 
a signal to prepare chromosomes for replication. In the G1 phase, Cyclin D combines 
with Cdk 4 or 6 and initiates progression to S phase of cell cycle. This complex 
phosphorylates pRb protein (retinoblastoma protein). pRb is a powerful growth 
inhibitory molecule which act as a break in cell cycle by binding and blocking the E2F 
transcription factor. E2F participates in turning on many genes involved in cell cycle 
progression.  The Cyclin D/Cdk complex phosphorylates and inactivates pRb, which 
leads to the release of E2F that is free to drives cells through the cell cycle. When 
moving to S phase, the level of cyclin A increases and cyclin A binds to Cdk2 and E2F 
forming the S phase promoting factor (SPF). The SPF enters the nucleus and prepares 
cells to duplicate their DNA. Mitotic cyclins such as cyclin B complex with Cdk1 
forming mitotic promoting factor (MPF) which initiates the assembly of the mitotic 
spindle, disaggregation of the nucleus envelope and condensation of chromosomes. At 
this point MPF activates anaphase-promoting complex (APC). This complex initiates 
anaphase by allowing sister chromatins to separate. At the end of mitosis, MPF is 
degraded by cyclin B, which completes mitosis and turns on the synthesis of G1 cyclins 
(Lukas et al., 1999, Lukas and Bartek, 2004).  
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Figure 1. 2. Cell cycle control. 
Schematic representation interaction of cell cycle control proteins.  
Stressful conditions that cause DNA damage drive the cell response by the restriction 
points following activation of a complex network of checkpoint pathways to delay their 
cell cycle progression and repair the defects. As cells progress through cell cycle, they 
rely on major cell cycle checkpoints (R). At the transition between G1 and S phase, the 
first restriction point exists (R1) where cells check on their normal growth pattern which 
includes growth factor withdrawal, contact inhibition and DNA damage. Following S 
phase, the second major checkpoint exists (R2) in which cells determine whether the 
DNA has any damage or mismatched DNA bases introduced to DNA during replication. 
The last major checkpoint exists in M phase (R3) at which cells check if chromosomes 
are connected to mitotic spindle and kinetochore. 
The cell cycle also contains inhibitory proteins that restrict movement through the cell 
cycle. Proteins p15 and p16 block the activity of Cdk partners of cyclin D and prevent 
progression from G1 to S phase. The proteins p21 inhibits both cyclin D and cyclin E 
(Busk et al., 2005).  
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p53 is a transcription factor that consist of four subunits (C-terminal regulatory domain, 
tetramerisation domain, DNA-binding domain, and N-terminal transactivation domain).  
Monomers of p53 following tetramerisation bind to its consensus DNA sequences of 
p53 target genes.  Transcription factors bind to the transactivation domain and mediate 
gene transcription by DNA polymerase. Deletion of both alleles of p53 often occurs in 
cancer. When DNA is no longer synthesised, there is no expression of p53 dependent 
genes. When only one allele is mutated (some tumours have a point mutations in one 
allele), and the other is wild type, p53 monomers still form tetramer, however there is 
no binding with DNA. When cells sense DNA damage, p53 is activated leading to 
inhibition of progression through cell cycle. p53 blocks cell cycle progression by 
activating expression of proteins that binds and inactivate Cdk proteins. p53 may also 
activates expression of DNA damage response proteins involved in the repair of or it 
capable to activates proteins that drive cells to apoptosis (Riley et al., 2008).  
The MDM2 gene product binds to p53 transactivation domain, preventing p53 from 
binding with DNA, thus blocking transcription of target genes. The MDM2 gene is 
amplified in about 1/3 human soft tissue sarcomas and its product is a ubiquitin ligase. 
By binding with the N-terminal transactivation domain of p53 monomers, MDM2 
ubiquitinates p53, which then is degraded in proteasomes. When the cell senses a DNA-
damage, p53 is activated. This inhibits further steps in the cell cycle. p53 acts through 
stimulation of proteins, amongst others p21 (which binds to cyclin D or E). Cells 
exposed to DNA damaging agents accumulate changes in DNA that eventually can 
cause inactivation of tumour suppressor genes (p53, Rb) or activation of proto-
oncogenes (e.g. c-myc, fos). Loss of the p53 protein is observed in almost 50% of 
tumour types (Hollstein et al., 1999). ATR (Ataxia telangiectasia and Rad3 related 
protein) with ATM (Ataxia telangiectasia mutated) are crucial players in a signalling 
response to DNA double strand breaks damage. These phosphoinositol 3-kinase like 
kinase (PIKK) enzymes are activated by the presence of DSBs leading to the 
phosphorylation of a range of downstream substrates (e.g. H2AX, CHK1, CHK2) and 
eventually to cell cycle checkpoint arrest and/or apoptosis (Shiloh, 2001). 
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 DNA damage and repair in cancer.  1.3.
1.3.1. Source of DNA damage  
The human genome consists of three billion base pairs, which code for between 30,000-
40,000 genes (Venter et al., 2001) which is about 5% of the whole human genome. 
DNA is under constant attack of various destructive agents from endogenous as well as 
exogenous sources as summarised in Figure 1. 3.  
 
Figure 1. 3. Factors causing DNA damage. 
Illustration summarising sources of DNA damaging agents, lesions they cause and DNA 
repair pathways employed to correct them. Also eventual consequences of repair failure 
are given (Hoeijmakers, 2001). 
 
Inside the cell, DNA is prone to damaging by by-products of normal cellular 
metabolism. Metabolites capable of damage to DNA include reactive oxygen species 
(ROS), derived from oxidative respiration and products of lipid peroxidation (Cadet et 
al., 2011). Other endogenous genotoxic events include spontaneous loss of bases, 
various types of base modifications (e.g. cytosine deamination, converting it to uracil) 
or errors occurring during DNA replication (Lindahl, 1993, Hoeijmakers, 2001). 
Exogenous or environmental sources of factors that are harmful to DNA include UV 
light or ionizing radiation and mutagens present in the diet. These sources cause 
alterations in DNA structure, which, if left unrepaired, may lead to mutations that 
enhance cancer risk. Maintenance of genomic integrity is essential for cellular 
homeostasis, therefore during evolution an efficient defence system against genomic 
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instability was developed which involves an arsenal of DNA repair pathways each 
specialized in removing a specific subset of DNA lesions. When these pathways work 
properly, they protect cells from causes of genotoxic stress and suppress tumorigenesis. 
Malfunctions associated with the DNA repair pathway are closely linked to genomic 
instability, which is the factor that enables tumorigenesis. There are six main, partially 
overlapping repair pathways operating in mammalian cells: Direct Repair, BER/SSBR, 
NER, MMR, NHEJ and HRR. The choice of DNA repair pathway depends on the lesion 
type, availability of repair proteins and the cell cycle phase in which damage occurs. 
Direct DNA repair relies on an enzyme that catalyses the reverse reaction to the reaction 
that caused damage DNA at the first place. An example of a direct DNA repair is repair 
of O6-alkyl guanine mediated by DNA alkyltransferase which transfers the alkyl group 
from the DNA to one of own cysteine (Eker et al., 2009) 
The base excision repair (BER) mechanism efficiently repairs modified bases, AP-sites 
(apurinic/apyrimidinic sites) and SSB. Mis-paired bases, incorrectly inserted during 
replication are processed by mismatch repair (MMR).  More bulky, DNA helix-
distorting lesions, which obstruct normal transcription and replication, are caused 
mostly by environmental factors (UV light) are corrected by nucleotide excision repair 
(NER) (Zheng et al., 2005) 
DNA double strand breaks (DSB) are more problematic lesions for repair and failure in 
repair of these lesions has the most dramatic consequence for cell survival. Two major 
(and some additional back-up systems) have developed in order to remove any DSB. 
These are nonhomologous end joining (NHEJ), and homologous recombination repair 
(HRR). The vast majority of DNA double strand breaks are repaired by the NHEJ 
pathway that operates throughout whole cell cycle. The HRR pathway is active only 
during late S and G2 phases, because it requires the sister chromatid as a template for 
accurate repair. This pathway is considered as highly efficient and virtually error free 
repair process, unlike NHEJ mechanism, which is error prone (Cline and Hanawalt, 
2003) 
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1.3.2. DNA repair defect in cancer  
Sustained genomic instability in cancer cells is often related to deficiency in one of the 
DNA repair pathways, which can account for the development of a more malignant 
phenotype. This is possibly due to redundancy in the function of the DNA repair 
pathways, and in many types of cancers, defects in one pathway, is compensated by 
upregulation of a complementary pathway. Upregulation of DNA repair pathways in 
cancer cells is one of the reasons that tumours become resistant to therapy, however, it 
can be also used as a target for improvement of the treatment efficiency.  The absence 
of one DNA repair pathway results in a hyper-dependence on one or more other DNA 
repair pathways and targeting these pathways can be employed in cancer therapy. The 
system in which inactivation of complementary pathways when the other one is already 
defective is referred to as “synthetic lethality” and recently has been employed in cancer 
therapy.  
The defects  in BER/SSBR relevant in cancer therapy include XRCC1 gene 
polymorphisms which was linked with increase a predisposition to breast cancer (Ali, 
Meza et al. 2008). The defects in NER are linked to diseases such as Xeroderma 
pigmentosum (XP), Cockayne syndrome and trichothiodystrophy (TTD),  and are all 
characterized by increased sensitivity to sun (de Waard, Sonneveld et al. 2008). 
Misfunctional components of HRR metabolic pathways are often acquired in cancer. 
For example, carriers of mutations in BRCA1 and/or BRCA2 genes are predisposed to 
develop ovarian and breast cancer. However, lack of some repair pathways in cancer 
cells is often compensated by a different complementary repair mechanism, allowing 
cancer cells to sustain efficient proliferation. This, phenomenon, provides the possibility 
to kill cancer cells during treatment (see section 1.1). PARP inhibitors can be 
synthetically lethal if used when various components of the HRR pathway exhibits 
mutations.  
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 DNA repair. 1.4.
1.4.1. Base Excision Repair (BER). 
Spontaneous, alkylated, and oxidised DNA lesions, when occurring in DNA are 
repaired by base excision repair (BER). This DNA repair mechanism aims to remove 
and replace a damaged nucleotide with the aid of DNA glycosylases (Figure 1. 4.). 
DNA glycosylases belong to a family of several substrate-selective enzymes able to 
recognize and excise a range of various base modifications such as uracil, 8-oxoguanine 
(8-oxo-dG), and 3-methyladenine. (Hegde et al., 2008). Removal of a damaged base by 
DNA glycosylases create an empty space in DNA, which is referred as 
apurinic/apyrimidinic (AP-site). The AP-sites, which are also quite often formed by 
spontaneous, non-enzymatic  hydrolysis of the N-glycosidic bond, become a substrate 
for  AP-endonuclease ( APE1) (Tell et al., 2009). In the next step of BER mechanism, 
the APE1 cleaves the AP site generating a single strand break. Further processing of 
damaged DNA depends on the structure of free DNA end follows by two pathways. If 
resulted terminus of single strand breaks is 3′-OH and 5’-phosphate it is processed by 
short patch BER (SP-BER). The other option, when 5′-terminus is occupied by reduced 
deoxyribose phosphate (dRP) follows by long path BER (LP-BER). This is because 
modified DNA ends must be restored to the conventional 3’-OH and 5-phosphate 
moieties in order for gap filling and subsequent ligation. The repair of DNA carried out 
by proteins involved in the LP-BER subpathway, involves removal of 5’-dRP moiety 
along with short 4–6 additional oligonucleotides by flap endonuclease (FEN-1). One of 
the DNA Polymerases ε, δ, or β then fill the missing strand and DNA Ligase reconnects 
broken ends. In SP-BER following removal of single nucleobases remaining 3’-OH and 
5′-phosphate, DNA strand termini are recognized by DNA polymerase β (Polβ), which 
replaces the missing nucleotide then sealed by a DNA ligase III in complex with X-ray 
cross-complementing protein 1 (XRCC1). SSB repaired by BER are potent activators of 
PARP-1, which plays important role in DNA repair as a sensor of broken DNA (see 
section 1.6.4). 
10 
 
 
Figure 1. 4. Base Excision Repair process 
Base excision repair regardless of the nature of damage, nature of DNA-glycosylases 
and DNA polymerases follows with three common steps. 1) Removal of the incorrect 
base by DNA-glycosylase. 2) AP-endonuclease nicks DNA on the 5’ site of the AP-site 
to generate 3’-OH terminus. 3) Extension of the 3’-OH termini by a DNA polymerases 
and replacement of AP-site with the correct nucleotide    
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1.4.2. Nucleotide Excision Repair (NER). 
Nucleotide excision repair (NER) is the primary DNA repair pathway that removes 
bulky, helix-distorting DNA damage. Most NER substrates arise from exogenous 
sources, with UV light as major source (Liu et al., 2010). DNA damage processed by 
NER includes therefore various intrastrand crosslink photoproducts, e.g. thymine 
dimers or cyclo-butane pyrimidine dimers. Mitomycin C or platinum-based 
chemotherapeutics agents also form intra and interstrand crosslinks. These lesions are 
potent blockers of DNA replication and transcription and if unrepaired can be toxic with 
mutagenic effects. Therefore, often NER is thought to be coupled with transcription, 
termed “transcription-coupled repair” (TCR) (Lagerwerf et al., 2011). Illustrated in 
Figure 1. 5. process of DNA repair by NER is carried on in sequential manner, usually 
divided into four stages. First XPC-RAD23B binds to DNA with base pairing 
disruption. Following that TFIIH is recruited to DNA with XPA, RPA and XPG to form 
the pre-incision complex. XPG processes 3’ incision and the XPF-ERCC1 nuclease 
complex produces a 5’ incision. After DNA incision in last step, DNA Polymerases 
along with PCNA fill in the gap created, releasing a single-stranded DNA fragment 
containing the lesion. The patch is sealed by a DNA ligase, either LIG3 or LIG1. 
 
Figure 1. 5. Nucleotide excision Repair mechanism (Wood, 2010).  
The illustration shows NER mechanism that is divided into 4 steps 1) recognition of 
distorted DNA 2) formation of pre-incision complex 3) incision and replacement of 
broken DNA fragment 4) ligation of fixed DNA.  
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1.4.3. Non homologous end joining (NHEJ). 
The more general and commonly used pathway for DNA double strand break repair is 
non-homologous DNA end joining (NHEJ). NHEJ can repair a DSB at any time during 
the cell cycle and does not require a homologous sequence, however a few homologous 
nucleotides flanking broken DNA ends are often utilized by the NHEJ enzymes. Repair 
of DSBs by NHEJ is initiated by binding of Ku70 and Ku80 proteins with free DNA 
ends (Figure 1. 6.).   
 
Figure 1. 6. Non Homologous End Joining.   
The drawings show subsequent steps of Non homologues end joining. The process starts 
from recognition of broken DNA ends by complex Ku70/80 that recruits other proteins 
to DSB that process and join broken DNA ends (DNA-PK, Artemis), and ligate broken 
DNA strand (Ligase IV, XRCC4, XLF)  
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The heterodimer Ku70/80 has an asymmetrical ring shape with a positively charged 
amino acid interior in which the negatively charged DNA backbone is accommodated. 
Ku70/80 acts as primary damage sensor in NHEJ. By formation of a ring-shaped 
structure around DNA, Ku70/80 provides a mechanism for bringing DNA ends together 
and protecting free DNA ends from nucleolytic degradation and loss of genetic 
information. This function distinguishes NHEJ from HRR, in which of the one DNA 
strand is degraded to expose the second strand for searching homologous DNA 
sequences. Ku70/80 bound with DNA ends, recruit the DNA-dependent protein kinase 
(DNA-PK) and activate its protein kinase activity.  
The Ku70/80 complex can bind to hairpin, overhang and blunt DNA ends and following 
recruitment of DNA-PK, end processing enzymes (Mre11/Rad54/Nbs1 and Artemis) 
join the complex. Artemis in addition to its endonuclease activity can be phosphorylated 
by ATM regulating cell cycle checkpoints (Kurosawa and Adachi, 2010). The 
assembled DNA dependent protein kinase (DNA-PK) complex phosphorylates 
downstream targets leading to activation of the DNA damage response and initiation of 
NHEJ. DNA-PK undergoes also autophosphorylation, which regulates its binding to 
DNA (Merkle et al., 2002). DNA-bound Ku also recruits DNA ligase IV/XRCC4 
complex, which causes inward translocation of Ku, allowing the ligase complex to 
transiently attach to the DNA termini and promotion of ligation (Kysela et al., 2003).  
1.4.4. Homologous Recombination Repair (HRR). 
HRR allows recombination of genetic information but also provides a precise, error free 
way to repair of DSB. Unlike NHEJ, HRR takes place during late S and G2/M phase 
when homologous chromatids appear in close proximity. The HRR process involves 
recognition of DSB and generation of a single-stranded region of DNA by the MNR 
complex, which is believed to be one of the earliest sensors of the DSB (Figure 1. 7. I). 
The MRN complex consists of three proteins (RAD50/MRE11/NBS) and by its  5’-3’ 
endonuclease activity allows resection of DNA strands exposing both 3’ DNA ends of 
the DSB.  In the following steps, (Figure 1. 7 II) resected single stranded DNA ends are 
coated with RPA proteins which subsequently recruits checkpoint protein complexes 
(e.g.  Rad17/Rfc2-5, Rad9/Hus1/Rad1 and ATR/ATRIP) which form repair protein foci 
at the DSB site. These foci are dynamic structures actively recruiting multiple DNA 
repair proteins at DSB site, which can be detected immunocytochemically. The RPA 
protein is subsequently replaced by Rad51 proteins with the aid of BRCA2 (Figure 1. 7 
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III). The Rad51 and its family proteins (Rad52, Rad54) play a central role in HRR, 
participating in the displacement/invasion of the single-stranded DNA which pairs with 
the recipient (blue) homologous partner forming a heteroduplex while unpaired 
recipient DNA forms a “D-loop” (Figure 1. 7 IV). Strand exchange forms a Holliday 
junction structure (X-over). While one DNA strand is displaced, DNA Polymerases 
synthesize a new DNA strand. In the last step DNA helicases (BLM, WRN) cut and 
resolve Holliday junction structure (Figure 1. 7 V). Depending on the strand incision, 
the most common HHR scenario occurs when a part of both DNA strands from one of 
the sister chromatids is inserted to its homologous partner (“crossover”). Less common 
is the scenario when only one of the homologous strands is left in the sister chromatid 
and this is referred to as “non-crossover” homologous recombination.   
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Figure 1. 7. Homologous Recombination (HR).  
Schematic illustration that represent subsequent steps in HHR. Following of recognition 
of DSB by MRN complex in following steps (II-V), DSB is repaired using its 
homologous counterpart.    
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 Human DNA Topoisomerases. 1.5.
The processes of DNA replication and transcription lead to DNA supercoils, which can 
be positive or negative. The positive supercoils results from over-winding DNA, 
negative supercoils result from under-wound DNA. When DNA is unwound, two DNA 
strands pull apart, creating tension that builds up upstream in DNA. For each twist that 
is un-wound one twist is added in front of the place that undergoes un-winding.  At 
some point, when strands cannot be separated anymore, the remaining DNA is too 
tightly twisted because there are no free ends to release the tension. This causes DNA to 
twist around itself and creates supercoils. To be able to separate DNA strands this 
tension has to be periodically removed. The way to remove DNA supercoils created by 
DNA metabolic processes is to cut and re-join DNA. The process of altering DNA 
topology i.e. relaxation of DNA supercoils is catalysed by ubiquitous nuclear enzymes 
called DNA topoisomerases.  
Human genome structure is maintained by six topoisomerases subdivided into two 
distinct types, however the overall catalytic mechanism is similar for both types of 
enzymes. All topoisomerases cut the DNA strand by nucleophilic attack from a catalytic 
tyrosine residue, transiently linking it with the phosphate end of the DNA break. Then 
the DNA helix is rotated and the introduced break is re-joined, leaving the DNA 
sequence unchanged but topologically different (Wang, 2002).  
Classification of human topoisomerases divides them into two types: Type I and Type 
II, depending on the catalytic functions (Vos et al., 2011).  The Type I enzymes cleave 
one DNA strand whereas Type II cleave both strands at the time of reaction. Type I is 
further subdivided onto 2 subclasses: Type IA, Type IB. Members of the Type IA 
(Topo3α , Topo3β) during catalytic reaction are linked to the 5′ end of DNA. Type IA 
enzymes relax only negative but not positive supercoiling.  Unlike Type IB, Type IA 
topoisomerases requires divalent metal ions and energy cofactor for their function.  
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Figure 1. 8. Classification of human DNA topoisomerases.  
Classification adopted from (Pommier et al., 2010) 
Two members of Type IB subfamily include TopoI which operates in nucleus and 
TopoImt operating on mitochondrial DNA. Type IB topoisomerases form tyrosyl-DNA 
covalent complexes at the 3′ end of cleaved DNA during catalysis and do not require 
ATP energy source to relax both negative and positive supercoils. 
Type II topoisomerases (TopoIIα, TopoIIβ), relax DNA supercoils and various other 
structures decantation by breaking both DNA strands. These topoisomerases act as 
dimers when processing DNA. TopoIIα is closely linked to cell proliferation, because 
its expression and activity can increase by 3-fold in G2 / M, and it is much expressed in 
rapidly dividing cells compared to quiescent cells. In contrast to Topo2β which 
effectively relaxes both positive and negative supercoils, TopoIIα is more efficient at 
relaxing positive supercoils (McClendon et al., 2005). The reaction catalysed by Type II 
topoisomerases is similar to Type IA, is energy consuming and require divalent metal 
ions as cofactors.  
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1.5.1. TopoI structure and catalytic activity 
Most topoisomerase related studies have focused on TopoI and TopoIIα and β, because 
only these topoisomerases can be a used as a target in cancer therapy (see section 1.5.3.) 
Relevant to this thesis, TopoI is an essential enzyme in vertebrates, as mice embryos 
lacking TopoI die early during development stage (Goto and Wang, 1985, Morham et 
al., 1996). However, one human cell line (p388/CPT45) with low levels of TopoI was 
selected based on resistance to camptothecin (Eng et al., 1990). Without TopoI, these 
cells spontaneously accumulate genomic alterations and replication defects (Tuduri et 
al., 2009). The role of TopoI in the nucleus is relaxation of both positive and negative 
DNA supercoils, which arise prior to or after chromatin remodelling during 
transcription, replication or DNA repair. Expression of TopoI is relatively constant 
during the cell cycle, although its activity is variable.  The number TopoI copies and its 
activity is kept at high level throughout the cell cycle (Kunze et al., 1990). 
TopoI has a molecular mass of ~100 kDa, and is composed of 765 aa, divided into four 
functional domains as in Figure 1. 9. The N-terminal domain (aa 1 to 214) with a 
nuclear localisation signal (NLS), the core domain (aa 215-635), the linker domain (aa 
636-712) and the C-terminal domain (aa 713 - 765) (Champoux, 2001b) .  
 
Figure 1. 9. TopoI molecular structure. 
This illustration shows the molecular domain exemplified in TopoI molecular structure. 
Active site amino-acids of TopoI are exemplified by arrows. Amino acids involved in 
CPT interaction sites are marked in dark green. 
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Figure 1. 10. DNA relaxation catalysed by Topoisomerase I (Pommier et al., 2010). 
Nicking, DNA rotation around nicked strand and religation of broken strand are three 
steps of reaction catalysed by TopoI.  
 
As it is schematically shown in Figure 1. 10, TopoI introduces single strand breaks in 
the DNA backbone by using an active site tyrosine as a nucleophile to attack and cut the 
phosphodiester bond generating a 3'-phosphotyrosyl linkage and a free 5'-OH group. 
The nicking results from the transesterification of an active-site tyrosine (Tyr-723) at a 
DNA phosphodiester bond forming a 3'-phosphotyrosine covalent enzyme–DNA 
complex. Introducing a gap in one DNA strand, TopoI then catalyses relaxation of DNA 
allowing rotation by one turn the free 5’- OH DNA end generated during cleavage, 
around the intact strand. After DNA relaxation, the covalent intermediate is reversed 
when the released 5'-OH of the broken strand restacks the phosphotyrosine intermediate 
in a second transesterification reaction. The generated 5’-OH group is used as a 
nucleophile in the subsequent ligation step, which restores intact DNA and releases the 
covalently bound enzyme. The intermediate step where TopoI is covalently bound to 
nicked DNA is referred to as “cleavage complex”. Under normal physiological 
conditions the rate of the religation step is much faster than the rate of cleavage, which   
ensures that the steady-state concentration of the covalent 3'-phosphotyrosyl TopoI–
DNA complex remains low. In other words the cleavage complex  is very transient and 
reaction equilibrium is moved toward religation step (Champoux, 2001a).  
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1.5.2. Regulation of TopoI activity. 
TopoI activity and expression in tumour cells is usually greater than in normal cells. 
There are data indicating that the activity of TopoI varies between patients suffering 
from the same tumour type, as well as data indicating that TopoI activity varies 
depending on the type of cancer (Holden, 2001). TopoI level was found to be elevated 
in malignant cells of colorectal cancer compared to benign tumours or healthy tissue. 
Elevated levels of TopoI in human malignant colorectal tumours correlates with the 
progression of the disease (Giovanella et al., 1989). TopoI catalytic activity and protein 
levels were significantly elevated in colon cancer and prostate cancer compared with 
their normal counterparts (Husain et al., 1994). Increased TopoI level was also observed 
in malignant ovarian cancer in comparison with its less aggressive counterpart form of 
this type of cancer (van der Zee et al., 1991).  
Low activity of TopoI was observed in lung cancer and breast cancer, while increased 
TopoI activity was found in colorectal cancer, cervical cancer and metastatic melanoma 
(Larsen and Gobert, 1999). TopoI expression level is usually higher in malignant tumor 
cells in comparison to primary tumors (Tsavaris et al., 2009).  
TopoI poison-induced cell cytotoxicity correlates with the level of TopoI generated 
DNA breaks which in turn is dependent on TopoI activities. Therefore, cell cycle phase 
specific cytotoxicity will be dependent on the number of created SSB and their ability to 
convert to DSB in these phases. The activity and distribution of TopoI tends to change 
when cells traverse from G1 to G2 phase. Meyer et al. (using A431 lung cancer cells) 
showed that the level of TopoI increases towards mitosis but it activity in this phase 
decreases. Immunostaining of interphase cells shows that TopoI distribution exhibits a 
homogenous granular pattern with tendency to concentrate in nucleoli. During mitosis 
TopoI is attached to chromosomes (Meyer et al., 1997).  
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1.5.3. Topoisomerases poisons. 
As described in the previous section, TopoI catalyses DNA relaxation by cleaving and 
religating DNA, forming an intermediate covalent enzyme-DNA complex. TopoI 
cleavage complexes are a selective target for camptothecins, which is isolated from the 
Chinese tree Camptotheca acuminita (Figure 1. 11.)  
 
Figure 1. 11. Natural source and molecular structure of camptothecin. 
Figure shows the plant that produces camptothecin and camptothecin molecular 
structure. 
 
The trapping of TopoI cleavage complexes by CPT represent a model of interfacial 
inhibition, which is a common molecular mechanism for many compounds, that act 
blocking enzymes being in specific conformational states of macromolecular complexes 
(Figure 1. 12). CPT stabilize TopoI cleavage complex, forming H bonds with three 
amino acid residues at the TopoI active site (Figure 1. 12 C). The bonds are formed 
between camptothecin N-1 position in arginine 364, between the camptothecin 20-
hydroxyl and aspartate 533, and between the camptothecin 17-carbonyl and asparagine 
722 (Marchand et al., 2006).  
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Figure 1. 12. Human TopoI in covalent complex with DNA and CPT (image adopted 
from PubMed webpage using Cn3D software). 
A) Representation of crystal structure of TopoI-DNA cleavage complex with 
intercalated CPT molecule. B)  DNA with basic amino acid residues (shown in purple) 
that catalyse the nucleophilic attack of DNA by the catalytic tyrosine Y723. C) CPT 
surrounded with hydrogen bond forming TopoI active side amino acid residues.   
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Under physiological conditions, CPT binds reversibly to the TopoI cleavage complexes, 
quickly establishing an equilibrium between the drug-enzyme-DNA and the dissociated 
complex. Once CPT is removed, the cleavage complexes reverse rapidly. Camptothecin 
inhibits only a fraction of the existing TopoI cleavage complexes with a guanine at the 
5′-end of the break. The sequence selectivity of CPT makes it a relatively poor TopoI 
catalytic inhibitor because a substantial subset of the TopoI cleavage complexes not 
bearing a guanine are protected from the CPT action (Jaxel et al., 1991, Tanizawa et al., 
1995) .  
Cleavage complexes can be readily reversed but under certain conditions can be 
irreversible. The irreversible cleavage complexes, referred to as “suicide complexes” 
can be formed if in close proximity to TopoI-cc complex DNA modification occurs (e.g. 
abasic site, mismatch, oxidized base). Such irreversible cleavage complexes have been 
(Figure 1. 13). DNA  alterations which can be converted into suicide complexes include 
abasic sites, mismatched loops, single-strand breaks, IR-induced DNA breaks or 
apoptotic DNA fragments (Sordet et al., 2008). In stressful, CPT-mediated conditions, 
suicide complexes can be also generated from reversible cleavage complexes by 
collision with progressing DNA or RNA polymerases (Hsiang et al., 1989). Such 
collisions convert cleavage complexes into DNA double-strand breaks with TopoI 
covalently attached to the 3′  DNA end. At the 5’-end DNA there can be DNA-RNA 
hybrids in the case of transcription-mediated damage or DNA duplexes formed by the 
newly synthesized leading strand in case of replication-mediated lesion (Figure 1. 13 B, 
C). CPT-induced cytotoxicity is thought to result from collision of the DNA replication 
fork with stabilized cleavage complex (Pommier, 2004).  
The relative contribution of replication or transcription to CPT-induced cytotoxicity 
depends on the CPT concentration, and for non-dividing cells, a much higher 
concentration is required to obtain a similar effect than in frequently dividing cells. In 
support of this, it was shown that cells in S phase were at least 100-fold more sensitive 
to CPT-induced  killing effect, although the amount of CPT-induced breaks and TopoI 
were equal in all phases of the cell cycle (Beidler and Cheng, 1995). Lesions induced by 
CPT were shown to be rapidly reversed after CPT removal, and therefore the important 
determinants of CPT cytotoxicity are the TopoI level, duration of the exposure to CPT 
and cell cycle phase (D'Arpa et al., 1990).  
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Figure 1. 13. TopoI-mediated DNA damage (Pomier 2006). 
(A) TopoI cleavage complex trapped by camptothecin (CPT). TopoI is covalently 
bound to the 3’-end of the broken DNA. (B) Transcription related conversion of the 
cleavage complex into a covalent TopoI–DNA complex (the RNA is shown in green). 
(C) Replication related conversion of the cleavage into a covalent TopoI–DNA complex 
by a colliding replication fork (the leading replication is shown in red; the lagging 
replication in blue). (D and E) Formation of the suicide complex by a single-strand 
break on the same (D) or the opposite (E) strand from the TopoI scissile strand. (F) 
Formation of an irreversible TopoI cleavage complex by pre-existing base lesion ((∗) 
abasic site, mismatch, oxidized base) at the 5’-end of the cleavage site. (G) The double-
strand break formation at two TopoI cleavage sites close to each other. (Pommier at. al, 
2006). 
 
CPT was first used in clinical trials in the 70s but because of the strong side effect, these 
trials were abandoned (O'Leary and Muggia, 1998) . Development of the CPT analog 
characterized by greater solubility (Wall et al., 1993),  resulted in the resumption of 
clinical trials  and two of its derivatives (hycamtin - Topotecan and CPT-11/Irinotecan - 
Camptosar) have been approved for the treatment of platinum-refractory ovarian cancer 
topotecan (Creemers et al., 1996, Creemers, 1997) and irinotecan (CPT-11) (Armand et 
al., 1995, Armand et al., 1999) in colorectal cancer.  
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Clinically approved camptothecin derivatives, despite their established efficacy in 
anticancer therapy, have also some limitations including chemical instability, drug 
resistance, long infusions and side effects. These compounds are quickly inactivated at 
physiological pH due to opening the lactone E ring of CPT. Irinotecan (CPT-11) is an 
inactive prodrug that is converted to its active metabolite SN-38. Irinotecan is the basic 
drug used to treat patients with primary and relapsed colorectal cancer. However, only 
about 20% to 30% of patients exhibit positive response to treatment (Ikeguchi et al., 
2011). Irinotecan treatment is often accompanied with frequent and severe side effects 
such as diarrhoea, neutropenia, nausea and vomiting. Assessment of the expression of 
TopoI can be an important tool utilized for increasing the effectiveness of therapy.  
One of the reasons for resistance to TopoI poisons is as described in section 1.5.2. 
TopoI activity and expression level which varies between cancer type and malignancy 
stage. For resistance to camptothecin the TopoI N-terminal domain and linker domain 
play major role. Total or partial deletion of the linker domain reduces TopoI sensitivity 
to camptothecin (Ireton et al., 2000, Fiorani et al., 2003). The N-terminal domain is 
dispensable for the formation of the TopoI-DNA complex but seems to have influence 
on the sensitivity to camptothecin – induced inhibition of religation process. Truncation 
of the N-terminus of TopoI results in a 4-fold reduction in sensitivity to camptothecin. 
To overcome the resistance to CPT several strategies have been explored to develop 
more potent TopoI inhibitors.  
For example, metabolically labile camptothecin in homocamptothecins lactone was 
replaced with a more stable beta-hydroxylactone which are potent anticancer agents. 
Gimatecan, a seven-position modified lipophilic camptothecin was  developed to 
provide fast uptake and accumulation in the cells as well as stability of 
TopoI/DNA/drug  ternary complex.  Diflomotecan, homocamptothecin and gimatecan 
are in Phase II clinical trial. The non-camptothecins TopoI poisons edotecarin and 
indolocarbazole that results in cleavage of DNA byt TopoI at C / TG in comparison 
with the TG /A specific for camptothecins, is currently in phase II clinical trial. Among 
non-camptothecins, edotecarin, an indolocarbazole that results in DNA C/T-G cleavage 
compared with T-G/A for camptothecins, is currently in Phase II clinical trial (Teicher, 
2008).   
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1.5.4. Repair of TopoI-mediated DNA damage.  
As described in the previous section, CPT-induced DNA damage can be repaired by 
several partially overlapping mechanisms (Figure 1. 14). Repair of TopoI-related DNA 
damage is less known in human cells, and most of the data on this process comes from 
budding yeast, in which the two redundant pathways that remove TopoI cleavage 
complexes from DNA exists. Removal of TopoI from DNA is mediated via hydrolysis 
of the bond between the TopoI tyrosine Y723 and 3’ end of DNA by tyrosyl- DNA 
phosphodiesterase1 (TDP1). In this pathway, TopoI covalently attached to DNA 
undergoes ubiquitination and proteasome-dependent proteolysis. Partially degraded 
TopoI polypeptide is then removed by TDP1. Following the removal of TopoI, TDP1 
generates a 3’-phosphate and a 5′-hydroxyl DNA terminus. BER-related enzymes 
further process the resulting gap in DNA. It was proposed that DNA breaks generated 
by TDP1 can be sensed by PARP-1 which mediates recruitment of XRCC1 protein, 
which in turn recruits polynucleotide kinase (PNK) which transfers the phosphate group 
from the 3′ to the 5′ terminus.  In the next step, XRCC1 acts as a scaffold protein for 
DNA polymerase β and DNA ligase III to fill and ligate the gap, completing the repair 
process (Plo et al., 2003). 
The removal of TopoI-cc can be carried out by several superimposed molecular 
pathways which involves endonuclease activity of Rad1–Rad10, Mre11–Rad50–Xrs2, 
Mus81–Mms4. As a result of endonuclease action TopoI is excised from the DNA 
along with a containing a few nucleotides segment of DNA. Rad1–Rad10 is an ortholog 
of human endonuclease XPF–ERCC1. Yeast Mre11–Rad50–Xrs2 is equivalent to 
human Mre11–Rad50–Nbs1 complex (MRN complex) which participates in 
homologous recombination. Those endonucleases cleave fragment DNA 5′ from the 
damaged region where DNA strands are separated. XPF–ERCC1 is also a critical 5′-
endonuclease in nucleotide excision repair (NER) both for global and transcription-
coupled repair (TCR) (Pommier, 2006, Pommier, 2009). 
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Figure 1. 14. Pathways involved in repair of TopoI-cc. 
Diagram showing enzymatic pathways used by human cells to repair TopoI cleavage 
complexes.   
 
Replication-related CPT cytotoxicity produces several well-characterized molecular 
responses. One of them is H2AX histone phosphorylation. The H2AX histone variant is 
phosphorylated within minutes after the formation of camptothecin-induced double-
strand breaks (DSB). The phosphorylated form of H2AX, (termed γH2AX) accumulates 
around each DSB and can be detected by immunofluorescence (Furuta et al., 2003). 
γH2AX is considered as a very sensitive marker of double-strand breaks produced by 
DNA damaging agents. H2AX is also functionally important, because its genetic 
inactivation sensitizes cells to camptothecin. Other biomarkers of CPT-induced DNA 
breaks are ATM (Ataxia Telangiectasia Mutated) activation by autophosphorylation at 
serine 1981 and phosphorylation of Chk2 (Checkpoint kinase 2) at threonine 68 by 
ATM and DNA-PK (Flatten, 2005).  
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 Poly (ADP-ribose) polymerases– PARP. 1.6.
Poly(ADP-ribose) (PAR) is a complex, nucleic acid-like biopolymer synthesised in cells 
by poly(ADP-ribose) polymerases using NAD+ as a substrate. Poly(ADP-ribosyl)ation  
influences a number of factors, including DNA  repair and cell cycle checkpoints and 
plays a role in the recruitment of DNA repair enzymes to strand breaks. The biological 
processes affected include maintenance of genome integrity, cell cycle progression, 
initiation of the DNA damage response, apoptosis, and regulation of transcription. 
 The enzymes which catalyses this reaction belong to the family of poly(ADP-
ribosyl)ases of which the founding and best investigated member is PARP-1 (see 
section 1.11). Since its discovery almost 50 years ago (Chambon et al., 1963), 17 
poly(ADP-ribose) polymerases have been identified. Although, they vary in molecular 
size and enzymatic capabilities, all have in common a ~50 aa long catalytic domain 
called the “PARP signature”. The PARP signature is highly conserved among 
vertebrates and between other species. This module is responsible for all PARP-1 
catalytic activities, including NAD hydrolysis, initiation, elongation, branching, and 
termination of ADP-ribose polymers.  
Some of the PARP family members can interact with each other and share common 
partners and common subcellular localizations (Ame et al., 2004). At present the 
nomenclature, and classification and number of 17 PARP-family members varies 
between published reports (Hottiger et al., 2010), however the most commonly-used 
classification of PARP proteins is based on their molecular domains or established 
function and includes DNA-dependent PARPs (PARP-1, PARP-2 and PARP-3), 
tankyrases, CCCH-type zinc-finger PARPs, and macroPARPs (Schreiber et al., 2006a). 
The DNA-dependent PARPs are PARP-1 and PARP-2 and PARP-3, which have been 
shown to be stimulated by DNA damage. The second most studied PARP family 
member is PARP-2, discovered many years later after PARP-1 in PARP-1 deficient 
cells which exhibited residual  PARP activity (Masutani et al., 2000). There is a 
growing amount of evidence regarding to the role of PARP-1 and PARP-2 in DNA 
repair. Three independent groups have created PARP-1 or PARP-2 knockout mice, 
which develop normally but show serious DNA damage defects caused by alkylating 
agents and ionizing radiation (Shall and de Murcia, 2000, Boehler et al., 2011a). It is 
believed that both PARP-1 and PARP-2 have overlapping cellular function as indicated 
by embryonic lethality of the PARP-1 and PARP-2 double knockout (Ame et al., 1999). 
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Both PARPs are activated by DNA breaks, and can form homo or heterodimers and poly 
(ADP-ribosyl)ate each other. Moreover these proteins have common partners in BER 
(Schreiber et al., 2002)  
PARP-3 (67 kDa) is not activated upon binding to DNA and is a poly-ADP-ribosylase. 
Originally, PARP-3 was identified as a core component of the centrosome, 
preferentially localized to the daughter centriole throughout the cell cycle. It was shown 
that amplification of PARP-3 interferes with the G1/S cell cycle progression (Augustin 
et al., 2003).  PARP-3 interacts with PARP-1 and activates PARP-1 in the absence of 
DNA, resulting in synthesis of polymers of ADP-ribose. Recently it has been 
demonstrated that PARP-3 can interact with Ku70/Ku80 and DNA-PK, contributing to 
the DNA damage response (Rouleau et al., 2009).  Another study has implicated the 
role of  PARP-3 in the accumulation of APLF (aprataxin polynucleotide kinase PNK-
like factor) at DSBs. APLF promotes ligase IV XRCC4/DNA complex conservation in 
chromatin at DSBs, therefore PARP-3 interacting with APLF may accelerate DNA 
ligation during nonhomologous end-joining (NHEJ) (Rulten et al., 2011). 
PARP-4/vPARP (193-kD) lacks the N-terminal DNA binding domain. PARP-4  is one 
of three proteins that compose large ribonucleoprotein complexes, known as vaults, 
which are involved in drug resistance and nucleo-cytoplasmic transport (Berger et al., 
2009). This PARP isoform was also shown to localize with the mitotic spindle 
(Kickhoefer et al., 1999).   
Tankyrase-1 and Tankyrase-2 plays a role in maintaining telomere length, and although 
the molecular structure of these two enzymes differ, their functions overlap. 
Phosphorylation of tankyrase during mitosis ensures correct mitotic spindle formation . 
The target partner for Tankyrase-1 is a protein TRF1 which is a negative regulator of 
telomere length. Knockout of both tankyrases genes in mice is lethal to embryos in the 
early development stage, however mice with only single-gene knockout are viable but 
grow smaller.  
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1.6.1. PARP-1 molecular structure. 
Poly(ADP-ribose) polymerase-1 (EC. 2.4.2.30)  is a 113 kDa protein, and beside 
histones is the most abundant nuclear protein with the number of copies estimated at 
between 10
5
 and 10
6
 per cell (Benjamin and Gill, 1980, de Murcia et al., 1994). The 
PARP-1 gene is located on chromosome 1q41-42, and encodes a 1014 amino acid long 
PARP-1 polypeptide which has a modular architecture with six molecular domains 
placed within 3 major functional units (Figure 1. 15): 46 kDa N-terminal DNA-binding 
domain (DBD), a 22 kDa central automodification region and a 54 kDa C-terminal 
catalytic domain   (Dantzer et al., 2006b, Hakme et al., 2008).  
 
Figure 1. 15. Molecular structure of PARP-1.  
The DNA-binding domain (aa 1 to 374) contains two Cys-X2-Cys-X28-30-His-X2-Cys 
(X-any other aminoacid) zinc fingers (ZnF1 and ZnF2) that mediate binding of PARP-1 
to DNA. PARP-1 zinc-fingers are structurally and functionally unique showing 
similarities only to zinc-fingers present in DNA polymerase ε and DNA ligase III 
(Petrucco, 2003). Among the first two Zinc Fingers, ZnF2 has the highest affinity to 
DNA damage. The ZnF1 also recognises DNA damage and additionally plays role in 
PARP-1 activation.  Although both Zinc Fingers are required for binding with DNA 
breaks, only the first one is required for DSB binding (Ikejima et al., 1990).  This zinc 
finger recognises single strand breaks and  interacts in this place with the DNA helix 
covering seven amino acids in either side around the break (Menissier-de Murcia et al., 
1989).  A newly discovered third zinc binding domain (ZnF3), is placed between the 
NLS and BRCT domain and its major role in PARP-1 activation following binding with 
DNA damage (Langelier et al., 2008). The N-terminal domain contains also a bipartite 
nuclear localization signal (NLS), and a caspase-3 cleavage site (Schreiber et al., 2006b, 
Hakme et al., 2008).  
The auto-modification domain (aa 375 to 525) has a BRCT domain which mediates 
protein-protein interactions. A molecular motif within the automodification domain 
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allows PARP-1 to form homodimers and ADP-ribosylate the adjacent PARP-1 
molecule. This reaction takes place on 15 conserved glutamic acid residues and has 
impact on DNA-binding due to charge repulsion between DNA and ADP-ribose 
polymers. The BRCT motif is common among many DNA repair or cell cycle 
checkpoint proteins and plays a role in physical interactions between DNA repair 
enzymes. Using the auto modification domain PARP-1 is able to bind with transcription 
factors like YY1 (Yin-Yang-1).The catalytic domain of PARP-1 bears the PARP-
signature – a 50 aa long highly conserved sequence with almost 100% sequence 
homology in vertebrates. C terminal domain is responsible for all catalytic activities of 
PARP-1 including initiation and elongation of PAR branches even up to 200 residues 
long (Masson et al., 1995). 
1.6.2. PARP-1 catalytic mechanism – poly(ADP-ribosylation). 
The majority of ADP-ribose polymers found in cells are produced by PARP-1. When 
activated upon binding to DNA, PARP-1 mediates rapid and reversible covalent 
attachment of ADP-ribose subunits onto target proteins. As a post-translational 
modification, PAR markedly changes biochemical properties of a protein, altering the 
DNA-binding affinity, the protein-interaction properties, and cellular location of target 
proteins (D'Amours et al., 1999). Using NAD+ as a precursor, PARP-1 catalyse the 
formation of long  ADP-ribose polymers by cleaving of the glycosidic bond between the 
ribose and the nicotinamide in NAD
+
, freeing nicotinamide as a by-product which is 
also a weak PARP-1 inhibitor (Figure 1. 16). PAR synthesis is initiated by transfer an 
ADP-ribose unit from NAD
+
 onto of glutamate, lysine, arginine, cysteine, phospho-
serine or asparagine amino acid residues of target proteins. Elongation and formation of 
branched polymers of the ADP-ribose involves addition of the ribose moiety to the 2'-
hydroxyl of the nicotinamide ribose or adenine ribose respectively (Alvarez-Gonzalez et 
al., 1994, Alvarez-Gonzalez and Mendoza-Alvarez, 1995). Autoribosylation of PARP-1 
decreases its affinity to DNA and results in reduction of PARP-1 catalytic activity. This 
in turn allows DNA repair proteins to gain access to the damaged DNA. A widespread 
DNA damage leads to hyper-activation of PARP-1, drastic consumption of NAD+, and 
depletion of cellular energy stores. Under extensive stressful conditions PAR acts also 
as caspase independent  activator of cell death (Yu et al., 2002, Koh et al., 2005).  
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Figure 1. 16. Maintenance  of  ADP-ribose polymer by PARPs and PARG (Patel et al., 
2005). 
PARP-1, using NAD
+
 as a substrate, catalyses addition of ADP-ribose to target proteins 
and formation of growing polymer chain releasing nicotinamide as a by-product. ADP-
ribose polymers can be rapidly degraded by PARG.  
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ADP-ribose polymers are degraded by poly(ADP-ribose) glycohydrolase (PARG), due 
to hydrolysis of alpha (1''- 2') or alpha (1'''- 2'') O-glycosidic bonds of ADP-ribose 
polymers to produce free ADP-ribose (Isabelle et al., 2010, Blenn et al., 2011, 
Davidovic et al., 2001). The cycle of formation and degradation of ADP-ribose 
polymers is measured in a few minutes following polymer formation. Degradation of 
the (ADP-ribose) polymers restores the catalytic activity of PARP-1 enzyme enabling it 
to bind with DNA again and start the next round of poly (ADP-ribosyl)ation. This rapid 
NAD
+
 consumption, synthesis and turnover of the polymer imposes a high energy cost 
to the cells therefore in cells, undergoing apoptosis PARG and PARP-1 are one of the 
first proteins cleaved, by caspases-3 (Boulares et al., 1999, Affar et al., 2001). 
Degradation of the (ADP-ribose) polymers allows re-association of the histones with 
DNA. The degradation of PAR to ADP-ribose units by PARG might be coordinated 
with action of at the site of DNA break  by incorporation of free DNA polβ-released 
phosphates into ATP providing local energy source for completion of the repair process 
by DNA ligase III (Oei and Ziegler, 2000).  
1.6.3. PAR acceptors 
In response to DNA damage, nearly 90% of ADP-ribose polymers are synthesized on 
PARP-1 (automodification), whereas the remaining is found on other acceptor proteins. 
Activated PARP-1 catalyses dynamic poly(ADP-ribosyl)ation of a 20 amino acid 
poly(ADP-ribose) binding motif which contains two conserved regions. One  is rich in 
basic amino acids, and the second has a pattern of basic amino acids scattered with basic 
residues. The main PAR acceptors are histones, especially histone H1 and H2B. 
Covalent binding of PAR to histones is strong and resistant to treatment with detergents 
or solutions with high salt concentration. The accumulation of negatively charged poly 
(ADP-ribose) on histone H1 and H2B tails causes local relaxation of chromatin 
structure facilitating the access of DNA repair proteins (Dantzer et al., 2006a). PAR can 
be attached to many nuclear proteins. Proteins identified based on PAR binding motive 
include  p53, p21(CIP1/WAF1), xeroderma pigmentosum group A complementing 
protein(XPA), MSH6, DNA ligase III, XRCC1, DNA polymerase epsilon, DNA-
PK(CS), Ku70, NF-B, inducible nitric-oxide synthase, caspase-activated DNase, and 
telomerase (Pleschke et al., 2000).  
PARP-1 also plays an important role during apoptosis, where it is cleaved by caspase 3 
with the formation of a N-terminal 24 kDa fragment containing the DNA binding motif 
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(Kaufmann et al., 1993). The 24 kDa fragment competes with full length PARP-1 and is 
able to inhibit poly(ADP-ribosyl)ation that promotes DNA repair and inhibit necrosis 
caused by over-activation of PARP-1 (Sukhanova et al., 2007). 
1.6.4. Role of PARP-1 in DNA repair 
One of the first reports providing evidence for the role of PARP in DNA damage repair 
was published by Durkacz et al., 1980. These authors discovered that inhibition of 
PARP activity by specific inhibitors (e.g. 3-aminobenzamide (3-AB)) or depletion of 
cellular NAD pool  decreased the re-joining of DNA breaks induced by the methylating 
agent, dimethyl sulphate (DMS) in L1210 cells (Durkacz et al., 1980).  
The role of PARP in DNA damage was also confirmed in molecular studies. The 
cytotoxic effect of MNNG (N-methyl-N'-nitro-N-nitrosoguanidine) and IR was 
intensified when PARP was inhibited by overexpression of the PARP DNA binding 
domain (DBD) in CV-1 monkey cells (Molinete et al., 1993, Schreiber et al., 1995). 
Similarly, potentiation of MMS-induced cytotoxicity in HeLa cells was observed 
following depletion of PARP activity by antisense RNA construct (Ding and Smulson, 
1994). 
A comprehensive source of knowledge about the role of PARP in DNA repair becomes 
available with generation of viable mice deficient in PARP-1 (Shall and de Murcia, 
2000). The viability of cells taken from these animals is considerably reduced following 
the exposure to IR or alkylating agents (e.g. MMS). Moreover, these cells treated with 
alkylating agents exhibit increased levels of genomic instability indicated by a higher 
rate of sister chromatid exchange. There is also evidence that the repair of DNA damage 
induced by MNU was slower in MEF cells derived from PARP-1null mice (Trucco et 
al., 1998).  
The number of studies that provide direct evidence for PARP-1 interaction with proteins 
involved in BER/SSBR is overwhelming. PARP-1 has a high affinity for SSB detection 
and is believed to be one of the first proteins that sense and responds to SSB. The 
interaction of PARP-1 with BER/SSB repair proteins is mediated via the BRCT or zinc 
finger domains.  For example, the BCRT motive allows interaction between 
automodified PARP-1 and XRCC1. Histones and chromatin modifying proteins are 
major PAR acceptors implicating PARP-1 in maintenance of chromatin structure. 
Addition of negatively charged PAR to histone causes chromatin relaxation and allows 
35 
 
other proteins to access a damaged site. Recruitment of XRCC1 negatively regulates 
PARP-1 activity removing it from damaged DNA site (Masson et al., 1998). This was 
demonstrated in PARP-1 null cells exposed to the DNA damaging agent, MMS, which 
were incapable of forming XRCC1 foci at the site of DNA breaks (El-Khamisy et al., 
2003). A direct interaction of XRCC1 with BER proteins, allows recruitment of DNA 
polymerase β and DNA ligase III to the damaged site, which are also able to bind 
directly to PARP-1 and facilitate short patch BER (see section 1.4.1). PARP-1 has been 
shown to be involved in long patch BER where it participates in FEN1-dependent strand 
displacement during DNA synthesis by DNA pol β. Inhibition of poly (ADP-ribose) 
synthesis by 3-aminobenzamide greatly reduces the interaction between XRCC1 and 
PARP-1. 
The main mechanism used by cells to repair DSB repair is NHEJ, which is dependent 
on a complex of DNA-PK, and XRCC4-DNA Ligase IV. A study by Audebert et al. 
2004 provided evidence for an alternative method for repair of DSB, independent of 
DNA-PK, in which the main role is played by PARP-1 with XRCC1-DNA Ligase III 
complex. This PARP-1 dependent mechanism involved in joining DSB was proposed 
by the authors to be an alternative or backup end joining (B-NHEJ) in contrast to the 
DNA-PK-dependent NHEJ often referred to as D-NHEJ (Audebert et al., 2004). Further 
studies by these authors have shown the B-NHEJ depends on the presence of C: G base 
pairs at the ends of the broken microhomology DNA sequences (Audebert et al., 2008). 
These observations points to PARP-1 as a bridge connecting BER/SSBR with NHEJ.  
The role of PARP-1 in HRR was demonstrated, when following PARP inhibition in 
Chinese hamster ovary cells with 3-Aminobenzamide, an increase in sister chromatid 
exchanges was observed (Morgan and Cleaver, 1982). These observations were further 
confirmed using cells derived from PARP-1 knockout mice (de Murcia et al., 1997). 
PARP-1 activity is essential to survival of cells in which progression of replication forks 
was blocked (e.g. by hydroxyurea). Stalled replication forks create DNA breaks, which 
can be recognized by PARP-1. The authors of this paper suggest that the activation of 
PARP-1 promotes replication fork restart by the employment of Mre11 endonuclease, 
which is required for DNA strand resection in HRR.  Therefore, PARP-1 recruiting 
Mre11 promotes the restart of blocked replication forks (Bryant et al., 2009b). 
Using DT40 PARP-1
-/-
 cells, it was shown that the replication forks were not slowed 
down when these cells were incubated in the presence of camptothecin. These results 
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were confirmed in PARP
+/+
 cells in which PARP-1 activity was reduced by PARP 
inhibitor or PARP-1-specific siRNA (Sugimura et al., 2008). These studies show 
PARP-1 participates in the regulation of HR at the time of HR start and inhibits the 
replication fork progression when DNA damage occurs in DNA. 
1.6.5. PARP inhibitors 
Identification of enhancement of cytotoxicity induced by radiation and  monofunctional 
DNA alkylating agents by 3-aminobenzamide (3-AB) (a nicotinamide analogue) 
provided the rationale for  development of PARP inhibitors as chemo- and 
radiosensitisers for cancer therapy (Durkacz et al., 1981). Nicotinamide is a by-product 
of the PARP reaction and a weak PARP inhibitor however its pharmacophore properties 
led to the design of further PARP inhibitors with optimal molecular interactions. The 
benzamide analogues including 3-AB were the first generation of PARP inhibitors. 3-
AB was a 10-fold more potent inhibitor than nicotinamide but acts non-specifically and 
its effective concentration is too high for clinical application. At concentrations between 
3-10 mM that are required for chemo- and radiopotentiation 3-AB was also affecting de 
novo purine biosynthesis (Milam et al., 1986). Structure-activity studies indicated 
desirable features for a potent PARP-1 inhibitor (Figure 1. 17). Such inhibitors should 
have an aromatic or poly aromatic heterocyclic ring system and a carboxamide group 
constrained the anti-conformation to 1,2 -bond, which is essential for inhibitor activity.  
An amide proton is required for putative hydrogen bonding.  Finally a non-cleaved bond 
is required at the position corresponding to the 3-position of the benzamide (Griffin et 
al., 1995). 
 
Figure 1. 17 Chemical features of potent PARP inhibitors. (Griffin et al., 1995)   
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A second-generation of benzamide analogues were developed in the 1990s. The 
inhibitors identified in these studies were PD128763 (Suto et al., 1991, Arundel-Suto et 
al., 1991) and NU1025 (Griffin et al., 1995) which were 50-fold more potent than 3AB 
in enzyme inhibition studies. 
Significant progress in development of second-generation PARP inhibitors was 
achieved after screening nicotinamide-resembling compounds (Banasik et al., 1992)  
These studies identified several very potent PARP inhibitors (e.g. phenanthridinones, 
phthalazinones) that further were used as a lead molecule for development of new 
PARP inhibitors. The PJ34 (phenanthridinone) inhibitor was used for development of 
INO-1001, which entered clinical trial in 2005 (Jagtap et al., 2005, Morrow et al., 
2009). The phthalazinones resulted in development of KU58684 with an IC50 of 5 nM 
and AZ2281 - olaparib (Menear et al., 2008) and the tetracyclic phthalazinone, GPI 
15427, with an IC50 of 31 nM (Tentori et al., 2003).  The development of third 
generation of PARP inhibitors started with crystallization of PP128763 and NU1025 
inhibitors in the NAD+ binding site of chicken PARP (Ruf et al., 1998). These tricyclic 
lactam indoles and benzamidazoles include AG14361 and AG014699, which was the 
first PARP-1 inhibitor used in clinical trial for the treatment of cancer (Plummer et al., 
2008).  
Many studies were dedicated to the use of the PARP inhibitors as chemo sensitizers in 
cancer therapy. For example, PD128763 was shown to be able to increase the 
cytotoxicity of temozolomide by 5-fold(Arundel-Suto et al., 1991)  
One of the most advanced PARP inhibitors to date is AG014699 showed in Figure 1. 
18. The PARP inhibitor AG14447 was identified as the most potent inhibitor (Tomas, 
Calabrese et al 2007) and it phosphate soluble salt (AG014699) entered clinical trial in 
combination with temozolomide in 2003. After promising phase I of clinical trials of 
this compound in patients with melanoma (Plummer et al., 2005), AG014699 is 
currently undergoing a phase II trial. 
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Figure 1. 18. Molecular structure of AG014699 
 
PARP inhibitors were shown to potentiate the cytotoxic effects of ionising radiation 
which is particularly valuable for cancer patients as most them receive radiotherapy as 
part of the treatment. PARP inhibitors increases the cytotoxicity and antitumor activity 
not only of ionizing radiation or DNA alkylating agents (e.g. temozolomide) but also 
are extensively tested in combination with topoisomerase I poisons (Plummer 2006).  
 PARP-1 and TopoI interaction. 1.7.
TopoI poison-based cancer therapy gives promising results however, the resistance to 
treatment is commonly observed (Liu, Desai et al. 2000).  PARP inhibitors are 
undergoing clinical trials with TopoI poisons. To date the emerging data suggest 
increased toxicity. The combination of the PARP inhibitor, ABT-888 (veliparib), with 
topotecan was investigated in Phase I trials in patients with lymphomas and refractory 
solid tumours. The combination of veliparib with the standard dose of topotecan caused 
myelosuppression and dose reductions were needed. In this study, the maximum 
tolerated dose of topotecan was 0.6 mg/m2/day and ABT-888 10 mg BID on days 1–5 
of 21- day cycles. Co-administration of veliparib with topotecan resulted in increased 
H2AX response in circulating tumor cells (CTC) and peripheral blood mononuclear 
cells (PBMCs), and more than 50% reduction of PAR level was observed in PBMCs. 
(Kummar et al., 2011). In another Phase I study, the PARP inhibitor Olaparib 
(AZD2281) in combination with topotecan dose-limiting toxicities of neutropenia and 
thrombocytopenia were observed and these were dose-related. A common adverse 
events (AEs) including fatigue and gastrointestinal consequences was observed 
39 
 
resulting in termination of this trials (Samol et al., 2011).  Therefore, a proper 
understanding of the interaction between PARP and TopoI poisons is essential to 
maximise efficacy and reduce toxicity. 
There are several studies where PARP inhibitors have been used to enhance 
topoisomerase I poisons. Early studies revealed that PARP activity was stimulated by 
camptothecin in L1210 cells and inhibition of PARP with NU1025 was able to enhance 
CPT -induced DNA breaks and cytotoxicity to a similar ~2.6-fold extent, connecting 
these two events (Bowman et al., 2001b). NU1025 and NU1085 also enhanced the 
cytotoxicity of topotecan up to 5-fold in a panel of 12 different cell lines including 
colon breast, lung and ovarian cancer cell lines. The effect of PARP inhibition on 
topotecan induced cytotoxicity in these studies was not related to p53 status in these cell 
lines and tissue specificity (Delaney et al., 2000). Support for the role of PARP-1 in 
TopoI poison-mediated cytotoxicity comes from genetic manipulation studies. Genetic 
inactivation of PARP-1 sensitizes cells to TopoI poisons (Chatterjee et al., 1989, 
Hochegger et al., 2006) and PARP-1 null mice are hypersensitive to TopoI poison 
toxicity; 64% of PARP null mice died within 2 weeks of exposure to CPT-11 (140 
mg/kg) but all of the PARP wt mice were still alive 8 weeks later (Burkle, 2000). 
In cell-based studies, AG14361 (the pre-clinical lead that led to AG014699 that went 
into clinical trial) was shown to be effective in potentiation of topotecan-induced 
growth inhibition in human colon (Lovo, SW620) and lung (A549) cancer cell lines. 
These in vitro data were supported by in vivo study in which irinotecan (2.5 mg/kg 
daily) antitumor activity in human colon cancer xenograft models was enhanced by 
AG14361 with a 2 to 3-fold enhancement of the irinotecan-induced tumour growth 
delay. In this study there was only mild body weight loss caused by irinotecan, which 
was not substantially increased by AG14361 (Calabrese et al., 2004). The in vivo 
activity of other PARP inhibitors has been investigated in combination with TopoI 
poisons: CEP-6800 caused a 60% enhancement of irinotecan-induced delay in the 
growth of human colon cancer (Miknyoczki et al., 2007).; xenografts, and GPI 15427 
also enhanced irinotecan antitumour activity (Tentori et al., 2006), confirming the in 
vitro data.  
As a direct prelude to the study described in this thesis the effect of AG14361 in 
combination with TopoI poisons on TopoI activity, DNA repair and cytotoxicity was 
investigated in K562 cells and various repair defective cell types. In this study (Smith et 
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al. 2005) PARP-1
-/-
 mouse embryonic fibroblasts were shown to be 3-fold more 
sensitive to topotecan than PARP-1
+/+
 cells. AG14361 potentiated topotecan-induced 
cytotoxicity in PARP-1
+/+
 cells approximately 3-fold. In comparison, these authors 
found only a 1.4-fold potentiation of topotecan in PARP-1
-/-
 cells, which was thought to 
be due to a contribution of PARP-2. PARP-1
-/- 
cells sensitivity to topotecan was not due 
to TopoI level, because the Western blot analysis of cell extracts showed that TopoI 
level was the same in both cell types. AG14361 also had no effect on TopoI activity, 
because relaxation of supercoiled plasmid by nuclear lysates obtained from K562 cells 
treated with or without AG14361 was the same. In contrast, alkaline elution data 
showed that AG14361 significantly retarded the re-joining of CPT-induced DNA breaks 
caused its accumulation after CPT removal (Smith et al., 2005). The extended 
persistence of these breaks was proposed to be via inhibition of PARP-1 dependent 
BER (Smith et al., 2005). The mechanisms explaining the role of PARP in repair of 
TopoI-induced DNA damage have not been elucidated. Cytotoxicity of TopoI poisons is 
related to formation of DSB mostly during DNA replication but, also to some extent 
during transcription. TopoI has several binding sides to PARP-1. With a native form of 
PARP-1, TopoI binds by its core and C-terminal domain, and to poly(ADP-ribosyl)ated  
PARP-1 via the TopoI N-terminal and core domain (Bauer et al., 2001). PARP-1 as one 
of the key BER enzymes is also involved in the repair of TopoI-mediated DNA damage. 
BER is significantly reduced in PARP-1 deficient cells, and BER deficient cells are 
hypersensitive to camptothecin (Caldecott and Jeggo, 1991). Autoribosylated PARP-1 
may recruit XRCC1 protein which in turn recruits tyrosyl DNA phosphodiesterase1 as 
described in section 1.5.4. It was shown that BER protects non-replicating cells from 
TopoI poisons. AA8 cells were only sensitive to CPT during S-phase, and BER 
deficient EM9 cells were CPT hypersensitive in the presence of replication inhibitor 
aphidicolin (Barrows, Holden et al. 1998). 
PARP inhibitors in response to TopoI-cc increase DNA breaks without increasing the 
number of  TopoI–DNA complexes (Bowman et al., 2001b, Smith, 2005). PARP 
inactivation is also associated with deficiency of Tdp1 and, Ku / DNA-PK toxic 
interference in homologous recombination (HR) pathway, which are most important for 
repair of TopoI-cc (Hochegger et al., 2006, Zhang et al., 2011) .  
There are two basic theories regarding the mechanism of sensitization of TopoI poisons-
induced cytotoxicity by PARP inhibitors: firstly, that PARP-1 modulates TopoI activity 
and secondly that PARP-1 repairs TopoI poison-induced DNA damage. In support of 
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the first hypothesis several authors show that PARP-1 can interact with TopoI and 
modulate it activity. These two proteins interact noncovalently and co-localise 
throughout the cell cycle (Elias et al., 2003).TopoI activity may be regulated by PARP-
1 depending on it autoribosylation status. An interaction of these two proteins is weaker 
when PARP-1 is autoribosylated (Yung et al., 2004). It was shown, that PARP-1 in the 
presence of NAD inhibited TopoI DNA relaxation activity (Ferro et al., 1983). The 
mechanism responsible for PARP-1 inhibitory activity on TopoI was suggested to be 
due to the accumulation on TopoI of a large negative charge from ADP-ribose that 
eventually causes repulsion between TopoI and DNA.  
For the project described here, the most important aim is to determine is the role of 
PARP-1 in repair of TopoI/camptotecin induced damage. If TopoI is trapped by 
camptothecin, the religation step is blocked and in consequence toxic SSB or DSB can 
be created. There is still open question what kind of DNA breaks are accumulated due 
to PARP-1 inhibition (Veuger et al., 2004). Repair of those SSB and probably DSB 
lesion may involve binding and activation of PARP-1.  
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 Aims.  1.8.
The overall aim of this project is to determine the nature and physiological relevance of 
the potentiation of TopoI poison-induced cytotoxicity by inhibition of PARP-1 activity. 
TopoI poisons have been used in cancer therapy with promising results, however the 
resistance to these anti-cancer drugs is commonly observed (Liu et al., 2000). PARP-1 
inhibitors are currently clinically tested and were proved not only as promising single-
agent therapeutic, but also as efficient agents that can be used to increase the therapeutic 
efficiency of the other common anticancer agents (Plummer et al., 2005). Based on the 
promising pre-clinical evidence PARP inhibitors are undergoing clinical trial with 
TopoI poisons, but the mechanism of the chemosensitisation has not yet been fully 
determined . 
Since the TopoI poison-induced cytotoxicity is predominantly restricted to S phase of 
the cell cycle the drug-resistant non-replicating pool of tumour cells can repopulate the 
tumour after chemotherapy withdrawal, therefore the enhancement of non- replication-
associated drug cytotoxicity is clinically relevant. 
The very potent and clinically active PARP inhibitor AG014699 and very specific 
TopoI poison Camptothecin will be used to answer on following main questions 
addressed in this thesis. 
These questions are: 
1. Is the sensitisation of TopoI poison-induced cytotoxicity by PARP inhibitors cell 
cycle specific? 
2.  Does PARP inhibition cause the accumulation of single strand breaks and does 
this elevated level of SSB can increase the amount of DSB in specific phase of 
cell cycle? 
3. Does PARP inhibition have an effect on TopoI poison-induced DNA damage 
repair? 
4. What kind of DNA breaks (SSB or DSB) are more important for mediation of 
cellular cytotoxicity? 
5. What is the possible mechanism by which PARP-1 plays in its role in the repair 
of SSB and DSB?  
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Chapter 2. Materials and methods  
2.1.  Materials  
All chemicals and reagents, including tissue culture media were provided by Sigma 
(Poole, Dorset, UK) unless otherwise stated. The PARP-1 inhibitor AG0140699 (1-(4 
dimethylaminomethylphenyl)-8-9-dihydro-7H-2,7,9a-benzo[cd]azulen-6-one)) was 
provided by Aguron/Pfizer Pharmaceuticals GRD, La Jolla, CA, USA. The powder 
form of AG014699 was dissolved in water, and 5 mM stock solution was stored in 
small aliquots at -20 C. In all experiments AG0140699 was used at a final 
concentration of 0.4 M. Camptothecin was dissolved in anhydrous DMSO, and small 
10 mM stock aliquots were stored at -20 C. Temozolomide, a gift from Cancer 
Research UK (London, UK), was made up at a concentration of 150 mM in DMSO and 
stored at -20 C. 
2.2. Equipment 
All tissue culture plastic-ware was purchased from NUNC (Fisher Scientific, 
Loughborough, UK). An MRXTC Spectrophotometer (Dynex Technologies, UK) plate 
reader was used to measure the absorbance of XTT. Cell cycle analysis was performed 
on FACScan (Becton Dickinson, USA) flow cytometer. Centrifugal elutriation was 
carried out using Beckman Avanti J-20 centrifuge equipped with JE-5.0 elutriation rotor 
and Sanderson elutriation chamber. Peristaltic pump (Model no. 7550-50) and tubing 
size 8 or 16 was supplied by Master Flex, Vernon Hills, USA. Digital pictures were 
taken using an Epi-fluorescence microscope (DMR, Leica, Wetzlar, Germany) in 8-bit 
CCD camera (RTcolor SPOT, Diagnostic Instrument Inc., Sterling Heights, USA). The 
MIEF-SYS Isoelectric Focusing horizontal electrophoresis unit used for comet assay 
was supplied by VWR, Radnor, USA or by ScotLabs, Chagrin Falls, USA. Z1 Coulter 
counter (Beckman Coulter, Bucks) Cell colonies were automatically counted with the 
aid of ColCount™ Oxford Optronix. 
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2.3. Tissue culture   
All cell lines were maintained in exponential growth phase in RPMI 1640 HEPES 
modified medium supplemented with 10% (v/v) foetal calf serum, glutamine, penicillin 
(100 units/ml) and streptomycin (100 µg/ml) at 37 
0
C in a humidified atmosphere of 5% 
CO
2
. 
Cell lines 
K562 
The K562 cell line was isolated from 53-year-old woman with chronic myelogenous 
leukaemia in blast crisis, positive for the Philadelphia chromosome (Lozzio and Lozzio, 
1975). K562 cells exhibit various erythroid characteristics with possible 
multipotentiality (Horton et al., 1981). These suspension cells with rounded regular 
shape are known to be convenient for elutriation (Kauffman et al., 1990).Cells were 
obtained from the ATCC (Manassas VA, USA). 
Lovo 
The Lovo cell line was isolated from a 56-year-old male patient with adenocarcinoma of 
the colon. The karyotype of this cell has been characterised as near diploid, with some 
stocks found to become tetraploid. (Trainer et al., 1988). Cells were obtained from the 
ATCC (Manassas VA, USA.) 
AA8  
AA8, Chinese hamster ovary cell line, was isolated as a spontaneous clone, which was 
heterozygous in adenine phosphoribosyltransferase Cells were obtained from Penny 
Jeggo, Sussex University. 
EM9 
EM9 cell line is a clone derived from AA8 cells. This line was obtained by isolation of 
resistant AA8 clones resistant to EMS (Thompson et al., 1982). The survival of EM9 
cells subjected to the action of DNA-alkylating agents, IR or CPT is significantly lower 
as compared to the survival of AA8(VanAnkeren et al., 1988). These cells are 
characterized by high frequency of SCE. Overall sensitivity to DNA-damaging agents is 
related to the lack of functional XRCC1 protein. (Thompson et al., 1990). Cells were 
obtained from Penny Jeggo, Sussex University. 
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2.4. Growth inhibition and cytotoxicity assay. 
2.4.1. XTT cell proliferation assay. 
The XTT reagent (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-S|(phenylamino)carbonyl|-
2H-tetrazolium hydroxide) is a yellow tetrazolium salt, that can be metabolised by 
mitochondrial dehydrogenases of the live cells to a spectrally different (orange), water 
soluble formazan product (Scudiero et al.,1988). The XTT assay has been commonly 
used to determine the effect of drugs on cell growth.  For the purpose of the experiments 
done for this thesis, the growth of Lovo and K562 cells exposed to CPT±AG014699 
was evaluated using commercially available XTT Cell Proliferation Kit II (Roche 
Diagnostics, GmbH) according to manufacturer's manual, and optimized by lab co-
workers (Elaine Willmore, Clark Crawford – personal communication). After exposing 
cells to drug for the required duration, drug was removed by centrifugation and cells 
were plated in fresh medium in 96 well plates in density 1000 cells/well and left to grow 
for 4-5 days. The working XTT reagent mixture was prepared by mixing the XTT 
reagent (1 mg/mL) with the electron-coupling reagent (phenazine methosulfate) at a 
ratio of 50/1 (v/v). After adding 50 µl of the XTT reagent mixture to each well, plates 
were incubated for 4 hours in a humidified atmosphere at 37 
o
C and 5% CO2, to allow 
cells to metabolize the tetrazolium salt. The absorbance of the formazan product was 
then measured on a MRXTCspectrophotometer at 450 nm. 
2.4.2. Clonogenic survival assay. 
The clonogenic assay was used to investigate the cytotoxicity induced by CPT and 
AG014699 in Lovo and K562 cells. This method enables evaluation of the capability of 
individual cells to survive after exposure to drug treatment. Cells exposed to anticancer 
agents when returned to drug-free medium may still be able to reproduce and form 
colonies. Cell survival is then estimated by counting the number of colonies.  
Exponentially growing Lovo cells, following drug exposure, were detached from plates 
using trypsin and counted using a haemocytometer or Coulter counter (Beckman). In the 
next step, several serial cell dilutions were prepared in fresh culture medium, from 
which cells were seeded at low densities into 90 mm plates (starting from 100, 250 and 
500 cells for the lowest and up to 10,000 cells for the highest drug concentration).The 
plates were then incubated up to 12 days allowing cells to form colonies. After the 
incubation period colonies were fixed using Carnoys’ fixative (methanol: acetic acid, 
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3:1), and stained with crystal violet (0.4% v/v in water) to aid counting. Colonies 
containing more than 30 cells were counted using an automatic colony counter (Oxford 
Optronix, UK). Only colonies which number contain more than 30 cells were counted 
on plates containing at least 5 colonies. Assuming that each colony comes from a single 
cell, the number of counted colonies estimates the number of cells that survived drug 
treatment. The plating efficiency of the cells was calculated as the percentage of 
colonies formed on the plates compared to the number of cells originally seeded. The 
clonogenic survival of drug treated-cells was calculated as the plating efficiency of 
treated cells expressed as a percentage of the plating efficiency of the DMSO alone or 
DMSO+AG014699 treated controls.  
2.4.3. Clonogenic survival assay by sloppy agar. 
The sloppy agar clonogenic assay enables measurement of cytotoxicity of cells growing 
in suspension. Cells are mixed with agarose that holds them suspended in one place 
where they can divide and form colonies. The K562 cells in exponential growth phase 
were separated into different cell cycle phases by elutriation performed in sterile 
conditions. The purity of each collected fraction was analysed by flow cytometry, and 
cell fractions containing the highest number of cells in G1, S and G2 cell cycle phase 
cells were used for the cytotoxicity assay. Asynchronous and elutriated cells at a density 
of 2.5x10
5 
cell/ml were exposed to drug for the desired time and used for clonogenic 
assay by sloppy agar. Following treatment, drug was removed by centrifugation and 
cells were diluted to a density of 1x10
3 
or 1x10
4
 cells/ml in fresh medium. Three 
different cell dilutions, containing from 100 to 10000 cells were used depending on cell 
cycle phase and drug concentration, mixed with 0.15% SeaKem ME agarose and plated 
in 6-well plates. Cells were left for 12 days for colonies formation. To visualise colonies 
in the gel, MTT dye at a concentration of 0.4 mg/ml was used.  
2.5. Staining cells for the cell cycle analysis by flow cytometry.  
The flow cytometer is a machine that enables counting, examining and sorting of 
individual cells suspended in fluid. A hydro-dynamically focused stream of fluid in 
which the cells are dispersed is passed through a beam of laser light of single 
wavelength. At this point a number of detectors are aimed at it: one in the line of the 
light beam (Forward scatter - FSC) and several perpendicular to it (Side scatter - SSC) 
and one or more fluorescent detectors. Each cell passing through the light beam scatters 
the light and excites fluorescent chemicals present in the cells that emit fluorescent light 
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at a different frequency than light source. The detectors pick up a combination of 
scattered and fluorescent lights. Analysing the light fluctuation with each detector, it is 
possible to extrapolate various types of information about the physical and chemical 
properties of each cell.  
 The forward scatter correlates with cell volume and side scatter reflects the inner 
complexity of the cell (i.e. shape of nucleus, amount of cytoplasmic granules). The flow 
cytometric analysis of cell cycle described in this thesis was always performed directly 
after elutriation and just before any next planed experiments. This was an important 
time scheduling restriction, which must be carefully considered while planning and 
arranging further experiments. As described in section 3.4.2, progression of elutriated 
K562 cells to the next phase of cell cycle is rapid, therefore an efficient protocol for 
staining DNA, allowing analysis of 16 fractions collected during elutriation by flow 
cytometry within less than 1h, was adapted from a method described earlier (Krishan, 
1975). 0.5x10
6
 cells were suspended in 0.5 ml PBS and 0.5 ml of staining buffer (0.5g 
sodium citrate, 1.5 ml Triton-X100, 0.05g propidium iodide (PI), 0.01 g ribonuclease A, 
250 ml of distilled water, stored in 4 
0
C protected from light) was added drop wise to 
the cell suspension. Staining was carried out at 4 
0
C for 20 min, and cells were 
subjected to cell cycle analysis by flow cytometry on a FASCcan (Becton Dickson) with 
the aid of CellQuest software. A minimum of fifteen thousand events per sample were 
collected and the data were stored as list mode files. PI signals derived from cells being 
analysed for their DNA content was gated out to exclude aggregates and distinct 
population of events with very low width and area, which were probably a debris 
resulted from staining procedures. Acquired data were than processed on ModFit LT 
software (Verity Software, Topsham, ME) using a manual analysis type that allows 
adjusting the place of G1 and G2 peaks of DNA on histograms plotted from events 
gated on FSC versus SSC scatter-grams. The AutoFit option on ModFit LT can analyse 
input data, generating report file showing analysis settings, DNA histogram and 
corresponding dot-plot with gated region (Figure 2. 1). The output report, provides also 
a summary statistics describing how model fits to experimental. 
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Figure 2. 1. An example of FACS report produced with the aid of ModFit LT software 
A design of FACS report template generated with ModFit that include DNA histogram 
with indicated cell cycle phases, two types of histogram legend, scatterplot and results 
of analysis. One histogram legend shows various statistics (% CV, cell number) that 
illustrates goodness of fit, second indicates the meaning of each peak on histogram. 
Blue text indicates the results of sample analysis.  Along with a histogram, 
corresponding scatterplot with gating can be generated.  
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2.6. Centrifugal elutriation in JE – 5.0 rotor. 
Elutriation is a method which allows the separation of cells according to their size and 
shape. Each cell can be characterized by its size (shape, volume) and density. Cells in 
culture do not differ from each other according to their density so differences in their 
size can be used to separate them. The smallest cells are in the G1 phase and the biggest 
in G2, therefore it is possible to separate cells in each cell cycle phase. 
Centrifugal elutriation in the JE – 5.0 rotor (Beckman Coulter, High-Wycombe, Bucks) 
showed in Figure 2. 1 combines two separation technologies: centrifugation 
(sedimentation under the influence of centrifugal force), and counterflow elutriation 
(separation by washing). Separation takes place in a funnel shaped elutriation chamber. 
Each cell in the elutriation chamber is acted upon by two opposing forces: a centrifugal 
force that is driving cells away from the axis of rotation and fluid velocity (driving cells 
toward axis of rotation – “counterflow”). While the rotor is spinning in the centrifuge a 
suspension of cells is pumped at constant flow rate from outside the centrifuge into the 
rotor to the narrow end of the elutriation chamber. When suspended cells are inside the 
chamber they migrate according to their sedimentation rates to the position in the 
gradient where the effect of those two forces upon them is balanced. For small cells the 
sedimentation is low and they are quickly washed toward axis of rotation, where they 
are caught in an increasing flow velocity caused by the rapidly narrowing chamber 
walls. Cells are washed out of the chamber, up through the rotor, and out into the 
collection vessel. The larger cells move through chamber more slowly and reaching 
equilibrium at the elutriation boundary, where the centrifugal force and counter flow 
were low and the chamber walls are at their widest point. The largest cells remain near 
the inlets of the chamber where centrifugal force is the highest. By increasing the flow 
rate in gradual steps, increasingly large cells can be washed out of the rotor and 
collected (adopted from Beckman elutriation manual).  
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Figure 2. 2. The JE-5.0 elutriation system and process of cells separation inside 
elutriation chamber (picture from Beckman elutriation manual). 
The heart of the elutriation system shown on the top picture is the elutriation chamber 
positioned in the JE-5.0 rotor that is connected by peristaltic pump with the buffer 
reservoir using plastic tubing. Cells injected by the valve are moved to the elutriation 
chamber where they can be viewed at the viewing point. At the elutriation boundary 
where opposite forces of centrifugal force and contraflow are equal, cells stay inside the 
chamber. By increasing the flow rate of the buffer, cells can be washed out of the 
chamber and collected in collection flasks. (adopted from Beckman elutriation manual)  
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2.6.1. Elutriation of K562 cells. 
Before starting the elutriation experiments the following preparation steps were 
performed. When cells were cultured after elutriation for longer period of time, 
elutriation was performed in sterile conditions. All external parts of elutriation system 
were sterilized in 70% ethanol. Before each experiment the centrifuge rotor, tubing, 
elutriation chamber were disassembled, cleaned with detergent and assembled again. 
The first run was performed using PBS as an elutriation buffer. This step was performed 
to verify whether the elutriation system was properly assembled, to confirm that there 
were no leaks from tubing connections that the stroboscope-lamp is adjusted, and 
pressure in elutriation chamber is minimal. Next, when the whole system was running, 
the peristaltic pump was calibrated. This was done automatically by switching the pump 
to calibration mode in which a known amount of buffer is pumped and collected over 
period of time. The difference between the volume of buffer that was set up on pump 
and volume that was collected was used to adjust correct the flow rate.  
To conduct sterile elutriation, the chamber and tubing system was sterilized by running 
6% H2O2 through the system followed by washing in sterile PBS. Cell fractions were 
collected in 50 ml tubes covered by para-film to keep in sterile condition.  
Before loading cells, the elutriation system was filled with flow buffer (RPMI1640 + 
10% FBS) and equilibrated by starting and stopping the centrifuge for several times 
before reaching the final rotor speed (2500 rpm) under minimal pressure. This important 
step was performed to remove any air bubbles present in the elutriation system, which 
may increase the pressure or disturb the buffer flow.  
For cell cycle separation by elutriation, 2.5-1.5x10
8
 K562 cells were collected by 
centrifugation and condensed in syringe as a single cell suspension in a small 5 ml 
volume of medium. Cells were then injected into the elutriation system filled with flow 
buffer at flow rate 15 ml/min. Cells were then allowed to segregate inside the elutriation 
chamber for 5-10 min then the flow rate was gradually increased up to 20-28 ml/min 
(depending on cell number injected into elutriation chamber) and decreased to 15 ml/ml. 
During this step the behaviour of cells in the elutriation chamber must be verified 
visually through the stroboscope-window and the pressure level in elutriation system 
must be constantly monitored.  For the first two fractions of K562 cells, 50 ml each 
were collected under a starting flow rate of 25-30 ml/min, and later fractions of 100 ml 
each (2x 50 ml) were collected by increasing the flow rate by 5 ml/min for each 100 ml 
52 
 
fraction. Eventually 8 fractions (2x 50 ml each) were collected. The content of each 
fraction was analysed by flow cytometry as described in section 2.5, and the purest 
fractions enriched with cells in G1, S and G2 cell cycle phase were selected for 
subsequent experiments. Using K562 cells it was possible to get fractions of cells that 
were more than 80% pure in each cell cycle phase. The elutriation protocol used for the 
K562 cells was adapted from the one used for Lovo cells. Elutriation of Lovo cells was 
discontinued for the reasons discussed in section 3.3.2.  
2.7. Comet assay  
Single cell gel electrophoresis, also called the comet assay, is a method used to measure 
the level of DNA damage in single cells. Cells embedded in agarose on microscope 
slides are lysed and subjected to electrophoresis. Organisation of damaged DNA is 
disrupted, therefore individual DNA strands lose their compact structure and relax when 
the electric field is applied, and the DNA expands out of the nucleus into the agarose. 
Intact DNA strands are too large to leave the nucleus, whereas the smaller are free to 
move in a given period of time. The amount of DNA that leaves the nucleus is a 
measure of DNA damage in the cell. Recently guidelines and technical requirements for 
this assay were described by (Tice et al., 2000) and assay specificity for detection of 
SSB or DSB was discussed by (Collins, 2004). It is commonly accepted that procedure 
of this assay is biased by several sources of variability; therefore, some optimisations of 
the experimental procedure are usually recommended. Following current and 
electrophoresis time settings adjustment, the optimal ones were chosen and excluding 
various electrophoresis tanks and different batches of Comet assay kit were common for 
all experiments. 
The comet assay was performed according to the Trevigen Comet assay protocol 
(Trevigen Comet Assay Kit, AMS Biotechnologies, Oxford, UK). All preparation was 
done under dimmed light to avoid additional DNA damage. 5x10
5
 cells were suspended 
in 1 ml PBS. 20 µl of the cell suspension were combined with 180 µl of low melting 
point agarose, at 37 °C, and 75 µl of this cells – agarose mixture was spread on each 
well of the 2-well comet slide (Trevigen Comet Assay Kit) which was precoated with a 
thin agarose layer. Slides were placed flat in the fridge for 20 minutes to allow gelling 
of the agarose. The slides were then immersed in chilled lysis buffer (Trevigen Comet 
Assay Kit) and placed in fridge for 30 minutes. After lysis, the assay was adapted 
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depending on whether the alkaline or neutral version of the comet assay was to be 
performed.  
Alkaline  
For the alkaline comet assay comets slides (after lysis) were incubated in chilled 
alkaline solution (NaOH – 300mM, EDTA – 40mM, pH>13) for 30 min at 4 °C. 
Treatment of DNA with alkaline solution of pH above 13 results in denaturation of 
DNA strands therefore allows detection of single as well as double strand breaks  Next, 
slides were placed flat into large electrophoresis tank (distance between electrode was 
20 or 25 cm depending on used tank) filled with the alkaline solution. During 
electrophoresis the tank was covered with a box to prevent more DNA damage coming 
from light. The level of electrophoresis solution in tank was adjusted to obtain current 
of 200-300 mA under applied voltage 0.75V/cm. Electrophoresis was performed for 
30min in electrophoresis buffer (NaOH – 300mM, EDTA – 40mM, pH>13). 
Neutral 
For the neutral comet assay, following the lysis step comet slides were briefly washed in 
1xTBE, pH=10 buffer and electrophoresis was carried with 1xTBE, pH=10 buffer at 
1V/cm for 30 min. In neutral conditions DNA strands are held together, therefore in this 
version of comet assay DSB are mainly detected. 
After electrophoresis, the slides from both neutral and alkaline were washed in dH2O, 
and then placed in 70% (v/v) ethanol for 5 minutes to fix the slides. The slides were 
then air-dried, and stained with 80 µl SYBR green (Trevigen Comet Assay Kit) diluted 
1 to 10,000 in TE buffer for 10 min. After removing the excess of SybrGreen slides 
were dried again. Slides were imaged using the Leica fluorescent microscope with x10 
or x20 magnification, equipped with CCD camera and Spot Advance software. The 
SpotAdvence software setting was: Exposure time 333 ms, gain 8 or 4 depending on 
staining efficiency, gamma correction was set to1, which assures that image grey levels 
linearly depend on the fluorescent signal emitted from a sample. When 20x 
magnification was used (section 4.3 and 0 for alkaline comet assay) several random 
images from each well of comet slide were collected to obtain approximately 100 cells.  
When magnification 10x (rest of experiments) was used 4 images surrounding centre of 
each well was recorded. All cells, possible to score were measured, from which a 
random sample of 100 cells was selected for analysis. Although similar conditions of 
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electrophoresis were used for all experiments, the source of variation in the range of 
measurements observed in some experiments is largely unknown. Possibly some 
variation can be explained by the fact that two different electrophoresis thanks (section 
2.1) were used for experiment or by the nature of used cell line. Nevertheless, similar 
pattern between repeats of single experiment was observed.  
Images are displayed with comet tails running from cathode on the left to anode on the 
right. As the endpoint measurement, the Olive tail moment was chosen. The OTM is 
expressed as (tail mean − head mean) × % of DNA in the tail/100.  
2.8. Topoisomerase activity assay 
Topoisomerase I (TopoI) is a nuclear enzyme that catalyses the relaxation of DNA 
supercoils. TopoI activity can be measured by an in vitro assay that relies on the ability 
of TopoI to relax super-coiled plasmid (Figure 2. 3). Super-coiled and relaxed DNA has 
different mobility in agarose-gel electrophoresis. The super-coiled DNA will travel 
faster and further down the gel from relaxed DNA. The TopoI activity was performed 
with K562 cells according TopoGen protocol as described in next section. 
 
 
Figure 2. 3. Gel image showing the results of TopoI relaxation activity assay (from 
www.TopoGen.com)  
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2.8.1. Lysate preparation.    
Following elutriation 5x10
6– 107 of cells  in G1, S and G2/M phase were harvested by 
centrifugation and washed twice in 5 ml of cold TEMP buffer (10 mM Tris-HCL, 
pH=7.5, 1mM EDTA, 4 mM MgCl2, 0.5 mM PMSF). Cells were then suspended in 3 
ml of cold TEMP buffer and left on ice for 10 min. Next, cells were homogenized in a 
tight-fitting Dounce homogenizer and checked for nuclei content by phase microscope. 
The nuclear fraction was then pelleted by centrifugation at 1500 x g for 10 min at 4 
0 
C 
washed in 1 ml of TEMP buffer and centrifuged at 1500 x g for 2 min (4 
0
C). The 
remaining nuclear pellet was suspended in a small volume (3 to 4 pellet volumes) of 
cold TEP buffer (10 mM Tris-HCL, pH=7.5, 1mM EDTA, 0.5 mM PMSF). An equal 
volume of 1M NaCl was added and samples were left on ice for 40 min followed by 
centrifugation at 15000 x g for 30 min (4
0 
C). The supernatant was then collected and 
total protein concentration was measured by BCA assay. 
2.8.2. TopoI relaxation activity. 
Nuclear lysates were diluted in TEP buffer  containing 0.5M NaCl, to obtain equal 
amount of protein per 1 µl. Sample reaction in a volume of 20 µl was assembled by 
mixing 16 µl of distilled H2O2, 2 µl of 10x assay buffer (100 mM Tris-HCL pH 7.9, 10 
mM EDTA, 1.5 M NaCl 1% BSA, 1 mM spermidine, 50% glycerol), 1 µl supercoiled 
DNA and 1 µl of test extract. After incubation at 37
0 
for 40 min, the reaction was 
terminated by adding 5 µl of 5x stop loading buffer (5% sarkosyl, 0.125% bromophenol 
blue, 25% glycerol). Samples were loaded on to a 1% agarose gel and electrophoresis 
was run at 2.5 V/cm in TAE buffer (40 mM Tris, pH=8, 20 mM acetic acid, 1 mM 
EDTA,) until the front of the loading buffer reached the end of the gel. The gel was than 
stained with 0.5 µg/ml ethidium bromide for 20 min, and briefly washed in distilled 
water. Images were captured on camera with the GelDoc system and a trans illuminator. 
2.9. Parp-1 activity assay  
The PARP activity experiments described in section 3.6 were kindly performed by 
Tomasz Zaremba  (an experienced user of this technique)  (Zaremba et al., 2011). The 
activity of PARP was measured by the method validated to GCLP standard that was 
used as a pharmacodynamics endpoint for clinical trials. This assay measures PARP 
activity that has been maximally stimulated by a double-stranded ologonucleotide in the 
presence of excess NAD
+
, therefore eliminating error due to variable activation of the 
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enzyme by DNA damage accidentally introduced during processing. The PARP activity 
was measured in asynchronous and elutriated K562 cells in triplicate samples collected 
from 3 independent experiments. 10
4
 cells were permeabilised with digitonin and the 
PARP activity was stimulated  in a reaction mixture containing 350 µML NAD
 +
 and 10 
µg/mL oligonucleotide (CGGAATTCCG) (Europrim, Invitrogen, UK) in a reaction 
buffer of 100 mM Tris-HCl, 120 mM MgCl2 (pH 7.8) in a final volume of 100 µL for 6 
min at 26°C. After blotting onto a nitrocellulose membrane (Hybond-N, Amersham, 
UK), the poly(ADP-ribose) was detected following incubation with the primary anti-
PAR 10H antibody (1:1000 diluted)  then a HRP-conjugated goat anti-mouse secondary 
antibody (1:1000 Dako, Ely, UK) and finally ECL reaction and chemiluminesence 
detection. Results were expressed relative to the number of cells loaded by reference to 
a purified poly(ADP-ribose) standard curve (0-25 pmol: Enzo Life Sciences). 
2.10. H2AX detection by immunofluorescence. 
Immunostaining of histone H2AX is a sensitive technique used for detection of DNA 
DSB. This approach was used in this thesis with the K562, EM9 and AA8 cell lines. 
The adherent EM9 and AA8 cells prior to treatment and staining for H2AX were 
growth onto microscope cover-slips. The suspension K562 cells following treatment 
were washed with cold PBS, and deposited using cytospin centrifuge onto microscope 
cover-slips placed on top of microscope glass. Next samples were fixed in cold 
methanol at -20 
o
C for 10 min, and re-hydrated with three changes of PBS for 30 min 
and blocked in blocking buffer (10% milk in PBS) for 1 hour. Cells were than incubated 
with primary antibody specific to phospho serine 139 of histone H2AX  (diluted 1:1000  
clone JBW301, mouse monoclonal antibody; Upstate, Millipore Corp which were 
diluted in blocking buffer containing 0.1% of TritonX-100) for 1h at 37 
o
C. Cells on 
covers-slips were washed 3 times for 10 min in PBS with 0,1% TritonX-100, and 
secondary antibody (goat polyclonal to Mouse IgG antibody Chromeo™ 546) was 
applied at a dilution of 1:1000 for 1h at 37
o
C. After the washing step (3x 10 min in 
PBS) coverslips were mounted onto microscope slides using Vector-shield Mounting 
Medium (Vector Laboratories, Peterborough, UK). For each sample, two images of 
DAPI and 2 corresponding images of H2AX were recorded on an Epi-fluorescence 
Microscope using Image Spot Advance software. The exposure time for H2AX 
fluorescence was 1111 ms, with gain 8 and gamma 1. The exposure time and gain was 
set using sample with expected higher fluorescence signal, so the recorded 8-bit images 
were not overexposed, 
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2.10.1. PZFociEZ - ImageJ custom macro.   
ImageJ is a public image processing program developed at the NIH. In this thesis 
ImageJ custom macro PZFociEZ was used for the analysis of the H2AX foci by 
measuring foci fluorescence intensity and number of focus within single analysis step. 
In Appendix possible applications for macro end examples of Image analysis were 
described. 
Some similar macros have been written before, and results were compared with the 
results obtained by visual scoring and FACS analysis (Kataoka et al., 2006, Cai et al., 
2009), The PZFociEZ macro that I have written is a first of this type where a 
combination of ImageJ built in functions and macros was combined together to provide 
all necessary tools for analysis of the H2AX. The principle of automatic analysis with 
macro is shown on Figure 2. 4 and Figure 2. 5. Figure 2. 4 shows the sequence of steps 
applied during creation of nucleus outlines. Figure 2. 5 shows subsequent steps of 
H2AX foci analysis are visualised and described. The basic idea lying behind this 
analysis is to reduce the image background leaving only the fluorescence signal, which 
belongs only to single foci. This can be seen in Figure 2. 5 surface plot 2s-5s. The 
image background (pixels outside the nucleus) and cell non-specific background was 
reduced with the aid of ImageJ Subtract Background options which uses the rolling ball 
algorithm. This was achieved by generation of the background image that was later 
subtracted from original image. After this step it was usually necessary to subtract a 
constant value from all images to remove any remaining background. For counting foci 
the Find Maxima option was used.   
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Figure 2. 4. A sequence of operation during generation of the selections for DAPI 
stained nucleus implemented in MaskEZ panel of the PZFociEZ macro 
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Figure 2. 5. A sequence of operation applied during analysis of images with H2AX 
foci by FociEZ panel 
The area in rectangular selections was used to generate a surface plot (images 2s-5s) that 
illustrates changes of the image during each analysis step.  
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2.10.2. Comparing image analysis between ImageJ and Image ProPlus software. 
To confirm that PZFociEZ macro is working, a comparison of analysis was performed 
on images recorded on two different fluorescence microscopes and analysed with the 
aid of PZFociEZ macro and Image ProPlus (commercially available image processing 
software). The sample cells used for this comparison were prepared as described in 
section 5.3. Briefly, the EM9 cells were exposed to temozolomide for 4 h and stained 
for H2AX as described in section 2.10. For this comparison images corresponding to 
control samples (no primary antibody and DMSO) and sample treated with 1000 nM 
TMZ were recorded on Olympus and Leica fluorescent microscopes. (Figure 2. 6).  So 
far several approaches have been applied for theH2AX foci quantification using image 
analysis reviewed in (Bocker and Iliakis, 2006). Analysis of H2AX foci is usually 
performed by visual counting of foci formed around DNA breaks or by measuring 
fluorescence intensity for whole nucleus or single foci. To obtain results described in 
these section 8-bit and 16-bit images were processed using ImageJ software with 
customized macros and Image ProPlus Software. Using Image ProPlus DAPI images 
were used to create the nucleus selection and then used for measurement of integrated 
density of the H2AX image. The background was measured at several places on the 
image and average was subtracted from measurements of foci integrated density. Using 
PZFociEZ macro images were analysed as described on Figure 2. 5 and Figure 2. 5, by 
measuring Integrated density and counting foci. First the DAPI Images were used to 
create outlines for each nucleus. Those outlines were than saved by ImageJ and used 
later for measurements performed on a second, corresponding image that was recorded 
for H2AX. The H2AX images prior to measurements were processed to reduce 
background and improve resolution of foci, as described in the previous section. The 
integrated density represents the sum of all pixel intensity values. For counting foci, the 
Find maxima option was applied. This option with given noise tolerance (10 for 8-bit 
images and 1000 for 16-bit images) enumerates single foci as pixels with highest value 
within area specified by noise tolerance value. Maxima are ignored if they do not stand 
out from the surroundings by more than this value. In other words the threshold is set at 
the maximum value minus noise tolerance and the contiguous area around the 
maximum above the threshold is analysed. For accepting a maximum this area must not 
contain any point with a value higher at than the maximum. Only one maximum within 
this area is accepted (see Appendix). Figure 2. 7 A and D shows that there that results 
obtained with Image ProPlus (A, D) are similar to the results obtained with ImageJ 
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(Figure 2. 7 B,E). A similar pattern was observed when counting of foci on 8- and 16 bit 
images were performed using ImageJ. A score almost 4 times higher in foci number is 
seen for 16 bit images resulting from higher resolution of images recorded on Olympus 
microscope. 
 
Figure 2. 6. Images of H2AX foci obtained using two different microscopes 
The EM9 cells seeded on microscope coverslips were treated for 4h with 0 and 1000 
nM of temozolomide and the level of DSB was evaluated by H2AX immunostaining. 
Images from the same samples of no primary antibody, untreated (0nM TMZ) or treated 
(1000nM TMZ) were recorded using Olympus (16-bit) and Leica (8-bit)fluorescent 
microscopes equipped with Hammamatsu and RTColour SPOT cameras respectively. 
 
Although some differences in absolute values were obtained comparing results of 
analysis between two-used software’s the overall trend in biological meaning is the 
same.  For several reasons the PZFociEZ macro was preferred over ProPlus. The macro 
provides better flexibility when choosing necessary options for image analysis. Macro 
reduces time needed for preparing nucleus outlines and for inspection of outlines 
accuracy. It is also freeware software available to all without any Licencing restriction 
therefore this may results in more common usage in scientific community.   
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Figure 2. 7. Comparison of the results analysis with the aid of PZFociEZ macro and Image ProPlus softwares of images obtained from 
Olympus and Leica microscopes 
16-bit images recorded on Olympus and 8-bit images recorded on Leica microscope were analysed using PZFociEZ macro and Image ProPlus software. 
Figure A,D Foci Integrated density measured using Image ProPlus, Figure B,E foci Integrated Density measured using PZFociEZ macro, Figure C, F 
number of H2AX foci counted using PZFociEZ macro. 
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2.11. Western blotting. 
Preparation of protein lysates.  
For K562 cells protein lysates were prepared as described in section 2.8.1. For AA8 and 
EM9 cell lines, cells in exponential growth phase (70% confluence) were trypsinsed, 
washed twice in cold PBS, and equal number of cells (2x10
6
) were lysed by addition of 
~3x cell pellet volumes of  SDS lysis buffer (6.25 mM Tris HCl pH 6.8, 2% SDS, 10% 
glycerol, 0.125% (w/v) bromophenol blue)  and heated to 95C for 5 min.   
 
BCA protein assay. 
To enable an equal amount of protein to be loaded onto the gel, a protein assay was 
conducted on all samples using Pierce BCA Protein Assay Kit (Pierce, Rockford IL).  
The assay is based on the reduction of Cu
2+
 to Cu
1+ 
by protein in an alkaline medium. In 
the first reaction step (biuret reaction) peptides, containing three or more amino acid 
residues chelates copper in an alkaline environment and form a light blue complex. 
In the second reaction step, bicinchoninic acid (BCA) reacts with the cations that were 
formed in step one producing an intense purple-coloured reaction product which results 
from the chelation of two molecules of BCA with one cuprous ion. The absorbance of 
this product can be measured on a spectrophotometer at 560 nm.   
The amount of protein in samples was evaluated based on standard curve of known 
BSA concentration range (0.125-2 mg/ml) set in triplicates for each concentration on a 
96-well plate. The BCA reagent provided with assay kit was mixed in a ratio of 25:1 
reagent A to reagent B and 200 µl added to each well.  The plate was incubated at 37 
0
C 
for 30 min and the absorbance of solution in each well was measured at 560 nm on a 
plate reader. The concentration of proteins in protein lysates was calculated by 
comparison to the standard curve.   
The cell lysates of known protein concentration were diluted in the buffer used for lysis 
to obtain equal volumes of sample with desired protein concentration. Protein dilutions 
were prepared and mixed with SDS lysis buffer containing 5% β-mercaptoethanol and 
heated to 90 
0
C for 5 min.  
Protein lysates along with molecular weight markers (MagicMark™ XP Western 
Protein Standard; Invitrogen, Paisley, UK) were loaded onto NuPAGE® Novex Bis-
Tris pre-cast gels (Invitrogen). After electrophoresis, the protein was transferred from 
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the electrophoresis gel to a nitrocellulose membrane (Hybond C, Amersham, Bucks, 
UK). The membrane was then blocked in 5% (w/v) dried milk in TBS Tween (50 mM 
Tris, 150 mM NaCl, with 0.05% Tween 20). 
The primary antibody applied to the membrane was diluted 1/1000 in 5% milk in TBS 
Tween and mixed for at least an hour using a Roller mixer. The membrane was washed 
three times in TBS Tween before following by application of the appropriate secondary 
antibody, diluted at 1/1000 dilution, in 5% milk (as above) which was mixed for 1 h as 
above. The membrane was washed 3 times for 10 min in TBS Tween to reduce non-
specific binding of the antibody.  Proteins immobilised on membrane were detected 
using an ECL kit (Amersham) added directly to the membrane for the required length of 
time.  
2.12. Statistical analysis. 
Data described in this thesis were analysed using One-way, or N-way analysis of 
variance depending on experiment design. The results of statistical analysis are given in 
format e.g. F(n-1, N-1)=f, where f is the F statistic of  the two numbers in parentheses, 
and  n= the number of groups and N=number of cases. This is used to calculate the 
mean sum of squares for the groups and cases to obtain f. The p value is then calculated 
for F. When the F statistic was significant at the level of 0.05, comparison between 
relevant groups was performed using a t-test to compare two samples or Fisher LSD test 
for multiple comparisons.  
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Chapter 3. Cell cycle dependent effect of PARP-1 inhibition on 
topoisomerase I poison-induced cytotoxicity in cells. 
3.1.  Introduction 
As described in the introduction, cell killing by TopoI poisons is thought to be largely 
due to conversion of TopoI-associated SSB to DSB by collapsed replication forks 
during S phase (section 1.5.3). It is possible that drug induced potentiation by PARP 
inhibition is strictly S phase dependent and there is some evidence in the literature to 
support this hypothesis.  
For example, in one of the earliest studies the effect of PARP-1inhibition on CPT-
induced cytotoxicity was demonstrated by Mattern et al. 1987. In this study, inhibition 
of PARP-1 by 5 mM 3-AB was shown to increase CPT-induced cytotoxicity by 1.5-fold 
in L1210 mouse lymphocytic leukaemia cell line after 16h exposure, but had no effect 
when 60 min incubation was applied (Mattern et al., 1987). These authors attributed 
sensitisation to the direct effect of PARP-1 on the TopoI activity. That is, in the absence 
of PARP inhibitor TopoI can be constantly poly (ADP-ribosylated) resulting in lower 
activity. Therefore, inhibition of PARP leads to loss of the inhibition of TopoI. Since 
the activity of TopoI can be correlated with elevated CPT-induced cytotoxicity because 
more DNA damage is generated, this can lead to increased sensitivity to TopoI poisons.  
In a later study, Smith et al. 2005 demonstrated that CPT-induced cytotoxicity in K562 
cells was time-dependent with the GI50 being 5 nM for 16h exposure and 30 nM for 30 
min. These authors also found that the PARP inhibitor AG14361 (at a concentration of 
0.4 µM) caused 2-fold sensitisation of the 16h exposure to CPT, but no sensitisation of 
the 30 min CPT exposure, confirming Mattern's observation. 
The data described above shows that inhibition of PARP-1 activity during continuous 
exposure to TopoI poison, for at least one cell doubling time, potentiates TopoI poison-
induced cytotoxicity and growth inhibition approximately by 2-fold, in various cellular 
models. The molecular mechanism behind this phenomenon is poorly understood, and 
there are some conflicting reports between data obtained with cell free and in vitro 
systems. 
For example, Yung et al. 2004 used cells co-transfected with fluorescent-tagged PARP-
1 and TopoI and demonstrated that unmodified PARP1 co-localizes with TopoI in live 
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cells, throughout the cell cycle due to direct protein-protein interactions. Following 
induction of DNA damage, this interaction is disrupted as was demonstrated by the 
reduced fluorescence signal of the co-localised proteins. Then, using cell free assays 
these authors demonstrated the interaction of TopoI with unmodified PARP1 was 
shown to enhance TopoI activity, and increase the TopoI-DNA binding affinity. They 
also showed that, the poly(ADP-ribosyl)ation of TopoI by PARP-1 regulates their 
interactions, and reduces TopoI activity. TopoI activity was reduced when the reaction 
was carried in the presence of automodified PARP-1 or even only with free poly(ADP-
ribosyl) polymers. These observations suggest that inhibition of PARP-1 activity will 
prevent poly(ADP-ribosyl)ation of TopoI that eventually elevates its activity, and on the 
other hand, DNA repair may be retarded due to PARP-1 inhibition. (Yung et al., 2004). 
 These findings are in contradiction to results obtained by Smith et al. who investigated 
effect of PARP inhibition on TopoI activity in K562 cells. TopoI activity was measured 
in a cell free assay, in a reaction containing supercoiled plasmid and nuclear extract 
prepared  from cells exposed to 0.4 µM AG14361for 30 min and 16h. These studies 
showed that PARP-1 inhibition does not affect TopoI relaxation activity.  This was 
further confirmed by experiments showing that inhibition of PARP-1 activity by 
AG14361 had no influence on cleavage complex formation induced by 10 µM CPT 
after 30 min incubation, These data support the alternative  hypothesis, that potentiation 
of CPT-induced cytotoxicity by PARP inhibitors involves repair of TopoI poison-
mediated DNA damage. This hypothesis is also supported by earliest studies of Barrows 
et al. who investigated CPT-induced cytotoxicity using parental AA8 and its 
BER/SSBR defective derivate EM9 cell line by its mutation of XRCC1. The effect of 
loss of XRCC1 conferred hypersensitivity to CPT-induced cytotoxicity and is expected 
to be similar to the effect obtained by PARP-1 inhibition because these two proteins act 
alongside in BER pathway. Using this model, Borrows demonstrated that 1h exposure 
to CPT of AA8 cells resulted in specific killing of cells being in S phase, whereas in 
EM9 cells CPT- caused death both in S phase and non S phase cells. Treatment of AA8 
cells with the DNA replication inhibitor aphidicolin protected them from CPT-induced 
cytotoxicity, but did not have an effect on EM9 cells. This suggests that repair of CPT-
induced DNA damage during DNA replication contributes to the cytotoxic effect of 
TopoI poison, rather than TopoI level or activity which was shown to be similar in both 
cell lines. (Barrows et al., 1998). 
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The cytotoxic activity of TopoI poisons is attributed to specific killing of the S phase 
cells. Nevertheless the consequences of exposure of cells to CPT are more complex and 
final results of its action depends on the cell line, drug concentration and exposure time, 
and cell cycle phase during which cells were exposed to drugs. For example, in 
lymphocytic leukaemia L1210 cells the consequences of exposure to CPT are 
manifested by delayed progression of cells through G2 phase and increased fraction of 
cells with aberrant ploidy. Identical treatment condition applied to myelogenous 
leukaemia HL-60 or KG1 cell lines caused rapid death of S and G2 phases (Del Bino et 
al., 1990). Goldwasser et al. provided another example that supports the complexity of 
CPT action. In their study, the mechanism of CPT-induced cytotoxicity was 
investigated in SW620 and KM12 colon carcinoma cell lines, chosen for experiments 
because of their markedly different sensitivity to CPT, despite similar level of TopoI 
protein. They showed that after 1h treatment with 1µM CPT, the more sensitive SW620 
cells showed impaired replication elongation and were irreversibly blocked in S phase, 
whereas the cells that were resistant to CPT were arrested in G2 phase. Treatment of 
these cell lines with aphidicolin, resulted in minimal protection from CPT-induced 
cytotoxicity in KM12 cells and more pronounced protection in SW620 (Goldwasser et 
al., 1996). These data suggest that DNA replication is a determinant of sensitivity to 
TopoI poisoning in cells that are inherently sensitive to CPT to a extent in CPT-resistant 
cells.  
Detailed studies, showing the cellular response to 1 hour exposure to topotecan, in the 
context of the phases of the cell cycle and various concentrations of topotecan, with the 
IGROVI (ovarian cancer) cell line, was published by (Lupi et al., 2004). Using 
propidium iodide and BrdU labelling for identification of cells in specific cell cycle 
phases they showed that the effect of topotecan treatment on cells follows complex 
dose- and time-dependent cell cycle block, growth delay and cell death scenario 
depending in which phase of cell cycle cells were exposed to topotecan. For example, 
cells exposed to topotecan in G1 or G2/M phase underwent a transient block before 
progressing to S-phase. This block was concentration-dependent and higher 
concentrations resulted in prolonged arrest and increased rate of cell death. The majority 
of cells exposed to drug in S-phase were killed or blocked  in S or G2/M for prolonged 
periods (3 days) following exposure to even low drug concentrations (< 1µM) of 
topotecan (Lupi et al., 2004).  
68 
 
In summary, the cellular response to TopoI poisons is complex and drug dosage, 
duration of treatment and influence of cell cycle phase on drug specificity all need to be 
taken into account. TopoI poisons have been used in chemotherapy for various types of 
cancer. Overcoming the commonly observed resistance to TopoI poisons is an aspect 
currently challenged by many studies. PARP-1 inhibitors are promising agents, which 
can be used as modifier of this resistance, and this thesis aims to verify their role in 
potentiation of CPT-induced cytotoxicity.  
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3.2. Aims 
Previous data show in multiple cell systems that the cytotoxic effect of TopoI poisons is 
selective to S phase cells and that PARP-1 inhibitors potentiate TopoI poison-induced 
cytotoxicity, however these two observations have not been linked. The question to be 
answered is: Does the inhibition of PARP activity sensitize cells to CPT at all phases of 
cell cycle, or is the sensitization cell cycle phase specific? 
Therefore, the aim of this chapter was to investigate the effect of PARP1 inhibition on 
TopoI I poison-induced cytotoxicity in cells that have been separated into different 
phases of the cell cycle by a non-stressful method. Potentiation of CPT-mediated 
cytotoxicity by the potent PARP1 inhibitor AG014699 was investigated in Lovo 
colorectal cancer cells growing asynchronously and after synchronization into G1, S, 
and G2-phase by centrifugal elutriation. The role of PARP1 inhibition in TopoI poison-
induced cytotoxicity was also studied in the K562 cell line. The K562 cell line was 
chosen due to superior elutriation capability and previously characterised response to 
CPT and PARP1 inhibitor treatment. The protein levels of TopoI and PARP1, as well as 
their enzymatic activity were determined for each cell cycle phase. 
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3.3. Effect of PARP1 inhibition on TopoI poison-induced cell cytotoxicity in 
elutriated and asynchronously growing Lovo cells. 
3.3.1. Effect of AG014699 on CPT induced cytotoxicity in Lovo cells after long and 
short exposure  
TopoI poisons are used clinically to treat colorectal cancer as described in section 1.5.3. 
Therefore the colorectal cancer cell line Lovo was selected for studies on potentiation of 
CPT-induced cytotoxicity to PARP inhibitors. To investigate the effect of AG014699 
on CPT-induced cytotoxicity in asynchronous cells, survival of cells following a short 
pulse (1h) and prolonged (24h) exposure to CPT±AG014699 was determined by 
clonogenic assay. 
Asynchronously growing Lovo cells were exposed to increasing CPT concentrations in 
the presence or absence 0.4 µM AG014699. This concentration was chosen because in 
previous studies it was shown that the similar, but less potent PARP inhibitor, AG14361 
at a concentration of 0.4 µM reduced PARP activity in K562 cells by 90% and was not 
cytotoxic to cells (Smith et al., 2005). Similarly, AG014699 was shown to be non-toxic 
(at 0.4µM), inhibiting PARP activity >90% in L1210 cells and was used to 
chemosensitise at 0.4 µM in SW620 cells  (Thomas et al., 2007). The cell cycle 
doubling time for Lovo cells is approximately 24h. Therefore, cells were exposed to 
drugs for 24h to cover a complete cell cycle. After the exposure period, cells were 
trypsinized and plated at known density for colony formation assay. Figure 3.1 A shows 
the cytotoxicity curve for Lovo cells exposed to CPT±AG014699 for 24h. Treatment of 
Lovo cells with CPT for 24h induced a sigmoidal concentration-dependent decrease in 
cell survival (Figure 3.1 A). Co-incubation with AG014699 significantly increased CPT 
induced cytotoxicity by 2-fold (LC50, camptothecin alone = 0.55 ± 0.033 nM, 
camptothecin + AG014699 = 0.29 ± 0.024 nM, t-test p = 0.09). During 24h exposure 
the majority of Lovo cells progressed through S-phase where they were exposed to CPT 
and killed. The survival curve for the 24h exposure reached a plateau phase at the level 
of 5-6% survival, and this reflects a sub-population of drug-resistant cells. The final aim 
was to determine the effect of CPT ± AG014699 in Lovo cells separated into different 
cell cycle fractions. After elutriation, Lovo cells will be in suspension and immediately 
treated with drugs for a short period (1 h) so that they do not progress to the next cell 
cycle phase. They therefore will not have enough time to attach to the surface of culture 
dish. An experiment was performed to investigate whether the cytotoxic effect of the 
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short pulse of CPT ± AG14699 treatment has the same effect on cells in suspension and 
adherent cells (Figure 3.1. B, C). Lovo cells were detached from plate surface by 
trypsinisation, spun down, re-suspended in fresh medium end exposed to CPT 
±AG014699 for 1h. After the exposure period, cells were centrifuged to remove drug, 
diluted into desired density and plated in known number for colony formation. In 
parallel adherent cultures of exponentially-growing Lovo cells were exposed to the 
same concentrations of CPT ±AG014699 for 1h. The cytotoxicity curves were obtained 
by plotting drug concentration versus percentage of cell survival and used to estimate 
dependency of treatment condition on drug induced-cytotoxicity (Figure 3.1 B, C). A 
concentration-dependent increase in CPT-induced cytotoxicity was also observed in 
asynchronous adherent and suspension cells after 1h exposure (Fig. 3.1 B and C) with 
approximately half the cells being killed at 10 nM and most of the remaining cells being 
resistant to concentrations as high as 300 nM. Comparing cell cytotoxicity induced by 
CPT during 1h incubation with 24 h incubation, a maximum of 45% cells were killed by 
10 nM CPT after 1h exposure, compared with 95% at 24 hr. The 45% of cells killed in 
10 nM CPT for 1h most probably correspond to the fraction of cells that were in S 
phase. Flow cytometric analysis of asynchronous cells indicated that approximately 
40% of cells are in S-phase (data will be shown in next section - Figure 3. 2). However, 
with prolonged incubation time (24 h) more cells go through S phase are killed, and 
hence the curve is a typically sigmoidal response. At a concentration of 10 nM, CPT 
was 10-fold less cytotoxic after 1h exposure than 1nM after 24h exposure. 
 The survival curves for adherent and suspension Lovo cells treated with CPT ± 
AG014699 enter plateau phase around 50-60% of survival, which makes calculation of 
LC50 very inaccurate, therefore comparisons of LC50 can be misleading. Instead of 
LC50, survival values taken from individual experiments for specified concentrations 
were used to compare differences between adherent and suspension cells and verified by 
t-student test. Results of the survival comparison shown in Table 3. 1 shows that there 
was no statistically significant differences in the treatment of Lovo adherent versus 
Lovo suspension cells between 30 nM CPT (p=0.38) and CPT±AG014699 (p=0.53). 
The same was for 100 nM CPT(p=0.23) and  CPT±AG014699 (p=0.8). The potentiating 
effect of AG014699 was not significant in both treatment conditions at concentration 30 
nM CPT (p=0.28 for adherent; p=0.48 for suspension), but was 1.2-fold (adherent) and 
1.4 (suspension) higher when CPT was used at concentration of a 100 nM (p=0.004 for 
adherent; p=0.0038 for suspension 
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Figure 3. 1. Effect of 0.4 M AG014699 on CPT induced cytotoxicity in Lovo cell line. 
(A) Lovo cells treated with 0.1, 0.3, 1, 3, and 10 nM CPT ± AG14699 for 24h. (B) Lovo cells treated with 10, 30 100 and 300 nM CPT ± 
AG14699 for 1h. (C) To mimic elutriation outcome where adherent cells have no time to attach to the plate, Lovo cells were trypsinised, re-
suspended in fresh medium and treated with 10, 30 100 and 300 nM CPT±AG14699 for 1h. Plot shows pooled means from at least 3 
independent experiments 
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% survival   
  adherent suspension adherent/suspensionp-value
 
30 nM 47.6±2.1 53.0±2.1 0.9
ns 
30 nM + AG14699 44.5±1 49.7±4.8 0.9
 ns
 
potentiation 1.1
ns
 1,1
ns 
 
100 nM 43.6±1.4 49.8±2.3 0.9
 ns
 
100 nM + AG14699 35±1.1
 
36.3±2.7 1
 ns
 
potentiation 1.2
** 
1.4
** 
 Table 3. 1.  Comparison of survival of adherent and suspension Lovo cells.   
The values of cell survival obtained from each of 3 independent experiments for 30 and 
100 nM CPT±AG014699 were used to determine differences between adherent and 
suspension Lovo cells using t-student test. Data represent mean ± SEM. Statistically 
significant differences at level .05 were denoted using * 
 
** - p<0.001, CPT vs. AG014699 
ns – Not significant at p=.05 
 
 
3.3.2. Separation of Lovo cell into different cell cycle fractions by centrifugal 
elutriation 
To obtain significant quantities in different phases of the cell cycle for subsequent 
experimentation, large quantities of exponentially growing asynchronous cells were 
required. 
Separation of the Lovo cell line into G1, S, and G2 cell cycle phases was performed by 
centrifugal elutriation as described in section 2.6. Typically, 1.5-2.5x10
8
 cells in 
exponential growth phase were collected by trypsinisation, spun down, re-suspended, 
and dispersed into a single cell suspension in 5 ml medium using a syringe with needle. 
The prepared cell suspension was injected into the elutriation chamber and subsequent 
fractions were washed out by increasing the flow rate of elutriation buffer.  Collected 
fractions were analysed for the presence of cells in the specific cell cycle phase by flow 
cytometry. 
Figure 3. 2 shows the cell cycle distribution of asynchronous Lovo cells and isolated 
cell cycle fractions. In exponential growth phase the cell cycle distribution of Lovo, 
contained 45% cells in G1, 40% in S and 20% in G2-phase. Eventually, elutriation 
allows separation of Lovo cell into fractions enriched in cell cycle phase specific cells 
to a maximum of 90% for G1, 55% for S and 65% for G2 cells. The efficiency of 
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elutriation for Lovo cell line was very poor. The fraction collected during elutriation 
contains maximally 60% of cells injected into elutriation chamber. The rest of the cells 
remain in chamber until the end of elutriation process. Despite many attempts, it was 
problematic to obtain better efficiency and purer cell cycle fractions. Lovo cells are very 
difficult to disperse into single cell suspension. Additionally, dispersed cells when 
introduced to the elutriation chamber tend to create multi cellular clumps that disturb 
buffer flow through the chamber, which significantly reduces resolution of collected 
fractions.  Another disadvantage of the Lovo cell line is the presence of a population of 
aneuploid cells that contaminates S and G2 fractions. 
 
Figure 3. 2. DNA histograms of asynchronous and elutriated Lovo cells. 
Asynchronously growing Lovo cells (A) were elutriated into specific cell cycle phase 
(B – G1, C – S, D – G2) and cell cycle distribution of collected fractions was analysed 
by flow cytometry. Obtained data were processed with ModFit LT software that allows 
automatic detection of cell cycle phases and ploidy of analysed cells.  
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3.3.3. Effect of AG014699 on CPT-induced cytotoxicity in elutriated Lovo cells. 
Previous experiments confirmed that CPT±AG014699-induced cytotoxicity in adherent 
Lovo cells is similar to cytotoxicity in Lovo cells treated in suspension. Therefore, it 
should be possible to conduct similar experiments on elutriated cells.  
The AG014699-induced potentiation of CPT-induced cytotoxicity was investigated by 
clonogenic assay in Lovo cells synchronised in specific cell cycle phase by elutriation.  
The content of cell cycle phase specific cells in each collected fraction was determined 
by flow cytometry and fractions containing 88% of G1, 55% of S and 65% of G2-phase 
cells were used for cytotoxicity assay.  
Table 3. 2 shows data collected from one successful experiment, therefore it should be 
interpreted with caution. The treatment of cell cycle phase synchronized Lovo cells with 
CPT at concentration of 30 nM reduced cell survival in all cell cycle fractions, but this 
was more pronounced in S phase. Increasing the concentration to 100 nM did not cause 
any further reduction in cell survival of G2 cells, but there was a modest decrease in 
G1with a greater effect seen in S phase.  
AG014699 potentiated CPT-induced cytotoxicity only in S phase separated cells by 1.6-
fold for 30nM CPT and by 1.9-fold for 100 nM CPT. CPT-induced cytotoxicity was 
unaffected by AG014699 in G1 and G2-phase cells. This most likely suggests that G1 
and G2 phase cells are a resistant population found in asynchronous cells (Table 3. 2). 
The results presented here cannot be verified, as no other successful experiments were 
performed, but the data are in agreement with other reports that show S phase specific 
cytotoxicity of TopoI poisons. The difficulties of trying to obtain pure G1, S, and G2 
fractions made Lovo an unsuitable model for these studies; therefore, studies with this 
cell line were discontinued in favour of cells that grow in suspension. 
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% survival 
 
G1 S G2 
30 nM 53.2 36.1 57.4 
30 nM + AG14699 58.3 21.9 57.5 
potentiation 0.9 1.6 1.0 
100 nM 45.3 26.0 58.5 
100 nM + AG14699 59.3 13.6 53.6 
potentiation 0.8 1.9 1.1 
Table 3. 2. Effect of AG14699 on TopoI poison (CPT) induced cytotoxicity in Lovo 
cells elutriated on G1, S, and G2 cell cycle phases. 
To confirm the S phase specific cytotoxicity, cells were separated by centrifugal 
elutriation into G1, S, and G2 phases prior to drug treatment. The table presents data 
from a single experiment where Lovo cells were elutriated treated for 1h with 
CPT±AG14699 before plating for colony formation. 
 
3.4. Effect of PARP1 inhibitor on TopoI poison-induced cell cytotoxicity in 
elutriated and asynchronously growing K562 cells. 
Because of the disadvantage of Lovo cells for efficient elutriation, this cell line was 
replaced by the K562 human myelogenous leukaemia cell line. Several published 
papers describe usage of various elutriation systems for cell cycle synchronisation of 
K562 cells confirming excellent predisposition of this cell line for the elutriation 
process (Kauffman et al., 1990, Banfalvi et al., 2007). The elutriation efficiency 
reported in those publications corresponds to the efficiency obtained with the protocol 
applied for experiments performed in this thesis. 
The K562 cell line has also been used for the investigation of the effect of PARP1 
inhibition on TopoI poison-induced cytotoxicity in earlier studies, where it was reported 
that K562 cells respond to PARP1 inhibitor-TopoI poison treatment (Smith et al., 2005).  
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3.4.1. Growth of asynchronous K562 cells.  
The purpose of this experiment was to find the optimal seeding density for K562 cells 
for routine maintenance of cells in culture and preparation of large quantities of 
exponentially growing cells. The K562 cells were seeded at a density of 1x10
4
 cells/ml 
and allowed to grow to maximal density.  The growth was examined by counting of 
cells at 24h intervals.  Two passages were performed using cells taken from the stock 
culture whose growth curve is shown on Figure 3. 3 Curve A. The first passage, 
occurred when cells were in exponential growth phase at density of 4.6x10
5
 cells/ml 
(Figure 3. 3 Curve B) and the second, when cells reached confluent phase at a density of 
1.5x10
6 
cells/ml (Figure 3. 3 Curve C). The growth kinetics of cells taken from an 
exponentially growing culture was unaffected and rapid. However, when cells were re-
seeded from a confluent culture, their growth was markedly reduced.  (Figure 3. 3 
Curve C). Based on these data, to obtain sufficient numbers of cells, K562 cells were 
seeded at a density of 1x10
4
 cells/ml 3 days before the elutriation experiment. All 
subsequent experiments were done using cells taken from exponentially growing culture 
whose density did not exceed 5x10
5
 cells/ml.  
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Figure 3. 3. Growth curve for K562 cells 
Asynchronous K562 cells were seeded at a density of 1x10
4
 (Curve A) cells/ml and 
counted every 24 hours. After reaching density 5x10
5 
(Curve B) and 1.2 x10
6
 (Curve C) 
cells/ml cells were re-seeded at a density of 1x10
4
 cells/ml and counting was repeated 
every 24 hours.  
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3.4.2. Separation of K562 cells into different cell cycle fractions by centrifugal 
elutriation.  
To obtain a sufficient number of cells in each fraction for subsequent experiments, 1.5–
2.5 x10
8
 of exponentially growing K562 cells were usually used. Cultured cells were 
collected by centrifugation, re-suspended in 5 ml medium, and injected into the 
elutriation system. By increasing stepwise the velocity of buffer flow, 16 fractions were 
collected and their purity was analysed by flow cytometry and the purest fractions were 
selected for subsequent experiments. Figure 3. 4 shows a representative analysis of the 
cell cycle distribution of K562 cells taken from asynchronously growing culture and the 
distribution of elutriated fraction selected for subsequent experiments. In exponential 
growth phase, the K562 cell culture consisted of 35% of G1, 54% of S and 11 % of G2-
phase cells (Figure 3. 4 A). Depending on the number of cells used for elutriation, it was 
possible to obtain between 1.5 x10
7
 and 4x10
7 
cells in fractions most enriched (above 
85%) with a cell cycle phase specific cells (Figure 3. 4 B, C, D). 
 
Figure 3. 4. DNA histograms of asynchronous and elutriated K562 cells 
K562 cells were subjected to elutriation as described in material and methods. Among 
18 collected fractions, fraction enriched with G1, S, and G2 cells were used for 
subsequent experiments. Representative DNA histograms of asynchronous (A), G1 (B), 
S (C) and G2 ((D) cell cycle phase are shown.  
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As the cytotoxicity of TopoI poisons is cell cycle phase-related, determination of the 
duration of each phase was necessary to ensure that drug-treatment is performed at the 
appropriate time. To accomplished this, K562 cells synchronized in G1-phase were 
allowed to grow in an incubator and progression to next cell cycle phase was verified by 
flow cytometry every 2h (Figure 3. 5). Results presented in Figure 3. 5 show changes in 
cell cycle distribution of G1 cells over the time and progression to next cell cycle phase. 
Cells were synchronized in G1-phase and placed in an incubator directly after 
elutriation (Figure 3. 5 A). Progression to the next phase was almost complete by 4 
hours (Figure 3. 5 B, C). At that time more than 90% of synchronised G1 cells moved to 
S phase. The S phase was lasted for the next 4h (Figure 3. 5 D, E).  Between hour 8 and 
10 of incubation, S phase cells entered G2-phase (Figure 3. 5 F). These results shows 
that synchronized cells should be exposed to drug within the first hour after elutriation 
and this was rigorously applied for all subsequent experiments. 
 
Figure 3. 5. DNA histograms of progression through cell cycle of K562 cells elutriated 
on G1-phase K652 
K562 cells were elutriated and G1 phase cells were seeded and incubated for 0 (A) 2 
(B), 4 (C), 6 (D), 8 (E) and 10 (F) hours. Flow cytometry analysis of cell cycle was 
performed after each time point and DNA histogram was plotted.  Representative 
histograms are shown.    
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3.4.3. Effect of elutriation process on K562 cell growth.   
Within the 2 hours that were required to complete the elutriation process, cells 
experience various procedures, which can be damaging to them. To ensure that the 
elutriation process does not have a negative impact on cells, their ability to grow after 
elutriation was investigated. 
Exponentially growing K562 cells were subject to elutriation as described in material 
and methods (section 2.6.1). Collected fractions were analysed by flow cytometry, and 
fractions that contained above 85% of cells in G1, S and G2 cell cycle phase were 
selected for XTT assay, which was performed every 24 hours. The growth curves for 
K562 cells separated by cell cycle fractions were compared with growth curve of 
asynchronous un-elutriated cells and are presented in Figure 3. 6. There were no 
statistically significant differences between the growth rate of asynchronous cells and 
elutriated cells, which confirms that the elutriation process is not harmful to cells. 
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Figure 3. 6. Growth curve for asynchronous and elutriated on G1, S and G2 cell cycle 
phases K562 cells. 
K562 cells were elutriated in sterile condition. Asynchronous, G1, S, and G2 cells were 
seeded at 2000 cells/well in 96 well plates. The XTT assay was performed at 24-hour 
intervals. Growth curves represent Mean +/- SEM from 3 independent experiments.  
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3.4.4. Effect of AG014699 on TopoI poison-mediated growth inhibition in 
asynchronous and elutriated K562 cells. 
As was demonstrated earlier in this chapter, AG014699 potentiated CPT-induced cell 
cytotoxicity in asynchronous and S phase elutriated Lovo cells. The purpose of this 
experiment was to ensure that s similar effect could be observed in K562 cells that were 
chosen as a better model for the elutriation. 
The effect of PARP inhibition on CPT-induced cytotoxicity in K562 cells was 
previously investigated using the PARP inhibitor, AG14361 at a concentration (0.4 µM) 
that reduced cellular PARP-1 activity by 90%, but did not have a growth inhibitory 
effect on K562 cells (Smith et al., 2005). Treatment conditions applied in our 
experiment refer to those used by Smith, where potentiation of AG14361 was 
investigated in K562 cells exposed to CPT for 30 min. In the growth inhibition 
experiment here, K562 cells were exposed to 3 nM and 10 nM CPT ± 0.4 µM 
AG014699 for 1h to evaluate the effect of the drugs in relation to cell cycle phase. 
The K562 cells were separated into cell cycle fractions by centrifugal elutriation. The 
content of cell cycle specific cells in each collected fraction was evaluated by flow 
cytometry and fractions containing above 85% cells in specific cell cycle phase were 
used for growth inhibition experiments. After 1h exposure to CPT± AG014699, drugs 
were removed from the medium by centrifugation and cells were allowed to grow in 
drug free medium for 5 days. The growth inhibitory effect of CPT±AG14599 was 
determined by XTT assay. 
Data presented in Figure 3. 7 shows that CPT has only a modest effect on the growth of 
asynchronous cells, for which there was no statistically significant differences in growth 
inhibition caused by 3 nM and 10 nM of CPT. For K562 cells synchronized in G1-
phase, 1h incubation with 3 nM CPT decreased cell growth by 4% and with 10 nM CPT 
by 7%. A similar effect was recorded for G2-phase cells where 3 nM CPT reduced cell 
growth by 11% and 10 nM CPT by 15% compared to untreated G2-phase cells. The 
potentiation of CPT-induced growth inhibition by AG014699 was not statistically 
significant and did not exceed 10% in asynchronous, G1 and G2 cells exposed to 3 nM 
and 10 nM CPT. In contrast, statistically significant CPT-induced growth inhibition was 
observed in K562 cells synchronized in S- phase, where incubation with 3 nM CPT 
reduced cell growth by 17% (p=0.03), and with 10 nM CPT by 39% (p=0.002) 
compared to untreated cells. The growth of the S-phase cells exposed to 3 nM CPT was 
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significantly reduced (by 17%, p = 0.038) when cells were incubated simultaneously 
with CPT and 0.4 mM AG014699. Co-exposure of the S phase K562 to 10 nM CPT and 
AG014699  for 1h resulted in a further 10% growth reduction compared to cells treated 
only with 10 nM CPT, but this reduction was not statistically significant (p=0.09). 
Data obtained in this experiment shows that the growth inhibitory effect of 
CPT±AG014699 in K562 and cytotoxicity induced by those drugs in Lovo cells were S 
phase specific. K562 cells were exposed to a lower CPT concentration than Lovo cells, 
which could explain the weaker inhibitory effect of CPT±AG014699 in K562 cells. 
Therefore, subsequent experiments were performed at higher CPT concentrations.  
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Figure 3. 7. Effect of AG4699 on camptothecin induced growth inhibition in 
asynchronous and elutriated K652 cells, 
 Elutriated and asynchronous K562 cells exposed to 3 and 10 nM camptothecin ± 0.4 
µM AG14699 for 1h. After treatment, cells were seeded at 1000 cells/well and XTT 
assay was performed after 5 days of culturing.  Data are the mean of 3 independent 
experiment ± SEM.   
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3.4.5.  Effect of PARP1 inhibitor on TopoI poison-induced cell cytotoxicity in 
elutriated K562 cells.  
The effect of anticancer drugs on cells can be measured by inhibition of cell growth and 
that may not reflect cell killing. The principle of the XTT assay is based on tetrazolium 
salt reduction by viable cells, and reflects the number of cells remaining after drug 
treatment. Results obtained from the XTT assay depend on proportional relationship of 
measured absorbance and the number of viable cell in culture. The measured signal may 
come from metabolically active cells whose fate is not yet decided. In addition a 50% 
reduction in XTT readout could represent: a) killing of 50% of the cells, with the 
remaining 50% growing at the same rate as controls or, b) a reduction of the growth rate 
of all of the cells such that they underwent one less cell doubling compared to control 
cells during the culture period, or c) a combination of some cell kill and some reduction 
in growth rate. For this reason XTT assays should be considered as growth inhibition 
rather than cytotoxicity assays. To determine how many cells are actually killed a 
colony forming, or clonogenic, assay must be performed. The clonogenic assay 
evaluates cell viability based on ability of single cells to re-proliferate and form a 
colony after exposure to drug. This assay more precisely represents the cytotoxic drug 
effect as opposed to the cytostatic effect, which can be important in the case of drugs 
whose activity is time-dependent. The clonogenic survival of K562 cells was 
investigated for determination of cytotoxic effect of camptothecin and its potentiation 
by AG14699.  
The data presented in section 3.4.4 shows that CPT-induced growth inhibition and its 
potentiation by AG014699 in KS62 cells is highest in S-phase. To confirm that this 
represents enhanced cell killing, potentiation of CPT-induced cytotoxicity in KS62 cells 
by AG0l4699 was evaluated by clonogenic assay. As the CPT concentration used in 
growth inhibition experiments appeared to be too low for IC50 determination, the 
clonogenic assay was done using higher concentrations.  
K562 cells were elutriated to obtain fractions enriched in G1, S and G2 cells. 
Asynchronous and elutriated cells were then exposed to camptothecin in the presence or 
absence of 0.4 µM AG14699 for 1h and plated out at a known density for colony 
formation. 
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The result in Figure 3. 8 show that CPT-induced cytotoxicity was concentration-
dependent for asynchronous and elutriated cells. CPT (10nM) significantly reduced cell 
viability in AS (p=0.034) and S-phase cells (p=0.005), but not in GI (p=0.06) and G2-
phase cells (p=0.069) when compared to un-treated cells. Incubation of cells with 100 
nM CPT was significantly cytotoxic in all assayed cell fractions (p<0.0006). 
Cytotoxicity induced by 10 nM CPT in S-phase cells was significantly l.4-fold (p=0.02) 
higher than cytotoxicity induced by 10 nM CPT in G1- phase cells, but not significantly 
different from 10 nM CPT in G2-phase (p=0.19). Cytotoxicity induced by 100 nM CPT 
in S-phase was 2.7-fold higher than in GI-phase (p=0.0001) and 3.4-fold greater 
(p=0.004) then in G2-phase. In S-phase cells AG0l4699 caused a significant 2.4-fold 
potentiation of the cytotoxicity of 10 nM CPT (p=0.02) and 1.9-fold (p=0.04) 
potentiation of 100 nM CPT. AG014699 also potentiated CPT-induced cytotoxicity by 
1.3-fold at 100 nM in G2-phase cells. AG014699 did not significantly increase CPT-
induced cytotoxicity in G 1 cells. 
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Figure 3. 8. Effect of AG14699 on CPT induced cytotoxicity in asynchronous and 
elutriated K562 cells. 
Asynchronous and elutriated cells in G1, S and G2 cell cycle phases K562 cells were 
exposed to 10 and 100 nM CPT ± 0,4 µM AG14699 for 1 h. Cytotoxicity was measured 
by sloppy agar clonogenic assay and expressed as percentage of control. Data are mean 
of 3 independent experiments ± SEM.  
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3.5. Variation in TopoI activity in different cell cycle phases  
The results presented in the previous section show that AG014699 had the biggest 
impact on CPT-induced cytotoxicity in K562 cells synchronized in the S phase of the 
cell cycle. Is also generally known that the cytotoxicity of CPT that is characteristic of S 
phase cell cycle is associated with the process of DNA replication. As has been 
described in the introduction of this thesis, one possible mechanism responsible for the 
resistance of cells to CPT-induced cytotoxicity is via reduction of TopoI activity.  
According to the hypotheses described in the introduction to this chapter, reduced 
activity of PARP-1 can re-activate and enhance the ability of TopoI to bind to DNA and 
thereby increase the amount of DNA damage, however, there is no evidence connecting 
this observation with TopoI activity in a particular cell cycle phase. Therefore, in this 
section, the TopoI activity was measured in different phases of the cell cycle in order to 
correlate the activity of TopoI with the cytotoxicity of CPT and the effect of AG014699 
on the cytotoxicity induced by CPT.  
TopoI activity was measured for cells in the different phases of the cell cycle that were 
obtained by the elutriation of asynchronous K562 cells. The method used to measure the 
activity of TopoI has been described in detail in section 2.8 and is based on the ability 
of TopoI to relax supercoiled plasmid DNA in the reaction medium, which lacks of 
ATP thereby preventing TopoII-mediated relaxation.  
 
For this purpose, cells synchronized in G1, S, G2, and asynchronous K562 were used to 
prepare nuclear extracts, which after measuring the protein concentration were diluted 
in order to obtain the same amount of protein in an equal volume in order to keep 
reaction conditions constant. Then, a series of dilutions were prepared so that the lowest 
(0.01µg) and highest (0.15 µg) correspond to the concentration of undetectable and 
detectable activity of TopoI relaxation, respectively. The results of this experiment are 
shown in Figure 3. 9. This figure shows the product of reaction catalysed by TopoI as 
relaxed and supercoiled plasmid DNA separated on 1% agarose gel (Figure 3. 9 A). The 
results of this reaction were quantitatively measured using the program ImageJ by 
measuring the integrated density of relaxed and supercoiled plasmid and presented in a 
graph (Figure 3. 9. B and B1) as a percentage of the fraction of relaxed plasmid.  
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As expected TopoI relaxation activity increases with increased amount of nuclear 
extract present in the reaction mixture. The activity of TopoI varies between the phases 
of cell cycle. The largest fractions of relaxed plasmid were observed in the S phase 
cells, with nearly 100% of supercoiled plasmid being relaxed by 0.15 µg of nuclear 
extract.  In G2 phase the activity of TopoI was approximately 20% lover for all nuclear 
extract concentrations comparing with TopoI activity in S phase. For 0.15 µg of nuclear 
extract prepared from G1 and asynchronous cells relaxed less than 40% of supercoiled 
plasmid.  
The high activity of TopoI in G2 phase and residual activity in G1 phase can be 
possibly explained as a part of the S phase cells which contaminates the G1 and G2 
fractions. The TopoI activity observed in G1 fraction may be related to a portion of G1 
cells which transverse to S phase after elutriation was completed. The number of S 
phase cells contaminants in G2 fraction can be  estimated approximately at 15% - 20%. 
This is possible because of the last 3 to 4 fractions of cells collected during elutriation 
were combined together to obtain enough G2 phase cells for subsequent experiments. 
Comparing the TopoI activity curves for S and G2 phase in Figure 3. 9 B1, these curves 
have a similar slope, however, the curve corresponding to G2 phase is shifted to the 
right. It is therefore possible the activity of TopoI derived from contamination of S 
phase cells was propagated linearly with increasing concentrations of nuclear extract, 
and suggests that the activity of TopoI in S phase is not only the main activity of TopoI, 
but most likely corresponds to the only TopoI activity observed in K562 cells. 
These data convincingly correlate with the results obtained in section 3.4.5 and suggest 
that the highest cytotoxicity induced by CPT in the S phase of cell cycle may be related 
to highest activity of TopoI in the S phase.  
In the next section, this discovery will be juxtaposed with the activity of PARP-1 in the 
different phases of the cell cycle. 
 
  
87 
0.01 0.02 0.04 0.08 0.15
0
20
40
60
80
100
AS
G1
S
G2
B
Nuclear extract [g]
T
o
p
o
I 
ac
ti
vi
ty
 [
%
 o
f 
re
la
x
e
d
 p
la
sm
id
]
0.00 0.05 0.10 0.15 0.20
0
20
40
60
80
100
AS
G1
S
G2
B1
Nuclear extract [g]
T
o
p
o
I 
ac
ti
v
it
y 
[%
 r
el
ax
ed
 p
la
sm
id
]
0.00 0.05 0.10 0.15 0.20
1
10
100
AS
G1
S
G2
50
Nuclear extract [g]
T
o
p
o
I 
a
c
ti
v
it
y
lo
g
 [
%
 r
e
la
x
e
d
 p
la
sm
id
]
B2
 
Figure 3. 9.  TopoI relaxation activity in asynchronous and elutriated on G1, S and G2 
K562 cells. 
Nuclear extracts were prepared from asynchronous and elutriated cells. 1 µl of these 
extracts containing from 0.01 to 0.15 µg protein was incubated with 1µg of supercoiled 
plasmid for 40 min.  Reaction products were separated on agarose gel. A) Gel image -
(Sc) is a negative control and corresponds to supercoiled plasmid, (R) is a positive 
control corresponding to relaxed plasmid. B, B1, B2) The gel was than quantified using 
ImageJ gel analysing options as described in section 2.8  
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3.6. Variation in PARP1 activity in different cell cycle phases. 
The results described in the previous section indicate that the cytotoxicity induced by 
CPT in the different phases of the cell cycle is associated with TopoI activity in these 
phases. Because inhibition of PARP activity increased the cytotoxicity of CPT mainly 
in the S phase of the cell cycle it is possible that this is due to PARP being more active 
in the S phase as compared to other phases of the cell cycle. To investigate this 
possibility, PARP activity was measured in asynchronous K562 cells, as well as those 
separated into the G1, S, and G2 cell cycle phase using elutriation. This experiment was 
carried out exactly as described in section 2.9. Figure 3. 10 shows the activity of PARP 
is different in phases of the cell cycle. The lowest activity of PARP was observed in the 
G1 phase. PARP activity increases along with the progression of cells to the next phase 
of the cell cycle. In comparison to PARP activity in G1 phase the activity of this protein 
in S phase was significantly 1.6-fold higher (p<0.001, LSD test). PARP1 activity in G2-
phase was approximately 2-fold higher than in G1 phase (p<0.001, LSD test) which 
exactly correlates with the increase in DNA content by cell cycle progression. Since the 
activity of proteins is often correlated with its expression in a cell, in the next section 
the level of PARP-1 and TopoI will be examined in elutriated fractions of K562 cells. 
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Figure 3. 10. PARP activity. 
Exponentially growing K562 cells were elutriated and fractions containing >90% cells 
in G1, S and G2 cell cycle phase were used to measure PARP1 activity as described in 
section 2.9. Data are the mean ± SEM of three independent experiments.   
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3.7. Variation in PARP-1 and TopoI proteins level in different cell cycle phases. 
In many types of cancers, elevated levels of TopoI have been observed which is used as 
a marker for chemotherapeutic efficacy (Pfister et al., 2009). The level of protein in the 
cells is often correlated with its activity.  However, if not, it means that for changes in 
activity, other factors such as post-translational protein modification  may be 
responsible. The level of protein in K562 cells was measured by Western blot. For this 
purpose, K562 cells were elutriated and 8 consecutive fractions were collected and used 
to prepare protein extracts, which was separated by SDS page electrophoresis. 
The results of this experiment are shown in Figure 3.11 On these graphs, it can be seen 
that the level of TopoI seems to increase with the progression of cells through 
subsequent phases of the cell cycle, even though its activity is higher in S phase than in 
G2. Therefore, it is possible that TopoI undergoes some post-translational activation in 
S phase. In contrast, PARP-1 expression showed a peak in S phase, but with otherwise 
constant levels of expression. Again, this does not correlate with the highest activity 
being observed in G2. Therefore, based on these data, both proteins are subject to post-
translational activation or repressions.  
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Figure 3. 11. TopoI and PARP-1 protein level in elutriated fractions of K562 cells. 
K562 cells were elutriated into 8 subsequent fractions and DNA content was verified 
using flow cytometry (A). Cells from each fraction were used to obtain total protein 
extract that was used in Western blots, which were quantified with the aid of ImageJ 
Analyse Gel option (B). Figure shows data of one experiment. Data on the graphs 
shows the integrated density values for each band normalized to the integrated density 
of actin.  
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3.8. Discussion  
The aim of this chapter was to investigate the cell cycle phase-dependence of the 
potentiation of TopoI poison-induced cytotoxicity by PARP inhibition using 
centrifugally elutriated cells. Originally, the Lovo colorectal cell line was tested, 
because TopoI poisons derivatives are used clinically to treat colon cancer (Armand et 
al., 1995, Magrini et al., 2002). 
 
The data show that CPT-induced cytotoxicity was both time and concentration 
dependent. The level of cytotoxicity after 24h exposure of Lovo cells to CPT cannot be 
achieved with a short pulse treatment even for high CPT concentrations.  CPT at a 
concentration of 10nM reduced the survival of cells by 50% after 1h and by 90% after 
24h treatment. The shape of survival curves for 1h treatment shows that cytotoxicity 
reached plateau level at around 50-60% of survival. This indicates a sub population of 
resistant cells, most likely cell cycle phase-specific because the resistant population is 
lost when cells are exposed for a whole cell cycle. Based on the literature, this resistant 
population is likely to be cells that were not in S phase during the incubation period. 
The S phase selective CPT-induced cytotoxicity is also consistent with reports where 
CPT-induced cytotoxicity was reduced by the DNA polymerase inhibitor aphidicolin 
(Goldwasser et al., 1996, Borovitskaya and D'Arpa, 1998, Zhou et al., 2002). The cell 
cycle distribution analysis by flow cytometry shows that the population of 
asynchronously growing Lovo cells contains about 40% of cells in S phase (Figure 3. 2 
A),which can be related to 50% of cells killed after 1h exposure. The differences can be 
explained by the fact that cells progressing from G1 to S and S to G2 would also be 
exposed during the 60 min. Comparing this with 24h exposure during which >90% of 
cells were killed suggests that virtually all cells will have gone through S phase.  
Inhibition of PARP-1 activity by AG014699 in Lovo cells resulted in potentiation of 
CPT induced cytotoxicity during long and short pulse exposure to CPT. There was a 2-
fold sensitization of CPT-induced cytotoxicity during 24h exposure, which supports 
previous reports (Bowman et al., 2001a, Calabrese et al., 2004, Smith, 2005). It was 
also observed that AG014699 potentiates CPT-induced cytotoxicity during a short pulse 
exposure, which appeared to be greater than at 24 hr.  This may suggest that 
potentiation was greater for more sensitive S phase cells. To confirm the hypothesis, 
that the potentiation of CPT-induced cytotoxicity by AG014699 was S phase-specific 
CPT cytotoxicity in cell cycle phase synchronized cells was investigated. A cell cycle 
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block by chemical agents has been criticised because it may have impact on normal cell 
metabolism (Cooper, 2003). In the experiment here, instead of chemical agents, for cell 
cycle phase synchronisation, centrifugal elutriation was used, therefore excluding the 
possibility that the cytotoxic effect may be compromised by the action of a chemical 
block.  
Separation of adherent Lovo cells by elutriation involves different conditions for drug 
treatment where cells have to be exposed to the cytotoxic agent while being in 
suspension, which may result in unpredictable response to treatment. To eliminate this 
possibility, AG014699 potentiation of CPT-induced cytotoxicity was evaluated in Lovo 
cells that were exposed to drugs in suspension. The data obtained shows that CPT-
induced cytotoxicity and its AG014699-mediated potentiation for cells treated in 
suspension is similar to adherent cells.  
During work on the protocol, for optimisation for elutriation of Lovo cells it was found 
that this cell line was not an ideal model for this technique. For efficient elutriation, the 
cells have to be dispersed into single cell suspension, which was problematic for Lovo 
cells, as they tend to aggregate into multicellular clumps. The Lovo cell line is 
characterised as near diploid cell line with modal number of 49 chromosomes (Ribas et 
al., 2003). However, a subpopulation of aneuploid cells was shown to overlap with S 
and G2 fractions and compromise proper evaluation of elutriated fractions by flow 
cytometry.  
Using these conditions, AG014966 potentiation of CPT-induced cytotoxicity was 
demonstrated for enriched in G1, S, and G2 cell cycle phase cells by clonogenic assay. 
Although it was only one successful experiment, CPT-induced cytotoxicity was greater 
for the S phase enriched cells, whereas G1 and G2 cells were 2-fold more resistant. 
There was a 2-fold sensitization of CPT-induced cytotoxicity by AG014699, which was 
selective only to S phase fraction. 
Lovo cells were replaced by the K562 cell line, because of its better predispositions for 
elutriation.  This cell line was used previously as a model to study TopoI poisons. 
(Padget et al., 2000).  
The elutriation efficiency for K562 was greater than for Lovo cells, and this allowed  
collection of fractions where content of cell cycle specific cells was usually above 85% 
(Figure 3. 4).The growth of K562 was unaffected by elutriation procedures and 
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elutriated cells were able to reach their normal proliferating state directly after 
elutriation.  
After 1h treatment, CPT had a similar effect in asynchronously growing K562 cells as 
in Lovo cells, with survival around 50% at 100nM in both cell lines. At concentration of 
10 nM CPT was less cytotoxic in K562 cells, reducing their survival by 30% compared 
with a >50% reduction of survival in Lovo cells. AG014699 does not affect the 
cytotoxicity induced by CPT in asynchronous K562 cells, consistent with previous data 
showing that the cytotoxicity of short TopoI poison exposures are not increased by 
PARP inhibition (Smith, 2005).In contrast, there was a modest but significant 20-40% 
reduction in survival of Lovo cells, suggesting that the effect of AG014699 is cell 
specific. The differential effect cannot be explained by a higher fraction of S phase cells 
because the S phase population in Lovo cells is about 10% lower than that in K562 
cells.  
The results of cytotoxicity experiments with elutriated cells shows that in both Lovo 
(Table 3. 2) and K562 survival of G1 and G2 phase cells was 1.3 to 2-fold higher than S 
phase cells following a 1h exposure to CPT. K562 cells were marginally more sensitive 
than Lovo cells to 100 nM CPT in G1 and G2 and about twice as sensitive in S phase. 
AG014699 did not significantly enhance the cytotoxicity in either of the cell lines in Gl 
and G2 phase but there was approximately 2-fold sensitization of 100 nM in S phase of 
Lovo and K562 cells. 
Consistently, S phase K562 and Lovo cells were approximately twice as sensitive to 
CPT as G1 or G2 cells. In both cell lines, AG014699 caused the greatest enhancement 
of cytotoxicity in S phase with little or no potentiation in G1 and G2. TopoI poison-
induced cytotoxicity is often associated with the level of the TopoI protein in cells, 
which can be  used as a biomarker of clinical efficacy of TopoI poison (Pfister et al., 
2009). There is some evidence in the literature that protein levels and activity of TopoI 
changes during the cell cycle. For example, Tricoli et al. showed that activity of TopoI 
in synchronized cells of TopoI released from the block in the early G1 phase gradually 
increased, reaching a maximum in the S phase, and then decreased in the G2 phase at 
the same time increasing protein levels in this phase (Tricoli et al., 1985).  
Meyer et al. also demonstrated cell-cycle phase dependent behaviour of TopoI. 
According to their research, activity and protein level of TopoI increased, when the cells 
pass from G1 to G2-M phase (Meyer et al., 1997). These studies support the results 
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presented here, which show that the level of TopoI in K562 cells increases during the 
progression from G1 to G2. The possibility that increased level of TopoI observed in G2 
phase is caused by decreased binding with DNA during G2 phase and therefore better 
extraction efficiency cannot be excluded. However, this experiment was performed only 
once therefore these results should be interpreted with caution.  
The very high level of TopoI activity in the S phase (~ 100% relaxation of supercoiled 
plasmid with 0.15µg nuclear extract – Figure 3.9 ) was consistent with the greatest level 
of CPT cytotoxicity in S phase (Figure 3. 8). The highest activity of PARP in G2 phase, 
but only a moderate effect of AG014699 on CPT-induced cytotoxicity observed in this 
phase, suggests that the role of PARP-1 plays in the G2 phase is not sufficient to cause 
cell death. 
The highest killing rate in S-phase can be explained by implication of P ARP-1 in the 
repair of CPT-induced DNA breaks. During S-phase the CPT stabilised cleavage 
complexes can be converted into highly cytotoxic replication-associated double strand 
breaks. Inhibition of PARP-1 at this point leads to impaired repair that result in the 
highest killing rate of S-phase cells. The S-phase specific mechanism of cytotoxicity 
enhancement by PARP-1 inhibitors is not exclusive to TopoI. Similar results were 
demonstrated by Liu et al, who used a different PARP inhibitor, ABT-888, to enhance 
temozolomide-induced cell cytotoxicity. Their results show that temozolomide-induced 
cell cytotoxicity and potentiating effect of ABT-888 was higher for cells synchronized 
by double thymidine block in S-phase than for cell treated during G1-phase. Increased 
cytotoxicity in S-phase was correlated with the level of DSB, which resulted from 
conversion of SSB induced by temozolomide treatment (Liu, Shi et al. 2008). 
Here, for the first time cells synchronized without any stressful condition by centrifugal 
elutriation were used to investigate potentiation of TopoI induced cytotoxicity by 
inhibitor. S-phase specific AG14699 enhancement of CPT induced cell cytotoxicity 
implicates inhibition of DNA repair. To verify this hypothesis the level and repair of 
single and double strand breaks induced by CPT±AG14699 were  measured in elutriated 
K562 cells as described in the next chapter.   
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Summary 
 AG014699 potentiates TopoI induced cell cytotoxicity in asynchronous Lovo 
and K562 cells by 2-fold. 
 Elutriation efficiency is better for K562 than Lovo cells 
 Elutriation does not affect the growth of cells.  
 The PARP inhibitor AG014699 potentiates TopoI poison-induced growth 
inhibition and cell cytotoxicity in K562 cells predominantly in S phase. 
 TopoI activity is highest in S phase and TopoI protein levels increase along with 
cell cycle progression.  
 PARP1 activity increase with cell cycle progression  
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Chapter 4. The effect of AG014699 on the formation and repair of 
CPT-induced DNA damage.  
4.1.  Introduction 
Several lines of evidence in the literature show that inhibition of PARP-1 activity 
potentiates CPT-induced cytotoxicity. These observations have been connected with 
higher level of DNA breaks, observed in cells exposed to topoisomerase I poisons and a 
PARP inhibitor, compared to topoisomerase I poisons alone. One of the first reports 
providing such evidence came from Mattern et. al, who showed that the level of SSB in 
cells exposed to CPT, was higher when PARP-1 activity was inhibited with 3-AB 
(Mattern et al., 1987). Other results showing the role of PARP-1 in the repair of TopoI 
poison-induced SSB include a study by Bowman et. al, who demonstrated that the 
activity of PARP-1 was increased by CPT and that inhibition of PARP-1 activity by a 
specific inhibitor NU1025, at concentration of 200 µM, caused 2.5-fold enhancement of 
CPT-induced DNA breaks and a similar 2.6-fold increase in cytotoxicity in L1210 cells. 
These results demonstrated that the involvement of PARP-1 in TopoI-induced 
cytotoxicity is reflected by increasing the level of DNA breaks (Bowman et al., 2001b)  
Cleavage complexes stabilized by CPT are usually transient and disappear quickly after 
the withdrawal of the CPT. Various DNA lesion already present nearby TopoI-
processed DNA can convert cleavage complexes into lethal lesions, usually due to 
collision with the replication fork or during transcription. Different types of TopoI 
poison-mediated DNA lesions implicate a number of repair pathways (described in 
section 1.5.4) including BER, NHEJ and HR. The evidence for interaction between 
TopoI and PARP-1 were described in the recent literature (Malanga and Althaus, 2004, 
Baumann et al., 2006, Cimmino et al., 2007). The results of cell-free system 
experiments performed by Malanga and Althaus, where short oligonucleotides and 
purified proteins were used, shows that poly ADP-ribosylated PARP-1 or free ADP-
ribose polymers do not prevent the binding of TopoI to DNA or its dissociation. 
Poly(ADP-ribosyl)ation of TopoI resulted in two actions: decreasing DNA cleavage, 
and, when TopoI was already connected to DNA, increasing the ligation step. This was 
observed even when formation of cleavage complexes was enhanced by CPT (Malanga 
and Althaus, 2004). Related results were published by Park and Cheng, but according to 
those authors PARP-1 itself enhanced the TopoI relegation activity of CPT-stabilized 
cleavage complexes (Park and Cheng, 2005).  
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Studies of interactions between TopoI and PARP-1 investigated in intact cells provided 
conflicting results: Smith et al. 2005 used PARP-1 wt and PARP-1 null cells treated 
with the TopoI poison, topotecan, in the presence and absence of the potent PARP 
inhibitor AG14361, to demonstrate a) that PARP-1 was a determinant of sensitivity to 
topoisomerase I poisons and b) that AG14361 enhanced the TopoI poison-induced 
cytotoxicity in a PARP-1 dependent manner. These authors investigated the role of 
PARP inhibition on CPT-mediated TopoI-DNA cleavage complex formation in K562 
cells using the TARDIS assay. Exposure of K562 cells to CPT alone in concentrations 
up to 10 µM for 30 min showed a dose-dependent increase in the number of cleavage 
complexes, which was unaffected by co-exposure with 0.4 µM AG14361. Similarly, 
AG14361 had no effect on TopoI-mediated relaxation of supercoiled plasmid measured 
in nuclear extracts from K562 cells treated with 0.4 µM AG14361 for 30 min and 16h. 
In contrast, when DNA breaks were measured by alkaline elution, AG14361 was shown 
to increase the level of CPT-induced breaks. Moreover, AG14361 increased the 
persistence of DNA breaks at 30 min and 16 h after a 30 min pulse with CPT. These 
data suggest that PARP-1 activity does not regulate TopoI activity or cleavable complex 
formation but instead enhances the cytotoxicity of TopoI poisons by inhibiting repair of 
the DNA damage they induce.  
The repair of TopoI poison-induced DNA damage involves several molecular pathways 
which protein components are common with BER or DSB repair pathways (section 
1.5.4). This  implicates the role of PARP-1 in DNA repair. With regard to the repair of 
CPT-induced DNA damage with BER, PARP-1 is proposed to be activated by CPT-
induced DNA breaks to recruit XRCC1(El-Khamisy et al., 2003). XRCC1 was shown to 
enhance the activity of  TDP1 and PNK, which removes the TopoI from DNA living 
SSB behind (Plo et al., 2003). XRCC1 also participates in recruitment and assembly of 
other BER proteins including DNA polymerase β and DNA ligase III which complete 
the repair (Cappelli et al., 1997, Dianova et al., 2004). 
Involvement of PARP-1 in the repair of CPT-induced DNA breaks is also supported by 
results obtained using cells defective in one of DNA repair mechanism. Cells defective 
in  HR was shown to be 10-fold more sensitive to CPT, BER-defective cells were 5x 
more sensitive, but NHEJ-defective cells were only 30% more sensitive to CPT-induced 
cytotoxicity (Smith et al., 2005). These data suggest that HR is most important and BER 
next most important pathway involved in the repair of TopoI poisons-induced DNA 
damage. 
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The observations suggested by Mattern at al., or by Smith et al., that prolonged 
exposure to PARP inhibitors is required for its efficient sensitization of CPT-induced 
cytotoxicity, which is S phase dependent, is more consistent with the role of PARP-1 in 
DNA double strand break (DSB) repair.  
PARP-1 was shown to be involved in DNA DSB repair by NHEJ  possibly by 
involvement in a back-up non-homologous end joining pathway (B-NHEJ) (Audebert et 
al., 2004, Audebert et al., 2006, Audebert et al., 2008, Iliakis et al., 2008, Iliakis, 2009) 
and in HRR (Helleday et al., 2005).  Some evidence indicates that PARP and 
components of the NHEJ pathway compete in the repair of DSB (Veuger et al., 2004, 
Wang et al., 2006) but other evidence suggests they co-operate in the same NHEJ 
pathway (Mitchell et al., 2009) and yet further evidence indicates that PARP has no role 
in DSB repair (Noël et al., 2003). 
Data from chapter 3 shows that S phase cells were most sensitive to the cytotoxicity of 
CPT and also that AG014699 had the most pronounced effect on cytotoxicity in S phase 
cells. Different, cell cycle-dependent, CPT-induced cytotoxicity and sensitization by 
AG0144699 could not be fully explained by PARP-1 or TopoI activity and protein level 
in each cell cycle phase. Another possible explanation for the S phase specific effect of 
AG014699 on CPT-induced cytotoxicity could be related to the role played by PARP-1 
during induction or repair of DNA breaks caused by CPT. None of the studies 
previously conducted had investigated whether the effect of PARP inhibition on DNA 
breaks induction or repair is also cell cycle-phase specific.  
99 
4.2. Aims 
The aim of this chapter was to investigate the effect of AG014699 on the formation and 
repair of CPT-induced DNA breaks in cell cycle-separated K562 cells. The possibility 
that the S phase-specific enhancement of CPT-induced cytotoxicity by AG014699 was 
due to S phase-specific inhibition of DNA repair was investigated by measuring the 
level of single and double strand breaks induced by CPT±AG014699 using alkaline, 
neutral comet assay and H2AX immunofluorescence after short exposure to drugs.  
The effect of PARP-1 inhibition on the recovery from CPT-induced DNA breaks was 
also investigated in asynchronous and cell cycle separated K562 cells.  
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4.3. The level of DNA damage in K562 cells measured directly after elutriation 
Elutriation allows the separation of cells into cell cycle specific fractions avoiding usage 
of chemical compounds e.g. aphidicolin. However, during elutriation experiments, cells 
are exposed to a changing environment that may generate DNA breaks, for example, 
during sample handling, or when a highly condensed cell suspension is injected into 
elutriation system. The data presented in section 3.4.3 showed that the elutriation into 
cell cycle phase enriched fractions does not affect the growth of K562 cells. 
Nevertheless, it was important to demonstrate that the elution process does not induce 
any background DNA breaks. 
To exclude this possibility, exponentially growing K562 cells were separated into 
fractions enriched in G1, S or G2 cells as described in section 2.6.1. Fractions with the 
highest content of cell cycle phase-specific cells and an asynchronous population of 
cells were subjected to alkaline comet assay, and the extent of DNA damage was 
determined by measuring Olive Tail Moment (OTM) (as described in section 2.7). 
Two independent experiments were performed and the results are given in Figure 4. 1, 
which shows a scatter plot of individual OTM values measured for each cell cycle 
phase-specific cells. Histograms shown in Figure 4. 2 indicate that OTM values of 
asynchronous as well as G1, S and G2 phase cells does not fit to a normal distribution, 
however this can be corrected by transforming data by calculation of logarithm or using 
BoxCox transformation (Box and Cox 1964). Histograms showing data after BoxCox 
power transformation were shown in Figure 4. 2 on the right panel.  
Transformed values of OTM were used in statistical analysis in order to determine if 
there was a difference in the means of the OTM for two independent variables of the 
variable level of “cell cycle phase”- (asynchronous (AS), G1, S and G2) and the 
variable level of “experiment” - (exp1, exp2). For this purpose, variance analysis was 
applied with OTM as dependent variable and cell cycle phase and experiment as two 
independent categorical factors.  
There were no significant differences among the means of OTM for cell cycle phase 
separated groups (AS, G1, S and G2) F(3, 963) =2.4, p = 0.07 and  between  two 
analysed experiments F(1,3) =3.1, p = 0.08. This indicates that the mean of OTM is the 
same between cell cycle phases and that there were no overall divergences between the 
two analysed experiments.  These data conclusively demonstrate that the elutriation 
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process does not induce DNA strand breaks and that there are no consistent or 
significant differences between the different cell cycle phases in terms of DNA 
breakage or fragility. 
There is inter assay variation that is commonly observed in comet assay (Tice et al., 
2000), and in order to be able to pool experimental data and to compare between 
experiments, OTM was expressed as % of the asynchronous untreated control.  
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Figure 4. 1. OTM measured in K562 cells directly after elutriation.  
Asynchronous K562 cells, and K562 separated into different fractions of cell cycle 
phases were separated by centrifugal elutriation and the level of total DNA damage was 
evaluated in these cells using alkaline comet assay. The extent of DNA breaks was 
given by calculating OTM for more than 100 cells scored in each independent 
experiment. Horizontal lines denote means and vertical bars denote SD obtained by 
pooling data from two independent experiments.  
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Figure 4. 2. Histograms of the Olive Tail Moment measured in populations of 
asynchronous and cell cycle separated K562 cells 
Asynchronous cells (A1), cells elutriated into G1 (A2), S (A3) and G2 (A4) cell cycle 
phases. The effect of BoxCox transformation of the OTM is shown on the right (B1-
B4), and was applied to correct not-normal distribution. The numbers beneath each 
figure shows the results of Kolmogorov –Smirnoff test.  
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4.4. The effect of AG14699 on the level of DNA breaks induced by CPT in 
asynchronous cells and K562 cells  separated into cell cycle subpopulations  
 
In the previous chapter, AG014699 was demonstrated to potentiate CPT-induced 
cytotoxicity by 2-fold in Lovo cells after 1h and 24 h exposures to CPT. The results of 
clonogenic survival in elutriated populations of Lovo and K562 cells shows that 
sensitisation of CPT-induced cytotoxicity by AG014699 occurs predominantly in S 
phase. As described in the introduction, inhibition of PARP-1 sensitizes cells to CPT 
possibly via the role of PARP-1 in DNA damage repair or via regulation of TopoI 
activity (Malanga and Althaus, 2004). In this context, the results presented in this 
chapter were performed to verify the role of PARP inhibition in the generation of DNA 
breaks induced by CPT in each cell cycle phase.  
To investigate the effect of AG014699 on CPT-induced DNA damage in different cell 
cycle phases, asynchronous K562 cells along with cells separated into specific cell cycle 
phases were exposed to CPT at concentration of 0, 10, 100 and 300 nM in presence or 
absence of AG014699 for 30 min. Following incubation, cells were quickly moved to 
centrifugal tubes, spun down, and re-suspended in cold PBS. All procedures after 
incubation were performed on ice in subdued light to avoid additional DNA damage. 
The level of total DNA breaks was evaluated with alkaline comet assay by measuring 
OTM. The images in Figure 4. 4 show representative comets for each treatment 
condition applied in this experiment. Comet tails are longer on images recorded for cells 
treated with CPT and AG014699 than in cells exposed to CPT alone. Data presented in 
Figure 4. 5 and collated in Table 4. 1 show an increase in the level of breaks with 
increasing concentration of CPT in all cell cycle phases. The lowest increase was 
observed in G1 phase cells and the largest increase in the level of DNA damage for all 
CPT concentration used for treatment was seen in S phase cells. Incubation of cells with 
AG014699 increased  CPT-induced DNA damage in all phases of the cell cycle. The 
highest level of DNA breaks were seen in S phase cells treated with CPT and 
AG014699, followed by G2 phase cells (Table 4. 1).  
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Figure 4. 3. Comets observed after 30 min exposure to CPT ± 0.4uM AG014699 and 
determined using alkaline comet assay 
Asynchronous (AS) and cell cycle phase separated (G1, S, G2) K562 cells were 
exposed to CPT  at concentration of 0 nM (left panel), 10  nM (middle-left panel), 100 
nM (middle-right panel)  and 300 nM (right panel) with or without 0.4 µM AG014699 
for 30 min and alkaline comet assay was used to evaluate the level of SSB. Conditions -
ScottLab electrophoresis tank, 0.75V/cm, 30 min.   
105 
0 0
1
0
1
0
1
0
0
1
0
0
3
0
0
3
0
0 0 0
1
0
1
0
1
0
0
1
0
0
3
0
0
3
0
0 0 0
1
0
1
0
1
0
0
1
0
0
3
0
0
3
0
0 0 0
1
0
1
0
1
0
0
1
0
0
3
0
0
3
0
0
0
200
400
600
800
1000
1200
1400
AS G1 S G2
- + - + - + +- - + - + - + +- - + - + - + +- - + - + - + +-
CPT [nM]
AG014699
O
T
M
 [
%
 o
f 
c
o
n
tr
o
l]
 
Figure 4. 4. The effect of PARP-1 inhibition on the level of DNA breaks in 
asynchronous and cell cycle phase separated K562 cells. 
Asynchronously growing K562 cells were cell cycle phase separated and exposed to 0, 
10, 100 and 300 nM CPT±AG014699 for 30 min following measurement of the level of 
total DNA breaks by alkaline comet assay. On bar chart: white bars – CPT alone, grey 
bars – CPT+AG014699. Graphs shows mean  of OTM ± SEM of 4 independent 
experiments expressed as % of control untreated cells. 
 
          
  
CPT [nM] 
% 
increase in 
OTM 
CPT 
% 
increase in 
OTM 
CPT+ AG 
CPT vs 
CPT+AG   
p-value 
 
AS 
10 -30.1 286.2 0.00 
 
100 131.2 504.1 0.01 
 
300 270.0 589.1 0.02 
 
G1 
10 13.5 138.2 0.26 
 
100 72.3 414.8 0.02 
 
300 193.3 603.9 0.06 
 
S 
10 47.5 408.6 0.01 
 
100 308.4 677.1 0.03 
 
300 455.1 914.8 0.08 
 
G2 
10 -19.5 521.2 0.08 
 
100 289.3 610.7 0.13 
 
300 314.9 799.0 0.03 
      
Table 4. 1 Effect of AG014699 on CPT-induced DNA breaks 
Data in the table show the increase in OTM above control cells, expressed as % of 
control untreated cells. The numbers were calculated form values of OTM from 4 
independent experiments as shown in Figure 4. 4. 
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 % increase in OTM = (
           
           
    100) - 100  
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4.5. Determination of DSB level in K562 cells exposed to CPT± AG014699. 
In the previous section, the effect of CPT and AG01499 on DNA breaks was found to 
be most marked in S and G2 phase cells. The alkaline comet assay allows evaluation of 
the total level of DNA damage rather than just SSBs, although these will be the majority 
of the breaks. SSB induced by CPT are not cytotoxic per se, but under certain condition, 
these breaks can be converted to lethal DSB. Therefore, in this section the effect of 
PARP inhibition by AG014699 on the level of DSB induced by CPT was studied. DSB 
level can be measured using a variety of techniques including neutral comet assay and 
γH2AX immunostaining. 
4.5.1. The effect of AG14699 on the DSB level in asynchronous and elutriated K562 
cells determined by neutral comet assay. 
In this section, the level of DSB was investigated using the neutral comet assay. The 
drug treatment conditions for these experiments were the same as described in section 0. 
Representative photomicrographs of the comets for all treatment conditions used in this 
experiment are shown in  
Figure 4. 6 The effect of AG014699 on CPT-induced DSB in asynchronous and 
elutriated K562 cells. 
 Images collected in this figure show the variation in the length of comet tails in the 
cells depending on the concentration of CPT, the phases of the cell cycle and the 
presence of AG014699. Images collected on the left panel show DNA double strand 
breaks in the form of comets tails in control cells that were treated with DMSO or with 
DMSO and AG01499. One can note that the tail length varies depending on the drug 
treatment conditions used in this experiment. Tail length increases with increasing 
concentration of CPT (middle and right panel) indicating a concentration-dependent 
increase in DSBs. The length of the comet tail is greater in pictures showing cells 
treated with CPT+AG014699. The longest comet tails can be seen on the right panel for 
S phase cells exposed to 100 nM CPT+AG014699. These images indicate that cells in 
the S phase of the cell cycle accumulate most DNA DSB. 
Images shown in Figure 4.6. were used to measure the OTM and the results were shown 
in Figure 4. 7. and Table 4. 2. Comparing cells in different phases of the cell cycle, it 
can be seen that the largest increase in the level of DNA breaks is in S phase, where 10 
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nM CPT increased the level of the DSB by 58.8% and 100 nM by 134.3% above the 
level of control cells. AG014699 increased double-strand breakage in S and G2 phases 
by 1.3 to 1.8-fold. Although an increase in DSBs was also observed with CPT in G1 
phase cells (60.9% for 10 nM and 92.2% for 100 nM), incubation with AG014699 did 
not cause a significant increase. Like the data obtained in the previous section, these 
results show that the DNA damage caused by CPT is greatest in S phase and G2. The 
effect of AG014699 is also most evident in the S phase of the cell cycle. 
 
Figure 4. 5. Comets showing the level of DNA double strand breaks in K562 cells 
Asynchronous (AS) and cell cycle phase separated (G1, S, G2) K562 cells were 
exposed to CPT  at concentration of 0 nM (left panel), 10  nM (middle panel) and 100 
nM CPT (right panel)  with or without 0.4 µM AG014699 for 30 min and neutral comet 
assay was used to evaluate the level of DSB. Conditions -VWR electrophoresis tank, 
1V/cm, 30 min.   
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Figure 4. 6 The effect of AG014699 on CPT-induced DSB in asynchronous and 
elutriated K562 cells. 
Asynchronous (AS) and elutriated (G1, S, G2) K562 cells were exposed to 0 nM, 10  
nM  and 100 nM CPT ±  0.4 µM AG014699 for 30 min for evaluation of DSB level by 
neutral comet assay. Data on bar chart and in table shows mean + SE of single 
experiment expressed as a % of control with at least 100 cells analysed: White bars – 
CPT alone, grey bars – CPT+AG014699. 
  
          
 
 
  CPT [nM] 
% 
increase 
in OTM 
CPT 
% 
increase 
in OTM 
CPT+ AG 
CPT vs 
CPT+AG   
p-value, 
LSD 
fold 
increase 
 
 AS 
10 24.2 69.8 0.01 2.9 
 
 
100 81.0 110.6 0.20 1.4 
 
 G1 
10 60.9 59.8 0.96 1.0 
 
 
100 92.2 108.7 0.48 1.2 
 
 S 
10 58.8 106.8 0.03 1.8 
 
 
100 134.3 204.5 0.03 1.5 
 
 G2 
10 31.2 57.3 0.02 1.8 
 
 
100 97.1 123.1 0.29 1.3 
 
      
  Table 4. 2. Effect of AG014699 on CPT-induced DSB 
Data in the table show the increase in OTM above control cells, expressed as % of 
control untreated cells. The numbers were calculated form values of OTM as described 
in the legend to Table 4. 1 from 4 independent experiments as shown in  
Figure 4. 6 The effect of AG014699 on CPT-induced DSB in asynchronous and 
elutriated K562 cells. 
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4.5.2. The effect of AG14699 on CPT-induced DSB in asynchronous K562 cells 
evaluated by -H2AX 
In the previous section, the effect of AG014699 on CPT-induced DSB level in K562 
cells was demonstrated with the neutral comet assay. In this section, the level of DSB 
was measured by H2AX immunostaining and analysed with the aid of custom-created 
PZFociEZ macro (see also appendix). The macro was validated as described in 
materials and methods chapter in section 2.10.2 and here more details about analysis are 
given.  
After the exposure of cells to 10 and 1000 nM CPT±AG014699 for 30 min, drugs were 
removed by centrifugation and cells were attached onto microscope cover glass using a 
cytospin centrifuge. Cells were than stained with antibodies to γH2AX as described in 
section 2.10 and mounted on microscope slides with mounting medium that contained 
DAPI. H2AX foci were examined under fluorescence microscope and 8-bit images 
were recorded, for H2AX and DAPI. The sample with the expected highest 
fluorescence signal was used to adjust the microscope illumination and acquisition 
settings to avoid sample overexposure so the fluorescence signal did not exceed 8-bit 
range of record images. This was the critical step for further analysis. Raw images were 
processed using ImageJ software with customized macros as described in section 
2.10.1.  Fluorescence of DNA staining with DAPI was used to define the area occupied 
by DNA of each cells. The outlines created for each nucleus were saved by ImageJ and 
used later for measurements performed on a second, corresponding image that was 
recorded for H2AX. The H2AX images prior to measurements were processed to 
reduce background using the rolling ball algorithm to reduce uneven picture 
illumination, and improve resolution of foci, as follows. 
Using macros PZFociEZ several measurements can be automatically obtained. First, the 
Area of selection in calibrated units, such as square micrometres was measured. Next, 
the Raw Integrated Density within selection was measured (RawIntDen- the sum of the 
values of the pixels in the image or selection) and then Mean Grey Value (average grey 
value within the selection: This is the sum of the grey values of all the pixels in the 
selection divided by the number of pixels) was calculated. Finally, Integrated Density 
(IntDen) was calculated as the product of Area and Mean Grey Value which 
corresponds to foci intensity per nucleus. Finally, the number of foci was counted using 
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the options find maxima at the noise tolerance set to a value of 10 and output set to 
“count”. The find maxima options determine the local maxima in an image, and under 
given noise tolerance, maxima are ignored if they do not stand out from the 
surroundings by more than this value. In other words, a threshold is set at the maximum 
value minus noise tolerance and the contiguous area around the maximum above the 
threshold is analysed. For accepting a maximum, this area must not contain any point 
with a value higher at than the maximum. Only one maximum within this area is 
accepted. When the output is set to count, the ‘find maxima options displays’ the 
number of maxima in the Results window. 
It should be noted that because of background subtraction using the rolling ball 
algorithm, the background of the image takes the value 0, therefore remaining pixels 
with a value above zero correspond only to single foci (Figure 4. 7) 
 
Figure 4. 7. Sample image illustrating background subtractions (BG) using rolling 
ball algorithm. 
Images of H2AX foci were recorded using the Leica fluorescence microscope. Images 
were subjected to corrections for removing background and uneven illumination. As a 
result under given noise tolerance any background illumination was reduced to 0, 
leaving signal that is only associated with foci.   
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Figure 4. 8. The measurements of H2AX analysis obtained with ImageJ macro. 
K562 cells that were exposed to CPT at concentration of 0, 1, 10, 100, 1000 nM for 30 
min before staining for H2AX foci. Images of foci were scored and analysed with the 
aid of PZFociEZ macro.  
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The single focus that is represented by one maxima recognised by software under a 
noise tolerance possibly may consists of other points that belongs to the area of maxima 
but are not counted as a maximum due to noise tolerance restriction. This focus can 
possibly represent additional DNA breaks, e.g. a signal coming from below the focus 
that represents other DNA break. The option check settings for FociRB serves mainly 
for visual comparison of the results obtained by Find Maxima option with counting foci 
by eyes. However, it is possible to apply the lowest possible noise tolerance to count all 
possible maxima (e.g compare number of foci counted with noise tolerance 10 – 119 
foci, with noise tolerance 50 – 15 foci, Figure A19).   
Figure 4. 9 shows photomicrographs of γH2AX foci. Very weak staining was found in 
control cells (left panel), in these cells incubated only with DMSO, as well as those that 
were incubated with DMSO + AG014699. The middle panel of Figure 4. 9 shows 
examples of γH2AX foci staining pattern obtained with treatment with 10 nM CPT ± 
AG014699. It is obvious that there are more cells expressing a positive coloration. It 
may be noted that the emergence of a more intense staining of cells with cells incubated 
with CPT + AG014699. The largest number of cells with most intense staining is visible 
in the right panel. Particularly intense staining was seen in the S phase cells incubated 
with 1000 nM CPT + AG014699. The staining pattern in these photos is similar to the 
pattern that was obtained by staining of comets that is shown in Figure 4. 4 and  
Figure 4. 6 The effect of AG014699 on CPT-induced DSB in asynchronous and 
elutriated K562 cells. 
 and suggests that the S phase cells treated with CPT and AG014699 are most 
susceptible to DNA damage. These images were then analysed using a macro 
PZFociEZ, and the results of this analysis are shown in Figure 4. 10 and Figure 4. 11.  
Figure 4. 10 A and B shows a quantitative estimate made by measuring γH2AX 
integrated density (IntDen) and the number of Foci. These data show that there was an 
increase in the amount of DSB with increasing concentrations of camptothecin. For 
cells in the G1 phase incubation with CPT significantly increased the Integrated 
Density.  There were no significant differences in the number of foci counted for cells 
in G1 phase between 10 and 1000 nM. In the G1 phase AG014699 only slightly 
increased the Raw Integrated Density for a concentration of 1000 nM CPT, however, it 
had no effect on the number of foci. The largest increase following CPT treatment, both 
in Raw Integrated Density and foci number was observed in S phase cells. A 
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concentration-dependent increase in the number of foci and Raw Integrated Density was 
recorded also in G2 phase cells. Data in Figure 4. 10 A and B shows that in the higher 
CPT concentration (1000 nM), AG014699 did increase both the foci number and 
integrated density. AG014699 had the biggest impact on the foci number in the S phase 
of the cell cycle, increasing the number of foci approximately by 2-fold compared to 
CPT alone. The weakest effect of AG014699 on the number of foci was demonstrated 
in G1 phase cells. Inhibition of PARP activity in G1 cells resulted in in approximately 
1.1-fold increase in the foci number regardless of CPT concentration. These results are 
consistent with data published previously which show that a high CPT concentration is 
needed to induce DSBs in non-replicating cells that are in G0/G1 phase. In summary, 
these data are consistent with the results of neutral comet assays (section 4.5.1), and 
show that PARP inhibition enhances CPT-induced DNA DSB predominantly in S and 
G2 phases of the cell cycle  
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Figure 4. 9. H2AX immunostaining pattern found in K562 cells exposed to 
CPT±AG014699  
Images of asynchronous (AS) and elutriated K562 cells were exposed to 0 (left panel), 
10 nM (middle panel) and 1000 nM) (right panel) CPT in the presence or absence of 0.4 
µM AG014699 for 30 min before staining for H2AX.  
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Figure 4. 10. Plot of Foci Raw Integrated Density and Foci number categorised by cell 
cycle phase, PARP Inhibitor and CPT concentration 
K562 cells were separated into individual cell cycle phases using elutriation, after 
having been treated with CPT for 30 min and then stained for the presence of H2AX 
foci. Using the macro PZFociEZ, Raw Integrated Density was measured (A) and, the 
number of foci was counted (B) for each cell for the same experiment. Data show 
results of quantification obtained for one representative experiment. Data shows Mean ± 
SEM calculated from at least 100 cells from a single experiment. The white indicates 
cells exposed to CPT and the grey bars indicates cells exposed to CPT±AG014699. 
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4.6. The effect of AG014699 on the repair of DNA breaks induced by CPT in 
asynchronous K562 cells  
4.6.1.  Repair of CPT-induced total DNA breaks in asynchronous K562 cells. 
In the previous section, AG014699 was shown to have the most marked effect on CPT-
induced DNA break level in S phase cells. This could have been caused by an increase 
in the number of induced breaks or reduction in their repair during the 30 min exposure 
period. PARP-1 is considered to promote DNA repair, therefore to clarify whether the 
accumulation in DNA breaks the presence of AG014699 was due to inhibition of repair, 
the effect of AG014699 on the repair of breaks was determined following a 30 min 
pulse of CPT followed by incubation in drug-free medium or medium containing 
AG014699 for 30 min, 1h and 5h.  
Alkaline Comet images presented in Figure 4. 11 show a reduction of comet tails in 
samples incubated in fresh medium (-AG014699) and after 5h incubation most of the 
cells do not have any detectable tail, which suggests complete DNA repair. Comparing 
this to images recorded for samples incubated in medium containing AG014699, the 
reversal of comet tail is slower and, even after 5h of recovery period, a mixture of cells 
with small and very long tails can be observed. This suggests that in the asynchronous  
population some cells repair DNA damage quickly and some cells repair DNA damage 
more slowly. 
Data plotted in Figure 4. 12 and summarised in Table 4. 3 show the kinetics of repair of 
CPT-induced DNA breaks during incubation in drug free medium or medium 
containing AG014699. Exposure of the K562 cells to CPT caused a significant increase 
in DNA breaks by 1.5- fold at 10 nM CPT and by 2-fold at 100 nM.  
Incubation of cells in drug-free medium caused rapid reversal of DNA breaks induced 
by 10 nM and 100 nM CPT, with levels similar to control within 1h of recovery period 
(p>0.07) ( Figure 4. 12  and Table 4. 3). Exposure of cells to AG014699 during the 
recovery period caused a significant delay in the repair of DNA damage induced by 10 
and 100 nM CPT. The most marked effect of AG014699 on DNA damage repair for 
both CPT concentrations was observed at 30 min recovery period. At this time point, 
9% (10 nM) and 41% (100 nM) of DNA breaks remained (p<0.01) in the absence of 
AG014699 but substantial damage remained in the presence of AG014699. PARP 
inhibition reduced DNA repair by 96% at 10 nM CPT, and 44% at 100 nM CPT. 
AG014699 caused 40% reduction in repair of DNA breaks induced by 10 nM CPT and 
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27% in repair of breaks induced by 100 nM CPT at 1h. At the end of the recovery 
period treatment with AG014699 had resulted in a 24% inhibition of the repair of 
damaged DNA at both CPT. 
 
Figure 4. 11. The comets observed after 30 min exposure to 10 and 100 nM CPT 
followed by incubation in fresh medium ± 0.4 µM AG014699 as determined by alkaline 
comet assay.  
K562 cells were exposed to 0, 10 and 100 nM CPT for 30 min. CPT was removed and 
cells were incubated in fresh medium or medium with AG014699 for up to 5h . The 
level of remaining DNA breaks was evaluated by alkaline comet assay after 30min, 1h, 
5h after CPT removal. VWR electrophoresis tank, 0.75V/cm, 200-300 mA, 30 min.   
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Figure 4. 12.  Effect of AG014699 on the repair of total DNA breaks formed during 30 
min exposure to 100 nM CPT 
K562 cells were incubated with 10 and 100 nM CPT for 30 min following by incubation 
in drug-free medium or medium with 0.4 µM AG014699 for 30 min, 1h and 5h. The 
level of DNA breaks was measured by alkaline comet assay. Data show the average 
OTM + SEM calculated from the sample of 100 randomly selected cells obtained from 
two independent experiments. Data, expressed as a percentage of untreated control 
(speckled bar), are OTM after 30 min exposure to CPT (black bar) followed by recovery 
in fresh drug-free medium (white bars) or that containing 0.4 µM AG014699 (grey bars) 
for the indicated times.   
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CPT 
concentration 
Recovery 
time 
% Increase in 
OTM 
% Damage 
remaining 
% Damage 
repair 
% 
Inhibition 
by 
AG014699 
10 nM 
0min 51 
   
30min -AG 5 9 91 
 
30min +AG 49 97 3 96 
1h -AG 5 10 90 
 
1h +AG 24 46 54 40 
5h -AG 13 25 75 
 
5h +AG 22 43 57 24 
100 nM 
0min 95 
   
30min -AG 39 41 59 
 
30min +AG 64 67 33 44 
1h -AG 8 8 92 
 
1h +AG 31 33 67 27 
5h -AG 0 0 100 
 
5h +AG 23 24 76 24 
Table 4. 3. The effect of AG014699 on the repair of DNA breaks induced by exposure 
to CPT for 30 min. 
Data in the table show the increase in OTM above control cells, expressed as % of 
control untreated cells. The numbers were calculated form values of OTM as described 
in the legend to Table 4.1 from 2 independent experiments as shown in figure 4.12. 
 
% damage remaining = (
                         
           
)   100% 
% damage repair = 100 - %damage remaining  
% inhibition of repair by AG014699 = 100-(     
                   
                  
 )  
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4.6.2. Effect of AG014699 on the repair of CPT-induced DSB in asynchronous 
population of K562 cells  
4.6.2.1. Neutral comet assay 
The reversal of DSB in the presence or absence of AG014699 was studied. K562 cells 
were treated with CPT ± AG014699 for 30 min, after which the drug was removed and 
replaced with fresh medium with or without 0.4 µM AG014699 for up to further 5h. 
Inhibition of the reversal of CPT-induced DNA DSBs by AG014699 during the 5h of 
recovery period can be clearly observed on images collected in Figure 4. 13 Incubation 
of cells with CPT results in induction of DNA breaks that is manifested by increased 
length of comet tail. During the recovery period in drug free medium, the length of 
comet tail was reduced in all cells. Cells incubated in medium with AG014699 still had 
a longer tails than controls at the end of recovery period, which suggests that repair of 
DNA DSBs was inhibited. 
 
Figure 4. 13. The comets observed after 30 min exposure to 100 nM CPT followed by 
incubation in fresh medium ± 04 µM AG014699 as determined by neutral comet assay  
K562 cells were exposed to 100 nM CPT for 30 min. CPT was removed and cells were 
incubated in fresh medium or medium with AG014699 for up to 5h. For each time 
point, the level of remaining DNA DSBs was evaluated by neutral comet assay. 
Conditions -ScottLab electrophoresis tank, 1V/cm, 30 min.   
122 
The results in Figure 4.14 and Table 4. 4 show that there is a time-dependent repair of 
DSB in the absence of AG014699 but that repair is significantly slower in cells 
incubated in medium containing AG014699. For example, after incubation for 30 
minutes, only 7% of DNA damage was repaired in cells incubated with AG014699, 
compared to 44% in cells incubated in fresh medium 
 
 
 
 
 
 
 
 
 
Figure 4. 14. The comets observed after 30 min exposure to 100 nM CPT ± 04uM 
AG014699 as determined by neutral comet assay. 
Asynchronous K562 cells were exposed to 100 nM CPT for 30 min. CPT was then 
removed and cells were incubated in fresh medium or fresh medium with AG014699 for 
up to 5h. The level of DNA breaks was evaluated by neutral comet assay after 30min, 
1h, 5h after CPT removal. (A) Data normalised to the value of OTM measured at time 0 
min (B) Raw OTM data plotted against recovery time. Data shows OTM mean 
calculated  from a single representative experiment.  
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Table 4. 4. The effect of AG014699 on the repair of DSB induced by exposure to CPT 
for 30 min 
Asynchronous K562 cells were exposed to 100 nM CPT for 30 min. CPT was removed 
and cells were incubated in fresh medium or medium with AG014699 for up to 5h . The 
level of remaining DNA breaks was evaluated by neutral comet assay after 30min, 1h, 
or 5h after CPT removal.  
Data was calculated as shown for Table 4. 3 
 
  
Recovery 
time 
% Increase 
in OTM 
% Damage 
remaining 
% Damage 
repair 
Inhibition 
by 
AG014699 
0 min 166 
   
30 min 93 56 44 
 
30 min +AG 155 93 7 85 
1h 56 34 66 
 
1h +AG 144 87 13 80 
5h 22 13 87 
 
5h +AG 66 40 60 31 
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4.6.2.2. H2AX immunostaining 
In this section, the effect of 0.4 µM AG014699 on the reversal of DSB induced by 100 
nM CPT was investigated, using H2AX immunostaining with the aid of the PZFociEZ 
macro. K562 cells were treated with 100 nM CPT ± AG014699 for 30 min, after which 
the drug was removed and replaced with fresh medium or fresh medium containing 0.4 
µM AG014699 for further 30 min, 1h and 5 h. Representative  pictures from this 
experiment are shown in Figure 4. 15. In this figure, foci fluorescence was barely 
detected in control DMSO-treated cells, but significant increase in foci intensity, foci 
number and in the number of foci positive cells was observed following exposure to 100 
nM CPT.  
 
Figure 4. 15. Representative staining of H2AX foci in K562 cells.  
K562 cells were incubated with 100 nM CPT for 30 min. When CPT was removed 
incubation was continued in fresh medium or medium containing 0.4 µM AG014699 
for up to 5h to allow the repair of damaged DNA to take place  
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Figure 4. 16 A and B shows that Raw Integrated density induced by 100 nM CPT 
gradually decreased in cells incubated in fresh recovery medium. Similarly, the average 
foci number per cell was reduced in fresh medium conditions. The presence of 
AG014699 over 5h recovery incubation retarded the rate of disappearance of the 
number of foci. 
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Figure 4. 16. The fluorescence and foci numbers observed after 30 min exposure to 10 
and 100 nM CPT ± 04uM AG014699 as determined by H2AX fluorescence. 
Asynchronous K562 cells were exposed to 100 nM CPT for 30 min following by CPT 
removal and incubation in fresh medium or fresh medium with AG014699 for up to 5h. 
The level of DNA breaks was evaluated by H2AX fluorescence after 30min, 1h, 5h 
after CPT removal. A) Mean foci number normalised to time 0. A1) Mean foci number-
raw data.  B) Foci Raw integrated density normalised to time 0 B1)  Foci Raw 
integrated density –raw data. Data plotted   from a one representative experiment out of 
4 performed.  
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4.7. The effect of AG014699 on the repair of CPT-induced DNA breaks in K562 
cells in different phases of the cell cycle. 
The previous section showed that AG014699 retarded the repair of CPT-induced DNA 
breaks. To clarify whether the rate of repair and effect of AG014699 was cell cycle-
specific, the reversal of CPT-induced DNA breaks was investigated in cells separated 
into the different cell cycle phases.  
4.7.1. The effect of AG014699 on the repair of total CPT-induced DNA breaks. 
K562 cells in exponential growth phase were separated into cell cycle specific fractions 
using elutriation and along with asynchronous culture were exposed to 100 nM CPT for 
30 min. After the incubation period, cells were centrifuged to remove CPT and re-
suspended in fresh medium or fresh medium containing 0.4 µM AG014699 and 
incubated for further 2h to allow repair of damaged DNA. Immediately after that, cells 
were collected by centrifugation and subjected to alkaline comet assay. The percentage 
of DNA damage remaining after a two-hour incubation period was calculated relative to 
the level of DNA damage in the cells incubated with 100 nM CPT without recovery. 
The result was later used to calculate the percentage of repaired DNA and the effect of 
PARP inhibition as described in the equations given in Table 4. 3. The results of these 
calculations are summarised in Table 4. 5 and Table 4. 6. Representative images of the 
comets are shown in Figure 4. 17. This figure shows that comet tails observed in cells 
incubated in 100 nM CPT for 30 min (left panel) are reduced in cells after 2h incubation  
in fresh medium (middle panel), but at the same time some smaller tails can be seen in 
cells incubated in medium containing AG014699 (right panel). These images were 
quantified by measuring OTM and numeric data are shown in Figure 4. 18 and further 
analysis is shown in Table 4. 5.  
Figure 4. 18 shows that the level of DNA damage induced in asynchronous K562 cells,  
during a 30 min exposure to 100 nM CPT was significantly reduced after the two hour 
recovery period in fresh medium in asynchronous cells and at all phases of the cell 
cycle. Repair of DNA breaks was most pronounced in S phase. Incubation with 
AG014699 consistently inhibited the reduction in DNA breaks at all phases of the cell 
cycle but the effect was greatest in S and G2-phases.   
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Figure 4. 17. Comets observed in asynchronous and cell cycle separated K562 cells 
evaluated by alkaline comet assay 
Asynchronous (AS) and cell cycle phase separated (G1, S, G2) K562 cells were 
exposed to 100 nM CPT for 30 min (right panel) following by incubation in fresh 
medium (middle panel) or with medium containing 0.4 µM AG14699 (right panel) for 
further 2h for DNA damage recovery. Control cells were exposed to vehicle [DMSO] 
for 30min. Conditions -VWR electrophoresis tank, 075V/cm, 200-300 mA, 30 min.   
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Figure 4. 18. The effect of PARP-1 inhibition on  DNA SSB break repair in 
asynchronous and cell-cycle-phase-separated K562 cells 
The level of total DNA breaks at the beginning and at the end of 2h recovery period was 
evaluated using alkaline comet assay by measuring the Olive Tail Moment, which was 
expressed as % of the OTM of control cells (asynchronous untreated cells). DNA breaks 
induced by 100 nM CPT (black bars) and after 2 h incubation in drug-free medium 
(white bars) or AG014699-containing medium (grey bars) in the K562 cells evaluated 
by alkaline comet assay. Data shows mean + SEM of 3 independent experiments. 
 
     
 
Treatment 
% increase 
in OTM 
% 
Damage 
remaining 
% 
Damage 
repair 
% 
inhibition 
of repair 
by 
AG014699 
  
AS 
100 nM CPT 66 
   
2h recovery -AG 35 54 46 
 
2h recovery +AG 53 81 19 60 
G1 
100 nM CPT 63 
   
2h recovery -AG 29 46 54 
 
2h recovery +AG 48
 
76 24 55 
S 
100 nM CPT 90 
   
2h recovery -AG 34 38 62 
 
2h recovery +AG 73 81 19 70 
G2 
100 nM CPT 50 
   
2h recovery -AG 24 48 52 
 
2h recovery +AG 49 97 3 93 
Table 4. 5. The effect of 0.4 µM AG014699 on the repair of CPT-induced DNA breaks 
in the K562 cells evaluated by alkaline comet assay  
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Analysis of data shown in figure 4.18 were calculated as described for Table 4. 3.  
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4.7.2. The role of PARP inhibition in the repair of CPT-induced DSB. 
As demonstrated in previous sections, AG014699 significantly retarded repair of DSB 
in asynchronous cells and it had greater impact on total DNA repair in S and G2 cell 
cycle phases of the cell cycle. Since DSB are the most cytotoxic lesion produced by 
CPT, and sensitization to CPT-induced cytotoxicity was greater in S phase, it was 
important to determine the effect of AG014699 on the repair of DSB in different phases 
of cell cycle.  
The results in Figure 4. 20 and Table 4. 6 show that 30 min exposure of cells to 100 nM 
CPT consistently increased the number of DSB in all phases of the cell cycle and in 
asynchronous cells. As in the previous section (4.5.1, 4.5.2) the greatest induction of 
DSB compared to DMSO control cells was observed in S phase cells (by 132%; p=0.03) 
and G2 phase cells (by 109%, p=0.04) with only a modest, 68% non-significant 
(p=0.18) increase in G1.  
Following CPT removal, the level of DSB in asynchronous and phase specific cells 
incubated in drug free medium was significantly decreased, over the recovery period. 
Repair of DSB in drug-free medium was greatest in S and G2-phase cells (p<0.003) 
with approximately 75% of breaks being repaired, compared to only 40%-50% in G1 
and the asynchronous cells (p<0.05). Incubation in AG014699-containing medium 
retarded repair in all phases of the cell cycle but the effect, compared to DNA damage 
measured in cells incubated in fresh medium,  was only significant in S (p=0.007) and 
G2 (p=0.01) with the most profound and significant inhibition being observed in S 
phase cell.    
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Figure 4. 19. The comets observed after 30 min exposure to 100 nM CPT followed by 
incubation in fresh medium  ± 04 µM AG014699 as determined by neutral comet assay 
Asynchronous (AS) and cell cycle phase separated (G1, S, G2) K562 cells were 
exposed to 100 nM CPT for 30 min (right panel) following by incubation in fresh 
medium (middle panel) or with medium containing 0.4 µM AG14699 (right panel) for 
further 2h for DNA damage recovery. Control cells were exposed to vehicle [DMSO] 
for 30min. Conditions -VWR electrophoresis tank, 1V/cm, 30 min.   
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Figure 4. 20. The effect of PARP-1 inhibition on DSB repair in asynchronous and cell 
cycle phase separated K562 cells 
Asynchronous (AS) and populations of cell cycle-phase-separated (G1, S, G2) K562 
cells were exposed to 100 nM CPT for 30 min following by incubation in fresh medium 
or with medium containing 0.4 M AG14699 for further 2h for DNA damage recovery. 
The level of DSB at the beginning and at the end of 2h recovery period was evaluated 
using neutral comet assay by measuring the olive tail moment that was expressed as % 
of the OTM of control cells (asynchronous untreated cells).  Data are DNA breaks 
induced by 100 nM CPT (black bars) and after 2 h incubation in drug-free medium 
(white bars) or AG014699-containing medium (grey bars) mean + SEM of 3 
independent experiments 
 Treatment % Increase in 
OTM 
% 
damage 
remaining 
% 
damage 
repair 
% inhibition 
of repair 
 
AS 
100 nM CPT 103 
   
2h recovery -AG 51 49 51 
 
2h recovery +AG 85 82 18 65 
G1 
100 nM CPT 68 
   
2h recovery -AG 39 57 43 
 
2h recovery +AG 54 79 21 51 
S 
100 nM CPT 132 
   
2h recovery -AG 34 26 74 
 
2h recovery +AG 101 77 23 69 
G2 
100 nM CPT 109 
   
2h recovery -AG 28 25 75 
 
2h recovery +AG 87 79 21 72 
Table 4. 6. The effect of 0.4 µM AG014699 on the repair of CPT-induced DSB in the 
K562 cells evaluated by neutral comet assay. 
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Analysis of data shown in Figure 4.20 calculated as described for Table 4.3.   
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4.8. Discussion 
The purpose of this chapter was to examine the impact of inhibition of PARP-1 activity 
on the amount of DNA damage resulting from exposure of cells to CPT. CPT-induced 
cytotoxicity is believed to be related to DNA damage. PARP inhibition is reported to 
increase DNA damage by TopoI poisons and retard the repair of CPT-induced DNA 
breaks in asynchronous K562 cells (Smith, 2005). In the previous chapter, the greater 
sensitivity of S phase cells to CPT was demonstrated. In this chapter, the effect of 
PARP inhibition on the induction of total DNA breaks and the more cytotoxic DSB was 
investigated after short drug exposures together with the repair of these breaks in 
different cell cycle phases. The aim was to correlate these findings with the 
observations made regarding cytotoxicity and PARP-1 and TopoI expression and 
activity. Since cell elutriation was used to separate cells into different phases of the cell 
cycle, it was important to demonstrate that this did not introduce DNA breaks. There 
was no evidence that the elutriation process caused DNA breakage in concordance with 
the data in Chapter 3 showing that elutriation did not affect cell growth or viability. 
Surprisingly, there were no cell cycle phase differences in the OTM, indicating that 
Okazaki fragments formed during S phase do not contribute to comet tails. 
In these studies, total DNA breaks were measured by alkaline comet assay. 
Topoisomerase I poisons, such as CPT, directly introduce DNA SSB, some of which 
may be converted to DSB through downstream processing or collision with replication 
forks (Tuduri et al., 2010). Therefore, most of the breaks measured by alkaline comet 
assay are SSB. As expected, DNA breaks were increased relative to the concentration of 
CPT administered. The higher levels of DNA breaks observed in S and G2 cells could 
be related to the higher DNA content in these phases. Induction of DNA breaks could 
also be related to TopoI activity, which was highest in S phase, and expression, which 
was highest in G2. AG014699 increased the level of breaks to a similar extent at all 
phases of the cell cycle so this does not explain the greater sensitisation in S phase. 
Conversion to of SSB to DSB is likely to be the cytotoxic event. Other studies have 
demonstrated that the potentiation of temozolomide, another DNA SSB-inducing agent, 
by a PARP inhibitor correlated with DSB, rather than SSB induction. In these studies 
17-24 h incubation with the PARP inhibitor, ABT-888,  was needed for maximum 
sensitization of asynchronous cells but only 7h was needed in S phase cells (Liu et al., 
2008). Similarly, potentiation of alkylating agent cytotoxicity (MMS) by the PARP 
inhibitor 4-amino-1,8-naphthalimide was associated with the accumulation of DSBs in 
S phase (Heacock et al., 2010). 
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DNA DSB were measured by two methods; neutral comet, which is a direct and 
physical method, and γH2AX focus formation, which is an indirect but more sensitive 
method that depends on DNA damage signalling by ATM/ATR and DNA-PK. These 
kinases all phosphorylate H2AX in response to DNA DSB or stalled replication fork 
(Darzynkiewicz et al., 2009). Comparing the data in section 4.5.1 and 4.5.2 it can be 
seen that the effect of CPT, with or without AG014699, on DSB induction is similar by 
both methods.  In contrast to the alkaline comet data, DSB induction, measured by both 
neutral comet and γH2AX focus formation was greatest in S and G2 phases and lowest 
in G1 phase. This suggests that collision with the replication fork is a major mechanism 
for the induction of DSB, but that other mechanisms (possibly related to DNA content) 
may operate in G2. AG014699 consistently increased the level of DSB, with the most 
marked effect in S phase consistent with the greatest cytotoxic enhancement in this 
phase. 
The mechanism by which DNA breaks were increased was investigated further in terms 
of measuring whether AG014699 inhibited the repair of these lesions. PARP-1 plays a 
major and well-documented role in DNA SSB repair with evidence also for a role in 
DNA DSB repair (Audebert et al., 2006, Wu et al., 2008, Mitchell et al., 2009, Iliakis, 
2009). Consistent with previously published data (Padget et al., 2000, Smith, 2005), 
there was a rapid resolution of total DNA breaks and also specifically DSBs. DSBs 
were slower to repair than total breaks with only 66% (Table 4. 4) of DSBs resolving 1h 
after removal of CPT, compared with >90% of total DNA breaks (Table 4. 3),  
The role of PARP in the repair of DNA breaks at different phases of the cell cycle has 
not been reported to date. Therefore the effect of AG014699 on the repair of total and 
DSB, induced by a 30 min pulse with CPT, was determined at all phases of the cell 
cycle. Repair of total breaks was marginally faster in S phase cells but broadly similar 
in all phases of the cell cycle. However, repair of DSBs was more rapid in S and G2 
phases than in G1, although this may reflect the lower levels of DNA breaks in G1 
phase to start with. AG014699 consistently inhibited the repair of DNA DSB across all 
phases of the cell cycle but had the most significant effect in S phase cells. Currently 
there is significant uncertainty about the role of PARP-1 in DNA DSB repair (Veuger et 
al., 2004, Wang et al., 2005, Mitchell et al., 2009) which may partially be due to the 
different systems used. Recently PARP-3 has been implicated in DNA DSB repair 
(Boehler et al., 2011b). There is no data on the inhibition of PARP-3 by AG014699 but 
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the possibility that the reduction in DNA DSB repair and the enhancement of CPT 
cytotoxicity by AG014699 is due to inhibition of PARP-3 cannot be excluded. 
DNA DSB are repaired by 2 major pathways, non-homologous end joining (NHEJ) and 
homologous recombination repair (HRR) and both processes involve a cascade of 
proteins to recognise, signal and repair the breaks, some of which are common to both 
pathways. HR requires the presence of the complimentary copy of DNA as a template to 
effect error-free repair and can therefore only take place during S and G2 whereas 
NHEJ is template independent and can occur at all phases of the cell cycle. The decision 
of which pathway to employ is cell cycle-dependent (Shrivastav et al., 2008). The faster 
resolution of DSBs during S and G2 phases suggests that HR may be the predominant 
mechanism for the repair of CPT-induced DSB consistent with the finding that the HR 
defective irs1SF cells were the most sensitive to CPT  (Smith et al., 2005). Likewise, 
the greatest inhibition of DSB repair by AG014699 during S and G2 may point to a 
direct role of PARP-1 (or PARP-3) in HR. 
In the previous chapter, CPT was shown to be more cytotoxic in S phase cells and 
AG014699 caused the greatest sensitisation of S phase cells. The observation that DSB 
induction by CPT is greater in S phase than in G1 explains the greater sensitivity of S 
phase cells to CPT. However, similarly high levels of DNA DSBs were seen in S and 
G2 cells, which does not explain why G2 cells are less sensitive to CPT cytotoxicity 
than S phase cells. Similarly, although AG014699 mediated inhibition of repair was 
most significant in S phase, there was still a very substantial inhibition in G2 cells. 
Clearly therefore DNA DSB induced by CPT and inhibition of their repair by 
AG014699 are major contributors to CPT cytotoxicity. However, the data in this 
chapter do not entirely explain why S phase cells are so much more sensitive to CPT-
induced cytotoxicity than G2 cells. 
  
138 
Summary 
 Elutriation procedures does not introduce DNA damage to processed cells 
 OTM data transformation can overcome some statistical analysis restriction 
 CPT causes concentration dependent increase in total and double stranded DNA 
breaks  
 AG014699 significantly increased the level of total DNA breaks mostly in 
synchronous S and G2 phase cells  
 AG014699 significantly increased the level of DSB in synchronous S and G2 
phase cells  
 AG015699 significantly retards the repair of total and DSB in asynchronous and 
elutriated cells K562 cells in all phases of cell cycle, but the most prominent 
effect of AG014699 is restricted to S phase cells. 
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Chapter 5. The role of the interaction between PARP and XRCC1 in 
DSB induction and repair  
5.1. Introduction  
Previous results chapters show that PARP inhibition results in the greater accumulation 
of CPT-induced total and DSB, and a slower rate of repair predominantly. The effect of 
PARP-1 inactivation on increased induction and decreased repair of CPT-induced DNA 
breaks was observed in all phases of the cell cycle, however the most pronounced effect 
was seen in S phase enriched K562 cells. The increased persistence of DNA breaks 
correlates with increased sensitisation to CPT-induced cytotoxicity in the presence of 
AG014699 also in S phase cells.  
As described in the introduction (section 1.6.4) repair of SSB is thought to be dependent 
on PARP activation recruiting XRCC1. XRCC-1 is a scaffold protein that is  necessary 
for the assembly of other BER/SSBR proteins including Polβ and Ligase III (Almeida 
and Sobol, 2007). As described in the introduction (section 1.6.4) one hypothesis for the 
mechanism of PARP-mediated DSB repair also involves XRCC1 and LigIII in a back-
up NHEJ (Iliakis, 2009). Thus both PARP-mediated SSB and DSB repair is thought to 
involve XRCC1 and LigIII. XRCC1 is a necessary partner for PARP-1 and loss of 
XRCC1 may have the same effect as loss/inhibition of PARP. There are evidences that 
PARP-1 is required for the assembly or stability of XRCC1 nuclear foci (El-Khamisy et 
al., 2003). 
Chinese hamster ovary AA8 cells, and their XRCC1-defective derivative, EM9 cells 
(Thompson et al., 1990, Barrows et al., 1998) are excellent tools to investigate if PARP 
is totally dependent on XRCC1 for its effect or whether it has a role beyond its 
interaction with XRCC1. 
Despite the good pre-clinical data indicating sensitization of TopoI poisons without 
undue toxicity (Calabrese et al., 2004), the only clinical studies reported to date 
indicates an increase in topotecan toxicity without any increase in tumour response 
(Kummar et al., 2011, Samol et al., 2011). Variable data have been obtained clinically 
with temozolomide (TMZ) and the related DNA alkylating agent, dacarbazine, with 
regards to efficacy but myelosuppression is a common feature (Plummer et al., 2008, 
Khan et al., 2011). These results may have beendue to inappropriate dose and/or 
schedule emphasising the need to thoroughly understand the biology of the drug 
interactions at the cellular level to aid intelligent drug treatment in patients. 
140 
To investigate the mechanisms underlying the chemosensitisation of TopoI poisons and 
other agents by PARP inhibition, and in particular the dependence on the interaction 
with XRCC1, the effect of AG014699 on CPT-induced DNA breakage was determined 
in cells proficient and deficient in XRCC1. In parallel in some of these studies the effect 
of AG014699 on TMZ and neocarzinostatin (NCS) –induced DSBs and cytotoxicity 
was determined in the same pair of cell lines by project students Scott Farrenden and 
Matthias Becker whose were worked under my supervision. 
TMZ (brand name - Temadar, Temodal) has been approved for treatment of cancer 
since early 2000. TMZ (4-methyl-5-oxo-2,3,4,6,8-pentazabicyclo [4.3.0] nona-2 ,7,9-
triene-9-carboxamide) is a monofunctional alkylating agent that is an imidazotetrazine 
derivative of dacarbazine. This product is actively absorbed by cells and under 
physiological conditions is converted to active MTIC (5-(3-methyl-1-
triazeno)imidazole-4-carboxamide) (Chabner i Longo, 1996). As an oral anticancer 
drug, TMZ slows or stops the growth of cancer cells in the body and is used mainly to 
treat gliomas and malignant melanoma(Danson and Middleton, 2001)as well as 
astrocytoma(Hegi et al., 2005). TMZ is usually given once daily for 5 days at a dose of 
200 mg/m
2
 and treatment is usually repeated every 28 days, although the length of 
treatment depends on the patient response. For example, in the treatment of malignant 
melanoma, there is a response to TMZ in 16 - 31% of treated patients (Stupp et al., 
2009). TMZ is a DNA methylating agent causing the formation O
6
-methylguanine (~ 
10% of total lesions), N
7
-methylguanine (~ 70%) and N3-methyladenine (~10%) 
(Newlands et al., 1997). O
6
-methylguanine, which is the most cytotoxic lesion, is 
repaired by MGMT, and if not repaired it becomes a substrate for MMR. Cells 
proficient in MMR cells are sensitive to TMZ and loss of MMR confers resistance to it. 
The most abundant lesions, N
7
-methylguanine and N3-methyladenine, are quickly and 
efficiently repaired by BER/SSBR. These methylated purines are removed by alkyl 
adenine glycosylase (AAG) resulting in an AP site. This is then hydrolysed by the 
endonuclease, APE-1, resulting in a SSB that stimulates PARP-1 activity. As with CPT, 
unrepaired TMZ-induced lesions obstruct the progression of replication forks and can 
result in the formation of DSBs at replication (Curtin, 2005, Tentori, 2006, Liu et al., 
2008). 
Neocarzinostatin (NSC) a macromolecular chromo-protein enediyne antibiotic secreted 
by Streptomyces macromomyceticus with anti-tumour activity. It consists of two parts, 
the unstable chromophore, and 113 amino acid apoprotein to which the chromophore is 
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tightly non-covalently bound. The chromophore is a potent DNA damaging agent, it is 
very unstable and the role of apoprotein is to protect it and release it to the target DNA 
leading to a di-radical intermediate, and finally cut double-stranded DNA. NCS causes 
SSB as well as DSB in ratio 6:1. This is a very high frequency of DSB induction, about 
3-fold higher than irradiation and unlike CPT or TMZ damage induction is not 
dependent on replication for their generation.  
Therefore in this chapter three agents that induce different types of DNA damage were 
investigated: CPT, which produces SSB with one end attached to topoisomerase I that 
may cause replication stalling and associated DSBs; TMZ, which induces base damage 
that results in DNA SSBs as repair intermediates that may also cause replication stalling 
and associated DSBs; and NCS which induces both SSB and a high level of DSB 
directly.   
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5.2. Aims   
The aim of the work described in this chapter was to establish whether inhibition of 
DNA repair and chemosensitisation by PARP inhibition is dependent on an interaction 
with XRCC1 or if PARP has a role independent of XRCC1. To verify if the effects of 
PARP inhibition are mediated by XRCC1 in both SSB and DSB repair, the effects of 
AG014699 on CPT, TMZ and NCS-induced DNA damage, repair and cytotoxicity in 
cells with and without XRCC1 was measured.  
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5.3. Verification of XRCC1 expression in AA8 and EM9 cells by Western blot  
Before conducting further experiments, it was important to determine if cells that were 
used had any possible background expression of XRCC1   
The level of XRCC1 was determined in whole cell extracts prepared from AA8 and 
EM9 cells using anti-XRCC1 monoclonal antibody by Western blotting, as described in 
section 2.11. To achieve this, an equal number of AA8 and EM9 cells were used to 
prepare whole protein lysate using Leamlli buffer. Three different volumes of lysates (5, 
15, 30 µl) for each cell line were loaded onto the gel and run on a 4-15% gradient gel 
and blotted onto nitrocellulose membrane before probing with anti-mouse XRCC1 and 
later anti actin antibody to verify loading . 
Figure 5. 1 shows overlaid images of membrane with protein standard, and bands 
corresponding to actin and XRCC1.Actin loading control, indicates that more protein 
extract (approximately two times more) of EM9 cells has been loaded (e.g. compare 
second actin band of EM9 with first actin band of AA8). Despite this no XRCC1 has 
been found in the EM9 cells but could be seen in AA8 cells. 
 
 
Figure 5. 1. Western blot of XRCC1 in AA8 and EM9 cells 
Total cell lysate in the volume of 5, 15, and 30 µl obtained from AA8 and EM9 cells 
was loaded per line. Western blotting was performed as described in section 2.11. Blots 
were probed with anti-XRCC1 monoclonal and antibody and anti-actin monoclonal 
antibodies and corresponding secondary antibodies.   
EM9 AA8          M 
144 
5.4. Effect of AG014699 on the formation and repair of DNA breaks in EM9 
and AA8 cells.   
The XRCC1 deficient cells have DNA repair dysfunction (Shen et al., 1998). Because 
PARP-mediated DNA repair is thought to be dependent on XRCC1 recruitment to the 
DNA break site, inhibition of PARP activity in EM9 cells should not have marked 
effects, in contrast to AA8 cells that have normal expression of XRCC1. To clarify this 
possibility the level of DNA damage (total and DSB) in AA8 and EM9 in cells exposed 
to TMZ, CPT and NCS were studied. To be comparable to previous data, AG014699 
was used at a concentration of 0.4 µM in all experiments 
5.4.1. CPT induced total DNA breaks measured by alkaline comet assay. 
AA8 and EM9 cells were incubated with CPT ± AG014699 for 30 min then subjected to 
alkaline comet assay in order to determine the induction of total DNA strand breakage. 
To examine the level of the repair of DNA damage caused by CPT, and the effect of 
AG014699 on this repair, cells were first incubated with the CPT alone for 30 min and 
then medium was replaced with fresh medium or medium containing AG014699, and 
incubations was continued for further 2h. After incubation, the cells were subjected to 
the alkaline comet assay to investigate the kinetics of DNA damage repair. 
Figure 5. 2 shows representative images of comets taken for this experiment. This 
photomicrograph shows a mixture of cells that differ in the length of the tail. Regardless 
of experimental conditions, a wide range of DNA damage can be observed, indicated by 
cells that do not have any tail and cells having very large tails This is because cells were 
asynchronous and the population of cells with large tails may represent the S phase 
population. Nevertheless, a tendency to increase the number of cells with large tail can 
be observed on images taken for 100 nM CPT comparing to control, DMSO treated 
cells. Both, the number of cells with tails and their comet tail length increases in images 
taken for the cells incubated with CPT + AG014699.  
Control EM9 cells have slightly longer tails than control AA8 cells, which is probably 
associated with a defective mechanism for BER in these cells leading to an increase in 
unrepaired endogenous SSBs. However, the mean OTM of comets in control AA8 and 
control EM9 was 1.1±0.24 and 1.27±0.33 respectively, which was not statistically 
significant (p=0.36, LSD). These values were taken as the 100% baseline control for 
normalisation of treated cells, which were expressed as a % of these untreated controls.  
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Quantitative data that were obtained from the analysis of comet images are shown in 
Figure 5. 3 and Table 5. 1. These data show that AG014699 had a significant impact on 
DNA breaks in both cell lines. A significant increase in DNA breaks was observed 
following 100 nM CPT treatment in both cell lines. The percentage increase in DNA 
damage level induced by CPT in EM9 cells was almost twice that in AA8 cells (119% 
versus 56% - bars 3 and 9). Exposure of cells to CPT + AG014699 caused a significant 
increase in the amount of CPT-induced DNA damage in AA8 cells by 2.3-fold 
compared to CPT alone (p = 0.02, LSD). In contrast AG014699 only increased the level 
of breaks from 119 to 160.5% in EM9 cells (bars 9 and 10).  
To examine the repair of DNA damage induced by CPT, EM9 and AA8 cells were first 
incubated with 100 nM of CPT alone for 30 min and then when CPT was removed 
incubation was continued in fresh medium or medium containing AG014699 for a 
further 2h (hatched bars in Figure 5. 3).  
In the AA8 cells, all the DNA breaks were repaired during the 2 h incubation in fresh 
medium and there was no significant difference from baseline [compare bar 1 and 5 in 
Figure 5. 3]. However, AG014699 completely blocked repair and there was no 
significant difference at 2 h in AG014699-containing medium from unrepaired CPT-
treated cells [bars 3 and 6]. Surprisingly, in EM9 cells repair was also virtually 
complete after 2 h in fresh medium (being only 8% higher and not significantly 
different from baseline, p= 0.16) [bar 7 and 11]. AG014699 had a significant impact on 
repair in these cells too, since only 50-60% of breaks had been repaired and the level of 
breaks was still significantly higher than both baseline (p=0.002) [bar 7 and 12] and 
cells that repaired in fresh medium (p=0.05) [bar 11 and 12].  
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Figure 5. 2. Images of comets showing induction and repair of CPT induced total DNA 
breaks.  
AA8 and EM9 cells were incubated for 30 min with 100 nM CPT ± 0.4 µM AG014699. 
To investigate the repair of CPT-induced DNA breaks following 30min with CPT alone, 
CPT was removed and incubation of cells was carried on for next 2h in medium without  
(-AG014699) or with (+AG014699) PARP inhibitor. The alkaline comet assay was 
performed to evaluate the level of total DNA breaks in these cells Conditions -VWR 
electrophoresis tank, 0.7V/cm, 200-300 mA, 30 min. 
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Figure 5. 3. Effect of AG014699 on induction and repair of SSB induced by CPT 
Comet images shown in Figure 5. 2 were used to determine DNA damage by 
measuring the OTM. The Values of OTM from each experiments were expressed as a 
percentage of CPT alone control. Means of 3 independent experiments+ SEM are 
shown.  
 
      
  
 
Treatment Conditions 
% Increase in 
OTM CPT 
% increase in 
OTM CPT+ 
AG 
 
 AA8 
30 min No Rec 56.0
3) 
131.1
4) 
 
 
2h Recovery 0.7
5) 
56.6
6) 
 
 EM9 
30 min No Rec 119.4
9) 
160.5
10) 
 
 
2h Recovery 8.3
11) 
47.2
12) 
 
      Table 5. 1. Formation and repair of total DNA breaks in AA8 and EM9 cells 
Analysis of data shown in Figure 5. 3. The % increase in OTM was calculated as 
described in the legend to Table 4. 1. The partially bracketed superscript numbers refer 
to the relevant bar in Figure 5. 3.  
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5.4.2. Effect of AG014699 on the formation and repair of CPT-induced DSB in EM9 
and AA8 cells.  
The treatment conditions in which the experiment was carried out are the same as 
described in section 5.4.1. The comets shown in Figure 5. 4 are different from those 
taken in alkaline comet assay. Comparable to the total DNA breaks the DSB observed 
in Figure 5. 4 are greater in EM9 cells in both control  The mean OTM of comets in 
control AA8 and control EM9 was 2.4±0.9 and 2.9±0.9 respectively, which was not 
statistically significant (p=0.16). These values were taken as the 100% baseline control 
for normalisation of treated cells which were expressed as a % of these untreated 
controls).  Treatment with CPT caused a greater accumulation of DSBs in EM9 
compared to AA8. In AA8 cells co-incubation with AG014699 doubled the increase in 
OTM from 81% to 161% but had only a modest effect in EM9 (Table 5. 2).The data in 
Figure 5. 5and in Table 5. 2 show an effect of AG014699 on the repair of CPT-induced 
DSB.  This effect was investigated following 2h recovery period during which cells 
exposed to CPT were incubated in fresh or AG014699 supplemented medium. 
Surprisingly in AA8 cells the repair of DSB in fresh medium appeared slower than in 
EM9 cells. However, after 2 hours incubation in fresh medium the level of DNA 
damage was not significantly different from the control (p> 0.1) in either cell line 
therefore it can be assume that both cell lines repaired DSB to similar extent.  
AG014699 significantly delayed the repair of DSB in both AA8 and EM9. At the end of 
2h recovery period there was still 55.% DSB left in AA8 cells and 41% DSB left in 
EM9 the delay in repair was significant in both cell lines (P<0.05). The data in both 
these experiments indicate that accumulation of total and DSB is dependent on PARP 
and XRCC1 together (i.e. AG014699 has no effect on break induction in EM9) but that 
PARP inhibition has an impact on repair over and above the loss of XRCC1 (i.e. it 
retards repair in EM9).  
.  
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Figure 5. 4. Images of comets showing induction and repair of CPT induced DSB DNA 
breaks.   
The experiment was performed as described in Figure 5. 2 but the neutral comet was 
used to estimate the level of DNA double strand breaks. Conditions -VWR 
electrophoresis tank, 1V/cm, 30 min.  
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Figure 5. 5. Effect of AG014699 in induction and repair of DSB induced by CPT 
Comet images shown in Figure 5. 4 were used to determine DNA damage by measuring 
the OTM. The Values of OTM from each experiments were expressed as a percentage 
of CPT alone control. Means of 3 independent experiments+ SEM are shown. 
 
 
 
      
  
 
Treatment Conditions 
% Increase in 
OTM CPT 
% increase in 
OTM CPT+ 
AG 
 
 
AA8 
30 min No Rec 80.7
3) 
161.0
4) 
 
 
2h Recovery 18.8
5) 
55.3
6) 
 
 
EM9 
30 min No Rec 126.1
9) 
153.4
10) 
 
 
2h Recovery 0.0
11) 
41.0
12) 
       Table 5. 2 Effect of AG014699 in induction and repair of DSB induced by CPT.
Analysis of data shown in figure 5.5. The % increase in OTM was calculated as 
described in the legend to Table 4.1. The partially bracketed superscript numbers refer 
to the relevant bar in Figure 5.5. 
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5.4.3. Effect of AG014699 on the formation and repair of CPT-induced DSB in EM9 
and AA8 cells determined by H2AX immunofluorescence 
Data from the previous section suggest that AG014699 plays role in the induction and 
repair of DSB induced by 100nM CPT in Chinese hamster ovary as well as K562 cells. 
In this section these data were confirmed using H2AX immunostaining, which is a 
more sensitive method than the comet assay.  
AA8 and EM9 cells were grown on microscope cover slips for 24h before treatment. 
The treatment with 100 nM CPT was conducted for 30 min in the presence or absence 
of AG014699. For investigation of the reversal of CPT-induced DNA breaks, cells were 
first incubated with CPT for 30 min, then medium was replaced with fresh medium or 
medium containing AG014699, and incubation was continued for further 2h. After the 
treatment, cells were stained for the presence of γH2AX and images of foci and DAPI 
staining in 8-bit grayscale were obtained by Leica fluorescence microscope using the 
Advanced-SPOT software, as described in section 2.10, because the foci were large and 
diffuse making them difficult to quantify by counting.  Data presented in Figure 5. 6 
shows the level of CPT-induced H2AX fluorescence in AA8 and EM9.  The level of 
H2AX fluorescence in control EM9 cells was slightly higher than in AA8 but this 
difference was not significant. Also AG014699 alone did not have significant effect on 
fluorescence intensity. Incubation of cells with CPT caused a similar (approximately 
150%) increase in the level of fluorescence intensity in both cell lines Table 5. 2. The 
presence of AG014699 during 30 min of incubation with CPT caused a further 40% 
increase in the DSB level in AA8 cells (bar 4) and 100% increase in EM9 cells (bar 10). 
After the removal of CPT, damage induced in AA8 was decreased by 30% but no 
apparent repair was observed in EM9 (compare bars 9 with 11). Curiously, in the 
presence of AG014699 (hatched bars in Figure 5. 6) H2AX fluorescence continued to 
increase in AA8 cells and this increase was even more pronounced in the EM9 cells.  
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Figure 5. 6 AG014699 effect on induction and repair of CPT-induced DSB 
 
      
  
 
Treatment Conditions 
% Increase in 
OTM CPT 
% increase in 
OTM CPT+ 
AG 
 
 AA8 
30 min No Rec 151.3
3) 
190.1
4) 
 
 
2h Recovery 116.7
5) 
310.5
6) 
 
 EM9 
30 min No Rec 145.2
9) 
244.8
10) 
 
 
2h Recovery 169.7
11) 
672.3
12) 
 
      Table 5. 3. Effect of AG014699 in induction and repair of DSB induced by CPT 
AA8 and EM9 cells were incubated for 30 min with CPT ± AG014699 and then 
subjected to staining for the presence of γH2AX foci. To investigate the repair of DNA 
damage caused by CPT after 30 min incubation in medium with CPT, the medium was 
replaced with fresh medium or medium containing AG014699 and incubation was 
continued for a further 2 hours. Using a macro PZFociEZ integrated fluorescence 
density of γH2AX foci per nucleus was measured. Data on the graph shows mean 
integrated density of three independent experiments ± SEM expressed as percentage of 
control (DMSO). The partially bracketed superscript numbers in the Table 5. 3 refer to 
the relevant bar in Figure 5. 6.  
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5.4.4. Effect of AG014699 on the formation and repair of TMZ-induced DSB in 
EM9 and AA8 cells. 
Data presented in Figure 5. 7 shows that TMZ increased the level of H2AX 
phosphorylation in both AA8 and EM9 cells. TMZ alone increased the level of γH2AX 
in EM9 cells  more than in AA8 cells (white bars). Incubation of cells with TMZ for 4 
hours with AG014699 resulted in higher induction of DNA damage in EM9 than in 
AA8 cells (grey bars). There was 55% increase in the level of DSB caused by 
AG014699 in AA8 cells and 62% increase in EM9 cells. Figure 5. 7 shows also the 
repair of TMZ-induced DSB during 2h recovery period in the presence or absence of 
AG014699 [bars 5, 6 and 7,12]. After 2 h incubation in fresh medium TMZ-induced 
DSBs in AA8 cells were efficiently repaired (85% reduction in fluorescence intensity – 
compare bar 3 with 5), while in the EM9 cells there was no reduction in γH2AX. The 
presence of AG014699 during the recovery period significantly slowed down the repair 
of DNA DSB in AA8 cells with only a 23% reduction in γH2AX (bar 3 and 6), and 
even increased its level in EM9 cells (bars 9 and 12).  
The kinetics of disappearance of H2AX fluorescence after TMZ removal was similar to 
after CPT removal, i.e. substantial reduction in AA8 but virtually no change in EM9. In 
the presence of AG014699, the reduction of H2AX fluorescence was minimal in AA8 
and actually increased in EM9.   
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Figure 5. 7. AG014699 effect on induction and repair of TMZ-induced DSB 
 
      
  
 
Treatment Conditions 
% Increase in 
OTM CPT 
% increase in 
OTM CPT+ 
AG 
 
 AA8 
4h No Rec 220.7
3) 
275.8
4) 
 
 
2h Recovery 135.3
5) 
197.3
6) 
 
 EM9 
4h No Rec 322.8
9) 
639.3
10) 
 
 
2h Recovery 329.4
11) 
472.4
12) 
 
   
    
 Table 5. 4. Effect of AG014699 in induction and repair of DSB induced by TMZ 
AA8 and EM9 cells were incubated for 4 h with TMZ and AG014699 and then 
subjected to staining for the presence of γH2AX foci. To investigate the repair of DNA 
damage caused by TMZ after 4 hours incubation in medium with TMZ, the medium 
was replaced with fresh medium or medium containing AG014699 and incubation was 
continued for a further 2 hours. Using a macro PZFociEZ integrated fluorescence 
density of γH2AX foci per nucleus was measured. Data on the graph shows mean 
integrated density of three independent experiments ± SEM expressed as percentage of 
control (DMSO). The partially bracketed superscript numbers in the Table 5. 4 refer to 
the relevant bar in Figure 5. 7. 
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5.4.5. Effect of AG014699 on the formation and repair of neocarzinostatin-induced 
DSB in EM9 and AA8 cells. 
CPT and TMZ primarily induce DNA SSB that are converted to stalled replication forks 
and replication-associated DSBs. To determine the effect of PARP inhibition on the 
repair of frank DSBs, cells were incubated with NCS. Disappearance of γH2AX foci 
formed in cells AA8 and EM9 after exposure to NSC±AG014699 for 1h was measured 
at 0, 1, 2, 4, and 24 hours after drug removal using the integrated fluorescence to 
determine the kinetics of DSB repair in the absence and presence of 0.4 µM AG014699. 
Figure 5. 8 shows a decrease in the integrated fluorescence integrated over time and is a 
measure of the rate of disappearance of DSBs. Both in AA8 cells and EM9 in the initial 
phase of incubation (1h after removal of the NSC medium) there is an increase of 
fluorescence intensity in all tested conditions. After 1h, the fluorescence intensity 
decreases with the progressive repair of damaged DNA. 
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Figure 5. 8.  The effect of AG014699 on neocarzinostatin-induced DSB 
AA8 and EM9 cells were exposed to neocarzinostatin for 1h and drug was replaced 
with fresh medium or medium containing AG014699 and incubation was carried on for 
up to 24 hours.  
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NCS causes a profound increase in γH2AX fluorescence intensity in both cell lines to 
an approximately equal amount at 1h. AG014699 caused a substantial increase in the 
level of γH2AX at this time in EM9 cells but delayed the peak in AA8 cells. In the AA8 
cells H2AX phosphorylation had returned to baseline 4 h after NCS removal, but was 
still elevated in the presence of AG014699 at 24 h. Repair was slightly slower in EM9 
cells and very substantially retarded by AG014699. By 24 h γH2AX levels had returned 
to baseline in both AA8 and EM9 cultured in drug-free medium but was still 
substantially elevated in the presence of AG014699, indicating compromised DSB 
repair, in both cell lines. 
5.5. The effect of PARP-1 inhibition on CPT, TMZ and neocarzinostatin 
induced cell cytotoxicity. 
DNA damage induction and repair data in previous section of this chapter indicates that 
AG014699 increased the level and reduced the rate of repair of DNA breaks in both 
AA8 and EM9 cells. To strengthen these data the effect of AG014699 on cytotoxicity 
mediated by CPT, TMZ and NSC was also examined. 
The effect of PARP inhibition on the cytotoxicity caused by exposure to CPT, TMZ and 
NSC was studied using clonogenic assay. AG014699-mediated potentiation of the 
cytotoxicity caused by CPT and  TMZ in EM9 and AA8 cell lines, was evaluated in 
parallel experiment, by seeding AA8  and EM9 cells in 6 well plates in different densities 
(125, 250, 500, 1000, 2500, 5000 cells) per well, in 2 ml of medium at the day before 
treatment with CPT or TMZ. The next day, medium was replaced with 2 ml of medium 
with an appropriate dose of CPT or TMZ ±AG014699 and incubated for 30 min or 4 h 
(control- 0.5% DMSO±AG014699 medium) and then replaced with fresh medium 
without drugs and incubation was continued for 7 days to allow the creation of colonies. 
When colonies were visible, plates were stained with crystal violet, and colonies were 
counted by eye. This method differs from that described in the section 2.4.2 however, is 
less complicated, therefore results can be obtained faster.  
The effect of PARP inhibition on the cytotoxicity caused by exposure to CPT, TMZ and 
NSC was studied using clonogenic assay. AG014699-mediated potentiation of the 
cytotoxicity caused by CPT and TMZ in EM9 and AA8 cell lines, was evaluated in 
parallel experiment, by seeding AA8  and EM9 cells in 6 well plates in different densities 
(125, 250, 500, 1000, 2500, 5000 cells) per well, in 2 ml of medium at the day before 
treatment with CPT or TMZ. The next day, medium was replaced with 2 ml of medium 
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with an appropriate dose of CPT or TMZ ±AG014699, incubated for 30 min (control- 
0.5% DMSO±AG014699 medium), and then replaced with fresh medium without drugs 
and incubation was continued for 7 days to allow the creation of colonies. On day, 
plates were stained with crystal violet, and colonies were counted by eye. This method 
differs from that described in the section 2.4.2 however, is less complicated, allowing to 
obtain the results shorter. 
For the NSC-induced cytotoxicity , cells were maintained in exponential growth phase 
before dosing with drug. Following the treatment, cells were trypsinized and plated in 
know densities in 90 mm petri dish and left to growth and form colonies allowing to 
obtain the results shorter. 
For the NSC-induced cytotoxicity, cells were maintained in exponential growth phase 
before dosing with drug. Following the treatment, cells were trypsinized and plated in 
know densities in 90 mm petri dish and left to growth and form colonies (section 2.4.2).  
Because of insufficient time most of these data are for a single experiment, so statistical 
analysis cannot be performed. However, the results obtained were consistent with 
predicted results. First, the cytotoxicity induced by CPT was studied in AA8 and EM9 
cells exposed to CPT for 30 min. The 30 min exposure was chosen to be able to 
compare these data with data from previous chapters where the same exposure time was 
used. Data in Figure 5. 9 shows that EM9 cells were more sensitive to CPT (estimated 
LC50 between 1 and 10 nM) than AA8 cells (LC50>100 nM). Nevertheless, 
sensitisation by AG was similar in both cell lines e.g. at 1 nM CPT AG reduced survival 
from 104% to 84% in AA8 and from 75% to 52% in EM9.  
Figure 5. 10 shows the results of the cytotoxicity experiment for AA8 and EM9 cells 
exposed to TMZ ± AG014699 for 4h. In both cell lines TMZ reduced survival, which 
was concentration-dependent at least in AA8 cells. However the concentrations of TMZ 
were too low to have a marked effect on cell survival. AG014699 caused a further 
reduction in survival, which was more marked in the EM9 cells. Clearly, these data, 
based on a single experiment are insufficiently robust to draw major conclusions but 
taken together these results were consistent with data obtained for CPT, and indicates 
that PARP inhibition sensitises cells to TMZ irrespective of XRCC1 status 
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Figure 5. 9. Survival of AA8 and EM9 cells following increasing concentration of 
CPT±AG014699 
AA8 and EM9 cells were incubated with CPT ± AG014699 for 30 min and cell survival 
was evaluated by colony forming assay. Graph shows data for one experiment.  
0
20
40
60
80
100
- + - + - + - +
AA8 EM9
TMZ [nM]
AG014699
1 1 10 10 1 1 10 10
C
el
l 
S
u
rv
iv
al
: 
%
 C
o
nt
ro
l
 
Figure 5. 10. Survival of AA8 and EM9 cells exposed to TMZ±AG014699. 
AA8 and EM9 cells were exposed to 0, 1, 10 µM TMZ for 4h and its survival was 
evaluated by clonogenic assay. Graph plotted using data from one experiment. 
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To investigate the role of PARP and XRCC1 in the survival of cells treated with a DSB-
inducing agent AA8 and EM9 cells were exposed to range concentrations of NSC ± 0.4 
µM AG014699 for 1h. Following incubations drugs was removed, cells were diluted 
and plated in desired density in fresh medium for colony formation assay.  
Figure 5. 11 shows that cytotoxicity caused by NCS in AA8 and EM9 cells is similar to 
cytotoxicity caused in these cells by CPT and TMZ. Neocarzinostatin causes more cell 
death in EM9 cells than in AA8 cells. For example, after incubation of AA8 cells with 
10 nM NCS 7.8% cells survived, whereas the same dose resulted in the 2.8% survival in 
EM9 cells. In AA8 cells co-incubation AG014699 reduced survival to 2.6% (a 3-fold 
reduction compared to NCS alone) and in EM9 cells survival was reduced to 0.8% (a 
3.5-fold reduction compared to NCS alone). Thus, AG014699 seems to have a similar 
effect in both cell lines. 
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Figure 5. 11. Effect of AG014699 on neocarzinostatin-induced cell cytotoxicity. 
The AA8 and EM9 cells were incubated with NSC±AG014699 for 1h and survival in 
response to treatment was evaluated by colony forming assay. Data show a 
representative experiment out of 3 that were performed.   
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5.6. Discussion.   
Investigations described in this chapter aimed to determine and describe the interaction 
of XRCC1 and PARP-1 in both SSB repair and DSB repair, and the effect of this 
interaction on cell cytotoxicity. To achieve this, the formation of DNA damage by CPT, 
TMZ and NCS, DNA repair and cell cytotoxicity by these agents was investigated in 
cells with (AA8) and without (EM9) functional XRCC1. The level of XRCC1 
expression in both cell lines was verified by western blot and these data show that 
XRCC1 level was not detected in EM9 cells (Figure 5. 1) confirming previously 
reported data (Shen et al., 1998). As was demonstrated by measurement of OTM using 
alkaline and neutral comet assay, CPT causes a greater accumulation of total and DSBs 
in EM9 compared to AA8, implicating a role for XRCC1 in both processes which is in 
line with other reports showing the hypersensitivity of EM9 cells to TopoI poisons 
(Barrows et al., 1998).  
AG014699 caused a significant increase in the induction of CPT-induced DNA breaks 
in AA8 (~2-fold), but not EM9 cells, indicating that XRCC1 and PARP are epistatic. 
However, repair of both total and double strand breaks in both cell lines was retarded by 
AG014699 implicating an independent role for PARP (Figure 5. 3, Figure 5. 3) 
Surprisingly, the comet data suggest that DNA damage was repaired to a similar extent 
in EM9 and AA8 cells during the recovery period. This is in direct contrast to research 
published by Plo et al. 2003, in which the repair of CPT-induced DNA damage was 
compared between XRCC1 deficient and XRCC1-complemented EM9 cells, and the 
XRCC1-complemented EM9 cells repaired CPT-induced damage faster.  (Plo et al., 
2003). However, the results obtained by measuring H2AX  integrated fluorescence 
using the same experimental conditions, in cells  exposed to CPT (Figure 5. 6) or TMZ 
(Figure 5.7), indicates slower DNA repair in the XRCC1 mutant EM9 cells, and 
supports previous observation. H2AX measured in CTP-treated AA8 cells then 
incubated in fresh medium was lower compared to EM9 cells, which shows more 
efficient repair of DNA damage. The same effect was even more pronounced for repair 
of DNA damage induced by TMZ. H2AX  integrated density measured after 2-hour 
recovery period in fresh medium was almost three times lower in AA8 cells compared 
to cells EM9. Additionally, γH2AX immunofluorescence continued to accumulate in 
the presence of AG014699 even after removal of CPT, especially in the EM9 cells, 
where they also apparently continued to accumulate after removal of TMZ as well. 
These studies suggest that the observed DNA repair depends on the activity of PARP-1. 
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γH2AX accumulates at stalled replication forks as well as DSBs. The persistence of 
γH2AX staining after the removal of CPT and TMZ (compare last bars of Figure 5.6 
and Figure 5. 7) may be related to replication fork arrest associated with accumulation 
of unrepaired endogenous SSBs. This hypothesis is supported by the greater 
accumulation and persistence of DSBs observed in CPT-treated S-phase cells as 
described in Chapter 4 . Increased H2AX was also observed at early time-points 
following recovery from NCS-induced DSBs. Multiple mechanisms for eliminating 
γH2AX as DNA repair completes are possible, including removal by histone exchange 
followed potentially by degradation, or, alternatively, dephosphorylation. Studies where 
parallel measurements of DSB by neutral comet and γH2AX foci counting show that 
γH2AX foci appearance and disappearance lags behind that of neutral comet DSB 
measurements (Mitchell et al., 2009). Integrated fluorescence increase as measured in 
this chapter may be as a result of greater phosphorylation or reduced de-
phosphorylation of H2AX at foci rather than an increase in the number of foci. This 
might explain the increase during repair incubation in the presence of AG014699 as 
these data are different from data in chapter 4 where the number of foci were counted.  
In contrast to the results of Smith et al. 2005 data in this chapter as well as in chapter 4 
show that 30 min incubation of K562, AA8 and EM9 cells with CPT+AG014699  is 
sufficient to increase the level of DNA breaks.  Although, longer exposure was not 
investigated here, a substantial increase in induction of DNA breaks was observed after 
30 min exposure.   
The data presented in this chapter show that AG014699 increases the persistence of 
DNA DSBs in cells treated with 2 types of DNA SSB-inducing agent (CPT and TMZ) 
and also a direct DSB-inducing agent (NCS) in both XRCC1 proficient and deficient 
cells. Furthermore, this was associated with an increase in cytotoxicity in both cell lines. 
Similar data have also been observed with paired XRCC1
+/+
 and XRCC1
-/-
 mouse 
embryonic fibroblasts in which the PARP inhibitor, 4-AN, increased MMS-induced 
DNA damage and increased the cytotoxicity of TMZ and CPT in XRCC1
-/-
 as well as 
XRCC1
+/+
 cells (Horton et al., 2008a). This may indicate a role for PARP-1 
independent of XRCC1. However, it could be argued that inhibition of PARP activity 
will not prevent PARP binding to DNA but will prevent PAR formation that is needed 
not only for XRCC1 recruitment but also chromatin relaxation and PARP-1 
dissociation. Thus, in the presence of an inhibitor the chromatin is not relaxed and 
PARP-1 remains bound to the break, which may hinder repair of the break (by either 
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BER/SSBR or back-up NHEJ) to a greater extent than loss of XRCC1. In support of this 
hypothesis is the recent observation that PARP inhibition increases the persistence of 
SSBs induced by dimethyl sulphate in EM9 leading to the suggestion that PARP 
inhibitors trap PARP at SSBs hindering their repair (Ström et al., 2011) .  It is likely that 
the unrepaired SSBs will ultimately be repaired at replication by other repair pathways, 
particularly homologous recombination repair (HRR) and it is also likely that those 
bound to inactive PARP-1 (and PARP-2) are more difficult to repair than those without 
PARP-1 or -2 attached. Further experiments in HHR competent and dysfunctional cells 
and using knockdown of PARP-1 as well as PARP inhibitors would be needed to 
confirm these hypotheses.  
The comparison of cytotoxicity results in this chapter has to be considered with caution 
because of insufficient amount of time meant that mostly single experiments were 
performed. Despite incomplete data, a similar effects of CPT TMZ and NCS 
cytotoxicity in EM9 and AA8 cells was observed. That is, in general, EM9 cells were 
more sensitive to the DNA damaging agent and that AG014699 increased the 
cytotoxicity of all agents in XRCC1-deficient EM9 cells as well as XRCC1 proficient 
AA8 cells. This supports previous reports showing role of PARP-1 in an alternative 
form of DNA repair, independent of XRCC1 probably B-NHEJ and /or HR. PARP-1 
can also be linked to replication fork restart (Bryant et al., 2009b)   
It is difficult to draw conclusions from these data whether this is the result of BER 
deficiency or loss of DSB repair mechanism such as B-NHEJ that depends on PARP-1.  
In some models the proposed mechanism of DNA repair by B-NHEJ can proceed 
without the requirement of BER scaffold protein XRCC1. Repair of DNA DSBs within 
2 hours after exposure is more dominated by D-NHEJ. Later, during repair inactivity of 
PARP-1 is more pronounced when it comes to repair the DSB. This indicates the data 
from the H2AX immunostaining of NSC treated AA8 and EM9 cells where after the 
initial rapid recovery phase a long period of the plateau followed, which was 
significantly greater for cells incubated with AG014699. These data suggest the role of 
PARP-1 in DSB repair could be more complex. 
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Summary 
 CPT, TMZ and neocarzinostatin induced cytotoxicity is potentiated by the 
PARP inhibitor AG014699 in AA8 and EM9 cells suggesting that the effect of 
PARP inhibition is greater than loss of signalling SSBR or back-up NHEJ via 
XRCC1.  
 AG014699 increased the level of total and DSB induced by CPT, TMZ and NSC 
 Repair of Total and DSB is quick without inhibitor but significantly retarded by 
AG014699. 
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Chapter 6. Summary and final discussion. 
TopoI poisons are have been in clinical use for several years, however resistance and 
side effect to them is common. One of the promising new solutions to improve the 
effectiveness of TopoI poison anticancer therapy, is the use of PARP inhibitors. PARP 
inhibitors are an exciting new class of anticancer drug, of which nine are currently 
undergoing clinical trial. Numerous laboratory, pre-clinical data indicate that the use of 
PARP inhibitors improve the anticancer activity of TopoI poisons and there are several 
different mechanisms that have been proposed. TopoI poisons exert their cytotoxicity 
largely during S phase of the cell cycle but it is not clear if potentiation by PARP 
inhibitors is also cell cycle phase-specific.  
Therefore, the hypothesis tested in this thesis is as follows: the potentiation of TopoI 
poison-induced cytotoxicity by PARPi is specific to S phase and the effect of PARP 
inhibitors on repair of TopoI poison-induced DNA damage (total or DSB) occurs 
preferentially in S-phase. Also, this thesis determined whether the variations in PARP 
and TopoI expression/activity in different phases of cell cycle are related to sensitisation 
effect of PARPi. 
Initially to test this hypothesis the Lovo colon cancer cells were used, because the TopoI 
poisons are clinically used to treat colon cancer. The effect of AG014699 on CPT-
induced cytotoxicity investigated during short (1 h) revealed a large (approx. 50%) 
resistant population that was reduced to ≤5% by longer exposure (24 h) that equates to 
approximately 1 cell cycle ( 
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Figure 3. 1) This suggests that only some phases of the cell cycle are sensitive to 
treatment. Supporting this hypothesis, flow cytometric analysis of asynchronous Lovo 
cells showed that ~40% of cell population is in S-phase and, most likely, this 
corresponds to the sensitive population (Figure 3. 2.). The study of CPT cytotoxicity 
using Lovo cells separated into cell cycle phase specific fractions by cell elutriation 
confirmed that the CPT-induced cytotoxicity and its sensitisation was S phase specific. 
The sensitisation by AG014699 seen in the asynchronous Lovo population was shown 
to be greatest during S-phase (Table 3. 2.).  
Because of difficulties in obtaining pure cell cycle specific fractions of Lovo cells due 
to the presence of an aneuploid sub- population of cells (Figure 3. 2) and problems with 
dispersion of the cells into a single cell suspension, Lovo cells were replaced with K562 
leukemic cells. Separation of cells by centrifugal elutriation did not affect the growth 
kinetics of K562 cells (Figure 3. 6) neither did it introduce DNA breaks (Figure 4. 1) 
and therefore is not harmful to the cells. Studies in K562 cells confirmed that CPT-
induced growth inhibition and cytotoxicity is greatest in S phase and also the 
potentiation by AG014699 is also greatest in S phase (Figure 3. 7 and Figure 3. 8).  
Increased sensitivity to TopoI poisons has been related to elevated levels of TopoI 
(Husain et al., 1994, Pfister et al., 2009). Data in this thesis shows that TopoI activity is 
highest in S phase cells and perhaps taking into account possible contamination of G1 
and G2 phases by S phase cells, only specific to S phase cells  (Figure 3.9), which 
corresponds well with higher sensitivity to camptothecin of S phase cells (Figure 3. 7 
and Figure 3. 8). In contrast, PARP activity (Figure 3. 10) increased throughout cell 
cycle, which may be related to DNA content. Cell cycle phase changes in PARP-1 and 
TopoI activity was not related to the levels of PARP-1 or TopoI expression suggesting 
that both proteins are regulated by posttranslational modification. If the mechanism of 
potentiation of TopoI poisons-induced cytotoxicity by PARP inhibition is via 
modulation of TopoI activity one would expect the greatest effect to be observed in G2 
phase, when the PARP activity is highest. However, this was not the case, suggesting 
that PARP-1 does not modulate TopoI activity, confirming data provided earlier by 
Smith et al, 2005.  
Topoisomerase I poisons introduce DNA SSB, some of which may be converted to 
DSB through downstream processing or collision with replication forks (Tuduri et al., 
2010). Therefore the formation of SSB and DSB following short exposures (30 min) to 
CPT±AG014699 was studied using the comet assay (alkaline and neutral), and histone 
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H2AX immunostaining, in asynchronous and separated into different phases of the cell 
cycle K562 cells. 
Using alkaline comets assay, which detect both single and double strand breaks, the 
greatest number of total CPT-related DNA breaks were shown to be induced in the S 
phase, however co-incubation of K562 cells with AG014699 increased the number of 
breaks in all phases of cell cycle to similar extent.  Previous reports Smith et al, 2005 
indicated that PARP-1 promotes the repair of TopoI poison-induced DNA breaks, but 
did not investigate repair in different phases of the cell cycle. The possibility that the 
observed increase in DNA breaks was due to inhibition of their repair was investigated. 
Repair was most rapid in S-phase and AG014699 virtually abolished repair in all phases 
of cell cycle (Figure 4. 12, Table 4. 3, Figure 4. 18, Table 4. 5). Therefore, the effect of 
AG014699 on total (mostly SSB) breaks does not explain the greater chemosensitisation 
in S-phase.  
The hypothesis that DNA DSB were more closely associated with chemosensitisation 
was investigated. DNA DSB were measured using two methods; neutral comet assay 
and γH2AX focus formation. γH2AX is used as a marker of DNA damage but most 
currently used detection methods are laborious. The software I wrote (Appendix) 
provides an efficient automated analysis of images acquired by immunofluorescence 
microscopy of nuclei. The data obtained using the PZFociEZ macro is comparable with 
the data obtained using other software (Figure 2. 6). The macro as an open source 
project is freely available, highly efficient (thousands of cells in several different 
pictures can be measured within a few minutes) and provides several analysis methods 
with different endpoint measurements. 
The investigation of the induction of DSB by both neutral comets and γH2AX showed 
that they were highest in S-phase and this was further increased by co-incubation with 
AG014699 ( 
Figure 4. 6 The effect of AG014699 on CPT-induced DSB in asynchronous and 
elutriated K562 cells. 
The overall conclusion from these data is that inhibition of DNA break repair by 
AG014699 leads to massive accumulation of DSB and stalled replication forks in S-
phase and that this is largely responsible for the cytotoxic potentiation. 
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Interestingly, the lack of potentiation in G1 phase suggest that DNA breaks was 
repaired prior entry  into S phase, despite PARP inhibition. Possibly, K562 cells were 
able to engage G1 checkpoint, despite mutant p53 such that repair of CPT-induced SSB 
is completed prior to progression into S phase such that cytotoxic DSB and stalled 
replication forks do not accumulate.  However, this was not tested experimentally to 
confirm this hypothesis. There are limitation to this experiments. The DNA induction 
experiments were performed directly after elutriation, therefore most of cleavage 
complexes is likely to be persist at the time when experiment was performed. In the 
cytotoxicity assays, due to size of the experiment, only two concentrations of CPT were 
used, therefore there is possibility that with wider range of CPT concentrations the 
potentiation of G1 phase cells may be detectable.   
 
Both the repair of DNA SSB and repair of DSB via back-up NHEJ is thought to involve 
recruitment of XRCC1 to the damage site by PARP-1 activation. An investigation of 
whether PARP-dependent repair and cell survival following exposure to camptothecin 
was dependent on XRCC1 was investigated in isogenic cells with (AA8) and without 
(EM9) XRCC1. In parallel, similar investigations were conducted to determine the 
dependence of PARP-XRCC1 interactions in the response to temozolomide (which 
causes base modification that is repaired by BER/SSBR) and neocarzinostatin, a radio-
mimetic that causes a high level of DSBs. Curiously, although CPT-induced DNA 
breaks were higher in EM9 cells they were repaired at same rate as in AA8 cells and 
AG014699 inhibited repair in both cells to similar extent (Figure 5. 3, Figure 5. 4, and 
Figure 5. 5 and Table 5. 1 and Table 5. 2). γH2AX foci measurement suggested that 
stalled replication forks continued to accumulate even after removal of CPT in EM9 
cells with a further increase in the presence of AG014699. Similar to CPT-induced 
DNA breaks, more TMZ-induced breaks accumulated in the EM9 cells and repair was 
slower, but again, AG014699 slowed repair in both AA8 and EM9 cell lines. These data 
suggest that PARP-1 has a role over and above its interaction with XRCC1 in the repair 
of TopoI poison, DNA methylating agent induced DNA damage, and this was further 
supported by cytotoxicity assays showing that AG014699 enhanced CPT and TMZ 
cytotoxicity in both XRCC1 functional and dysfunctional cells. 
The induction of DSBs by neocarzinostatin was similar in both AA8 and EM9 cells and 
so were their repair kinetics (Figure 5. 8.).  Again, AG014699 inhibited repair in cells 
lacking XRCC1 as well as XRCC1 functional cells. Effects of AG014699 on DNA 
repair in both cell types correlated with the observed chemosensitisation to 
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neocarzinostatin in both AA8 and EM9 cells (Figure 5. 11). These data suggest that 
PARP has a function independent of XRCC1 in the repair of DNA DSBs. They also 
cast doubt on the role of PARP and XRCC1 in back-up NHEJ.  
An alternative hypothesis is that inhibition of PARP, which does not prevent it binding 
to DNA but does inhibit its dissociation, results in PARP causing an obstruction at the 
break that hinders repair irrespective of XRCC1 status.  
To summarise the investigations carried out in this thesis and the overall conclusions: 
CPT-induced breaks are highest in S-phase, possibly related to higher TopoI activity in 
this phase (Figure 3.9), and this results in greater sensitivity of S-phase cells to CPT-
induced cytotoxicity. PARP inhibition leads to greater accumulation of SSBs in S-phase 
but has a similar impact on repair in all phases. PARP inhibition preferentially increases 
stalled replication forks/DSBs in S-phase and almost completely blocks their repair. The 
accumulation of these lesions is greatest in S-phase cells treated with CPT and 
AG014699 correlating with cytotoxic potentiation. Chemosensitisation and inhibition of 
DNA repair by AG014699 is independent of XRCC1, possibly due to an independent 
role of PARP in repair or an obstruction formed by inactive PARP at the site of the 
break. 
The data presented in this thesis are the first demonstration that potentiation of CPT-
induced cytotoxicity by PARP inhibition is S phase–specific and closely linked to the 
accumulation of stalled replication forks/DSBs through inhibition of their 
reactivation/repair. The major strengths of the work are: (i) Use of potent and specific 
PARP inhibitor that is undergoing clinical evaluation, (ii) use of a method to separate 
the cells into different cell cycle phases that does not impact on DNA integrity or cell 
viability, (iii) the ability to directly correlate DNA breakage and repair to cytotoxicity 
by virtue of using exactly the same experimental conditions and (iv) the investigation of 
the role of XRCC1 in isogenically paired cell lines is valuable as it suggests that PARP 
inhibitors will be effective in tumours that have compromised XRCC1 function due to 
well-documented polymorphisms that are associated with cancer. 
However due to time limitations there are some weaknesses: The data in the XRCC1 
wild-type and mutant cells were not repeated a sufficient number of times to be 
sufficiently robust for publication. Similarly, the evaluation of PARP-1 and TopoI 
expression and activity assays requires further repetition to validate the data presented 
here. The kinetics of the removal of γH2AX foci in different phases of cell cycle 
remains to be determined.  
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The results presented in this thesis provide a number of opportunities, which possibly 
can be applied in clinical trials. The data presented here indicate that PARP inhibitors 
preferentially sensitize S-phase cells to TopoI poisons. Patients with rapidly growing 
tumors, with a high S-phase fraction would therefore be predicted to benefit most from 
the combination of PARP inhibitors with TopoI poisons. Staining the diagnostic biopsy 
for Ki67 may identify such tumors. It will be also important to identify how fast, 
following a drug dose the tumor cells will recycle entering  another cell cycle  and what 
will be the fraction of S-phase cells in repopulating  tumor before applying  next dose of  
drug.   
Slow growing tumors may be less responsive to ensure that all tumor cells pass through 
S-phase exposure to both drugs would need to be sustained. Data in this thesis indicates 
that PARP-1 inhibitor was able to increase SSBs levels up to 5-fold in G1 phase cells 
but was ineffective on DSB formation in this phase. TopoI poisons are less cytotoxic for 
G1 phase cells, which are somewhat similar to the quiescent tumor cell population, 
which can regenerate the tumor after therapy withdrawal. A clinical trial that can 
address this problem, probably requiring several cycles of therapy to kill the reactivated 
tumor would be required.  A careful balance is needed to avoid toxicity to proliferative 
normal tissues, such as the bone marrow and gut mucosa.   
The data in Figure 3. 1 shows that only a small fraction of the tumor cells (presumed the 
S phase fraction) would be killed by a single dose of a TopoI poison that persisted in the 
circulation for a short time. Repeated dosing for the patient would be required to kill 
remaining tumor cells as they entered S phase. The schedule would be dependent on the 
fraction of cells in S phase, the half-life of the drug and the rate of re-entry into S-phase 
of remaining quiescent cells. Assuming 40% of tumor cells are in S phase and that drug 
concentration to kill S phase cells persist for 1h and that 72 hours are required for the 
remaining 60% of cells to enter cycle (again with 40% in S phase) then a modest dose 
of drug given every 3 days might prove more efficient than a most common current 
topotecan (half –life = 2-3 hours) and camptosar (half –life = 6-12 hours) dosing 
schedules:  once daily dosing for 3 to 5 consecutive days repeated every 21 days, and 
once weekly for 3 or 6 weeks, respectively.  
One of the reason for the resistance to TopoI poisons in tumor cells is lower TopoI 
expression/activity with TopoI activity reported to be correlated with its expression 
(Holden, 2001, Pfister et al., 2009). The data obtained in this work suggest than the 
activity of TopoI in S phase is much greater than would appear from its expression. 
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Therefore, it may be possible to use PARP inhibitors to potentiate TopoI poison-
induced anticancer activity in rapidly growing cancers predicted to be resistant by virtue 
of low TopoI expression. Survival of the cells exposed to PARP-1 and TopoI will 
depend on DNA repair capacity (in particular DSB) by tumor cells and thereby the 
factor limiting the use of PARP-1 and TopoI in the treatment of particular type of 
cancer. The data presented in this thesis suggest that the polymorphisms in XRCC1 that 
are associated with cancer will not affect the ability of PARP inhibitors to improve 
TopoI poison therapy. 
A number of further studies are indicated to follow on from the work presented here: 
Firstly, the weaknesses described above should be addressed. The possibility that 
inactivated PARP, bound to the DNA break formed a physical obstruction to the repair 
of the DNA could be investigated by comparing the data obtained here with similar 
studies knocking down PARP-1 (by siRNA or shRNA). The data described here should 
be confirmed in different cell lines, particularly in those with defects in DNA repair 
such as DNA PolB, which is commonly altered in tumours (Horton et al., 2008b). 
PARP inhibition had a major impact on the repair of DNA DSBs and it is possible that 
stalled replication forks continued to accumulate in the presence of AG014699 even 
after CPT withdrawal. It has been proposed that PARP is necessary to reactivate stalled 
replication forks and PARP inhibitors are selectively cytotoxic to cells lacking 
homologous recombination repair (HRR) (Bryant et al., 2009a). It would therefore be 
interesting to investigate how the CPT-induced DNA DSB are repaired at different 
phases of the cell cycle and the impact of PARP inhibition compared with PARP 
knockdown on the repair pathways. Apart from a plasmid-based assay, which is not 
appropriate for these studies due to lack of histones, there is no way to determine non-
homologous end-joining activity. However, there are sufficiently potent and specific 
DNA-PK inhibitors to address whether NHEJ is important.  The more likely scenario in 
S and G2 cells is that HRR is the predominant pathway. Assembly of Rad51 foci 
detected by immunofluorescence can be applied as an indicator of  HRR function. This 
latter assay has been applied to primary cultures of tumour tissue (Mukhopadhyay et al., 
2010) so it may be possible to predict which patients will benefit most from this 
therapy. The PZFociEZ macro can be applied for efficient analysis of Rad51 foci, which 
would make this analysis quicker. 
It is clear from the data presented in this thesis that PARP inhibition causes S-phase-
specific chemosensitisation of TopoI poisons that is related to the impact of PARP 
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inhibition on DNA breaks. This has clinical implications suggesting rapidly growing 
tumours would be most sensitive. Identification of patients with tumours that have a 
high proliferative fraction may be possible using the diagnostic biopsy. As with most 
research, the data presented here have thrown up as many questions as answers. It is 
now important to identify how CPT-induced DNA damage is repaired in the presence of 
a PARP inhibitor, if inhibited PARP-1 is equivalent to lack of PARP-1 or whether it 
forms a physical obstruction at the site of the break and on the basis of these data can 
we predict whether defects in specific DNA repair pathways would render cells 
exquisitely sensitive to PARP-inhibitor-TopoI poison combinations that could be 
exploited clinically. 
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A. APPENDIX - PZFociEZ, ImageJ macro for H2AX foci analysis - 
documentation. 
 
A.1. Introduction  
Immunodetection of the H2AX histone using fluorescence microscope has been 
applied as a biomarker for monitoring drug response in clinical trials before (Redon et 
al., 2010). The methods for analysing H2AX emitted fluorescence signal are laborious 
and involves counting by eye the H2AX corresponding dots, or measurements of 
fluorescence signal from whole cells as an integrated density.  On top of that before any 
measurements applied each image usually requires to be processed (e.g. background 
correction).  There is a lack of methods allows effective analysis of H2AX 
immunofluorescence and minimizing the researcher's participation.  
The purpose for writing PZFociEZ macro was to fill this gap and provides at least semi-
automatic methods for analysis H2AH foci fluorescence.  
The macro significantly reduces time needed for analysis and increases the number of 
scored cell.  It also provides several analysis methods that can be easily applied to 
various experimental conditions.  The PZFociEZ macro is an application written in 
ImageJ macro language. ActionBar plugin written by plugin Jerome Mutterer 
(http://imagejdocu.tudor.lu/doku.php?id=plugin:utilities:action_bar:start) was used to 
create GUI. The macro has a collection of most frequently used options for analysing 
pictures with  H2AX foci made with the aid of fluorescence microscope.  
The PZ-FociEZ panel (Figure A2) is a main control panel which provides an access to 
most option applied at the beginning of image analysis. These options were divided into 
two sets. First, is a collection of the necessary options predisposed  to create outlines of 
nuclei, inspection and corrections of these outlines and for preparation of imagess for 
the batch analysis. The second set of options is available as a panel FociEZ and includes 
several different options for a comprehensive measurement of H2AX foci. Figure A 1 
show the structure of folders in which macro is organized.  All of these options with 
examples of application  were described  in following  sections. 
In this Appendix the whole functional software is provided.  To make it runnung one 
needs to copy the source code from section A5 and save it as a text file in PZFociEZ 
folder (Figure A 1). Next, the ActionBar plugin must be installed.  
PZFociEZ macro is free to use for everybody -   
For support or questions write to author -pawel.znojek@pzfociez.com. 
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A.2. Folder map 
 
 
Figure A 1. Schematic of folder structure in macro PZFociEZ 
 
Folder map for PZFociEZ macro. Within ImageJ folder the icons pictures (section A3) 
shall be copied and saved as PNG format using given name in the directory: 
Plugins/PZFociEZ/icons/ _Kwiatuszek. Each part of source code (section A5) should be 
saved as txt file in folder PZFociEZ .  
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A.3. PZ-FociEZ  
 
Figure A 2. PZFociEZ macro graphical user interface.  
A.3.1 Open Image – Access to images 
A.3.2 Open ROI for this Image – When ROI set for given image is saved in the 
same folder as the image, pressing this button opens and displays nucleus outlines on 
the image.  
A.3.3  Create ROI Mask – (see section A3) 
A.3.4 Fluorescence Intensity Measurement And Foci Counting – (See section 
A4) 
A.3.5  Merging Dapi With Foci Images – applies pseudo colour (Red, Blue or 
Green) colour on greyscale image and merges two images with different colour (written 
by Jerome Mutterer). 
 
 
Figure A 3. Diagram illustrating steps applied when merging two images. 
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A.3.6  ZoomTool –Allows to increase or decrease the magnification of the image.  
A.3.7 OvalROI [x] – Switching to ImageJ drawing mode allows to draw an ovals 
on the image. [x] indicates keyboard shortcut available when Start-up Macros (A2.12.) 
option is initiated.   
A.3.8 Free Hand ROI [c] - Switching to ImageJ drawing mode allows to draw an 
lines in various directions on the image 
A.3.9 Set Scale – shortcut to ImageJ Set Scale command (Analyse/Set Scale…) 
This dialog allowsto define the spatial scale of the active image so measurement results 
can be presented in calibrated units, such as mm or µm. 
 (See more in ImageJ Documentation -http://imagej.nih.gov/ij/docs/guide/userguide-
27.html#toc-Subsection-27.8).  
A.3.8 Set Measurements - shortcut to ImageJ Set Measurements command  
(Analyse/Set Measurements).   
See more in ImageJ Documentation -
http://imagej.nih.gov/ij/docs/menus/analyze.html#set 
 
Figure A 4. Set Measurements dialog window.  
 This dialog window allows choosing several options, which can be used as endpoint 
measurements.  
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A.3.10 Start-up Macros – Clicking this button installs several macros to provide 
handy keyboard shortcuts applicable during edition of nucleus outlines.   
A.3.11 Close All Windows – pressing this button closes all open images 
A.3.12  Files Log – Allows displaying in Log window a list of files in selected 
folder.    
 
Figure A 5. Displaying files using Log Files option. 
Files Log returns a list of files in selected directory or subdirectory. By clicking on the 
path to file in the Log windows, it is possible to open an Image or ROI set 
A.3.13  Help- Help and documentation to PZ-FociEZ macro available at 
www.pzfociez.com. 
A.3.14 Hide IJ - allows to hide/unhide ImageJ panel 
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A.4.  MaskEZ Panel 
 
A.4.1. OpenImage - Access to images 
A.4.2. OpenNext-opens subsequent images from selected folder 
A.4.3. Make Mask – Automatically creates nucleus outlines and display them on the 
image. 
 
Figure A 6. Results of Make Mask option 
After opening Dapi image and chosing MakeMask option nucleus outlines will apear on 
the image. To save outlines one can either chose SaveRoi (see A.4.15) or  SaveRoi/n-
Dapi (see A.4.14) options. Using OpenNext (see A.4.2.) option will open corresponding 
foci image on which outlines will be also displayed.  After applying any required 
corrections, one can use SaveRoi-Foci (see A.4.15) option to save ROI set assigned for 
foci image. Notice that one nucleus outlines is missing. This may happened depending 
on image quality and can be quickly corrected using MakeAgain option. 
A.4.4. Binary – create binary (black and white) images (shortcut to 
Process/Binary/Make Binary) 
 
Figure A 7. Greyscale and binary images.  
The binary option is used before MakeAgain (A.4.5.) option.  
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A.4.5. MakeAgain – Creates nucleus outlines using binary image 
 
Figure A 8. Example of making nucleus outlines on more demanding images. 
The MakeMask options sometimes is insuficient, however it is possible to easly create 
nucleus outlinas using MakeAgain option in combination with options described in next 
sections.  
 
A.4.6. Multiply – multiplies image by given number.  
 
Figure A 9. Example of Multiply option usage.  
The multiply, subtract (A.4.7.) or smooth (A.4.10.) options can be used to increase 
image contrast and prepare image for making nucleus outlines.   
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A.4.7. Subtract – subtract constant value from the image 
 
A.4.8. Watershed – automatic separation or cutting apart particles that touch each other
 
Figure A 10. Graphical example of watersheding binary image 
The wathershed algorithm is used to separate particles on the binary image. 
 
A.4.9. Invert 
 
Figure A 11. Illustration showing results of inverting image 
The invert option reverts coulors on the image.  
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A.4.10. Smooth – makes images looking smooth using gausian blur option.  
 
Figure A 12. The "smooth" option applied to create the outlines of nuclei 
A combination of Binary and smooth options used to create nucleus outlines. 
 
A.4.10. FillHol - This command fills holes (four connected background elements) in 
objects by filling the background 
A.4.10. Erode - Removes pixels from the edges of objects in a binary image 
A.4.11. Dilate - Adds pixels to the edges of objects in a binary image. 
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Figure A 13. Example of Erode, Dilate, FillHoll, Smooth, Binary and MakeAgain 
option usage.   
Due to poor staining or insufficient image quality the option MakeMask sometimes 
gives unsatisfactionary results. In this cease the contrast of Dapi image can be improved  
by convertion of the image to binary and applying a sequence of options (Erode, Dilate, 
FillHoll, Smooth, Binary and MakeAgain - the order might be different) ending with 
binary convertion following by MakeAgain option.   
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A.4.12. SubsBG - Subtract background  
A standard ImageJ method for correcting uneven background on the image. 
 
Based on the ‘rolling ball’ algorithm by Stanley 
Sternberg (see Sternberg S, Biomedical image 
processing, IEEE Computer, Jan 1983). Imagine a 
3D surface with the pixel values of the image being 
the height, then a ball rolling over the back side of 
the surface creates the background.  
Rolling Ball Radius - The radius of curvature of the 
paraboloid. As a rule of thumb, for 8-bit or RGB 
images it should be at least as large as the radius of 
the largest object in the image that is not part of the background. Larger values will also 
work unless the background of the image is too uneven. For 16-bit and 32-bit images 
with pixel value ranges different from 0—255, the radius should be inversely 
proportional to the pixel value range (e.g., for 16-bit images (pixel values 0—65535), 
typical values of the radius are around 0.2 to 5). 
Light Background - Allows the processing of images with bright background and dark 
objects. 
Create Background (Don’t Subtract) -  If checked, the output is not the image with the 
background subtracted but rather the background itself. This option is useful for 
examining the background created (in conjunction with the Preview option).  
Create Background can be also used for custom background subtraction algorithms 
where the image is duplicated and filtered (e.g. removing ‘holes’ in the background) 
before creating the background and finally subtracting it with Process▷Image 
Calculator… 
Sliding Paraboloid  If checked, the ‘rolling ball’ is replaced by a paraboloid that has 
the same curvature at the apex as a ball of that radius. This option allows any value of 
the radius > 0.0001 (The ‘rolling ball’ algorithm requires a radius of at least 1). The 
‘sliding paraboloid’ typically produces more reliable corrections since the ‘rolling ball’, 
a legacy algorithm, is prone to edge artifacts. E.g., to reduce the computing time the 
‘rolling ball’ algorithm downscales the image in a way that is not consistent. The 
‘sliding paraboloid’ algorithm does not use downscaling and thus produces no 
downscaling artifacts. Nevertheless, the ‘sliding paraboloid’ is also an approximation, 
since it does not really use a paraboloid (an exact implementation would require a great 
computing effort) but it rather slides in different directions over the image. 
Disable Smoothing For calculating the background (‘rolling the ball’), images are 
maximum-filtered (3 × 3 pixels) to remove outliers such as dust and then smoothed to 
reduce noise (average over (3 × 3 pixels). With Disable Smoothing checked, the 
unmodified image data are used for creating the background. Check this option to make 
sure that the image data after subtraction will never be below the background.  
Adopted exactly from 
http://imagej.nih.gov/ij/docs/menus/process.html#background 
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Figure A 14. Subtract background examples. 
 
The numbers crossing the arrows indicates rolling ball radius. “Subtract 10” indicates 
that a value of 10 was subtracted from the image.  
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A.4.12 ShowAll - displays all outlines on the image 
A.4.13 ShowNone –removes outlines from image 
Correcting Nucleus outlines on Foci image.  
 
Options Enlarge [f] (make bigger) Shrink [s] (make smaller), DelateROI 
[a] (remove outline from image, AddROI [t] (adding new outline to 
image), UpdateROI [d] (updates ROI set in ROI Manager when outlines 
was modyfied, CombineROI [f] (connects single separate outlines) can be 
applied  to correct nucleus outlines on the foci image. These options are 
also avaliable as a keybort shortcuts when StartUp =macros  
 
.  
 
Figure A 15. Example of correcting misaligned nucleus outlines on foci image.  
Misaligned Dapi mask with corresponding Foci Imaage can be corrected as follow   
185 
A.4.14 SaveRoi/n-Dapi- automatically creates new folder called DAPI and saves the 
active image with corresponding ROI set in this folder. This option is used with Batch 
analysis and allows collecting all images for the analysis in a single folder.  
A.4.15 SaveRoi-Foci- automatically creates new folder called Foci and saves the active 
image with corresponding ROI set in this folder. This option is used with Batch analysis 
and allows collecting all images for the analysis in a single folder. 
A.4.16 OpenWRoi – option similar to OpenNext. It opens subsequent images with 
corresponding ROI.   
A.4.17 SaveRoi – saves ROI set of nucleus outlines in the same folder as the image for 
which outlines was created 
 
A.5. FociEZ panel 
 
Figure A 16 FociEZ graphical user interface.  
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A.5.1  Open – Access to image or ROI 
 
A.5.2 SurfacePlot – Displays a three-dimensional graph of the intensities of 
pixels in a grayscale or pseudo colour image (non-RGB images). The plot is based on 
the existing selection or on the entire image. A stack of plots can be produced when the 
source image is a stack or hyperstack. In this case, closing the plot stack window will 
abort the plotting process (adopted from ImageJ user guide) 
 
Figure A 17. Examples of the surface plots created for single cells. 
Surface plot options can be used to estimate the accuracy of background subtraction  
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A.5.3 Subtract Background - see section A.4.12. 
 
A.5.4 MeasureAndDraw – this macro was adopted form (Katoka, Bindokas 
et al. 2006) with some modification applied. It does not require a stack image consisted 
of DAPI/Foci. Instead requires to open DAPI image first and then Foci Image.  
 
A.5.4 FindMaxima – Determines the local maxima in an image based on 
given Noise tolerance.  
 
Figure A 18. Find Maxima dialog window 
Detailed information available in 
(http://imagej.nih.gov/ij/docs/menus/process.html#find-maxima)  
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Figure A 19. Example of application of the find maxima option for H2AX foci 
counting. 
 
Choosing different maxima noise tolerance one can adjust automatic foci counting 
much counting by eye.  
 
  
189 
 
A.5.5 Check Settings For FociRB - This allows  to choose settings for 
processing the image with FociRB macro which uses the rolling ball algorithm for the 
background subtraction to provide a clean image for counting the foci. By changing the 
available parameters, one can select the appropriate settings so that the automatic 
counting of foci corresponded to the counting of foci by eye. 
 
Figure A 20. A method applied for background subtraction with FociRB option. 
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A.5.6 FociRB - macro for analysing foci. It uses rolling ball algorithm to 
subtract background from image (A.4.12), and find maxima option to count foci number 
(A.5.4). Use Check settings option (A.5.5) first to adjust settings so the score of foci 
counting be equal visual scoring. 
 
Figure A 21. Analysis of H2AX foci using FociRB option. 
When running FociRB macro, the dialog window will appear first. In this window, the settings selected 
by Check Settings For FociRB (A.5.5) has to be entered. Following background subtraction, the image 
background should be reduced to 0 as shown on surface plot above. Obtained results will indicate a 
unique Label for each cell, which consists of chosen results name, image name, and cell coordinates 
followed by chosen endpoint measurements. CorDen and CorMean are options which uses for 
substtraction background calculated from first layer of pixels oudside the outlines. If the outline is 
crossing the several bright points which belongs to nycleus this CorDen and Cor Mean becomes negative 
and outlines for such nucleus shall be corrected (using one of options designed for Correcting Nucleus 
outlines). 
  
191 
A.5.7  IntegratedDensity- macro for measuring foci integrated density.  
 
 
Figure A 22. Dialog window for settings selection for IntegratedDensity macro.  
This macro uses global background subtraction (A.4.12) and measures total Integrated 
Density for each selected nucleus and saves results for single image. 
 
A.5.8  IntegratedDensity with Counting- macro for measuring  foci 
integrated density along with counting foci. 
 
Figure A 23. Dialog window for settings selection for IntegratedDensity with Counting 
This macro works as macro above but additionally counts foci number.  
 
Scattered foci or foci beyond the resolution are treated as a part of the background. The 
option IntegratedDensity with Counting allows to count foci using images without 
background subtraction. This analysis may provide additional information if the 
background inside the cell nucleus is considerable.  
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A.5.9  Batch- allows automatic analysis of all images using one of selected 
method (IntegratedDensity with Counting, IntegratedDensity or FociRB). 
 
Label – allows to add additional label to results label.  
SubstractBackground – Rolling ball radius for 
general background subtraction (available for all types 
of analisis) 
CreateBackground - Rolling Ball radius for creating 
an image with specific background that is later 
subtracted from original image (available only for 
FociCountingRB options) 
SubstractValue – constant value that will be 
subtracted from image to remove any remaining 
background (see A.4.12.), (available for all types of analysis) 
MaximaNoiseTolerance – Noise tolerance used by Find Maxima options to count foci. 
To run the Batch analysis: 
All images about to be analysed has to be placed in one folder along with corresponding 
ROI set.   
a. Open ROI set from the folder where image about to be analysed  are collected 
A.5.1 
b. Click Batch icon (A.5.9) and enter settings into dialog window 
c. Choose one of the available analysis 
1. FociCountingRB – See A.5.6 
2. IntDensity – See A.5.7 
3. IntDensityWirhCounting- See A.5.9 
d. OK 
A.5.10  Edit Source Code – allows access to source code for this panel  
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 A.6. Icons 
 
 Icons – PZFoci-EZ panel 
 Sun-1.png Mercury-1.png dapi32.png  Foci32.png MergeFoci32.png 
Moon-1.png Mars-1.png Jupiter-1.png Web_32.png  Saturn-1.png 
  Earth-4.png  skull_icon-3.png  Pies-1.png  Horseman.png  
 
Icons - FociEZ panel   
g-9.png g-6.png g-4.png g-8.png g-2.png  
g-5.png  g-7.png g-3.png  wenus.png D-2.png  
 g-13.png  
Images adopted from NASA. 
 
A.7.  Source code.  
 
A.7.1. _PZ-FociEZ.txt 
 
run("Action Bar", "/plugins/PZFociEZ/_PZ-FociEZ.txt"); 
exit(); 
open(); 
<Grid> 
<line> 
<button> 
label=<html><font color=blue size=+1>Open Image</font></html> 
icon=_Kwiatuszek/Sun-1.png 
arg=open(); 
<line> 
<button> 
label=<html><font color=blue size=+1>Open ROI for this Image</font></html> 
icon=_Kwiatuszek/Mercury-1.png 
arg=<macro> 
d = getInfo("image.directory"); 
f = getInfo("image.filename"); 
t=getTitle(); 
roiManager("reset"); 
roiManager("Open" d+""+f+".zip"); 
roiManager("Show All"); 
</macro> 
<button> 
label=<html><font color=blue size=+1>Create ROI Mask</font></html> 
icon=_Kwiatuszek/dapi32.png 
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arg=run("Action Bar", "/plugins/PZFociEZ/MaskEZ.txt"); 
<button> 
label=<html><font color=blue size=+1>Fluorescence Intensity Measurement And Foci 
Counting</font></html> 
icon=_Kwiatuszek/Foci32.png 
arg=run("Action Bar", "/plugins/PZFociEZ/FociEZ.txt"); 
<button> 
label=<html><font color=blue size=+1>Merging Dapi With Foci 
Images</font></html> 
icon=_Kwiatuszek/MergeFoci32.png 
arg=run("Action Bar", "/plugins/PZFociEZ/color_and_merge.txt"); 
<button> 
label=<html><font color=blue size=+1>Zoom [z]</font></html> 
icon=_Kwiatuszek/Moon-1.png 
arg=setTool("zoom"); 
<button> 
label=<html><font color=blue size=+1>OvalROI [x]</font></html> 
icon=_Kwiatuszek/Mars-1.png 
arg=setTool("oval"); 
<button> 
label=<html><font color=blue size=+1>Free Hand ROI [c]</font></html> 
icon=_Kwiatuszek/Jupiter-1.png 
arg=setTool("freehand"); 
<button> 
label=<html><font color=blue size=+1>Set Scale</font></html> 
icon=_Kwiatuszek/Web_32.png 
arg=run("Set Scale..."); 
<button> 
label=<html><font color=blue size=+1>Set Measurements</font></html> 
icon=_Kwiatuszek/Saturn-1.png 
arg=run("Set Measurements..."); 
<button> 
label=<html><font color=blue size=+1>Start up Macros</font></html> 
icon=_Kwiatuszek/Earth-4.png 
arg=run("Install...", "install=plugins/PZFociEZ/StartMacros.txt"); 
<button> 
label=<html><font color=blue size=+1>Close All Windows</font></html> 
icon=_Kwiatuszek/skull_icon-3.png 
arg=while (nImages >0) close(); 
<button> 
label=<html><font color=blue size=+1>Files Log</font></html> 
icon=_Kwiatuszek/info_32.png 
arg=<macro> 
dir = getDirectory("Choose a Directory "); 
  count = 1; 
  listFiles(dir);  
  function listFiles(dir) { 
     list = getFileList(dir); 
     for (i=0; i<list.length; i++) { 
        if (endsWith(list[i], "/")) 
           listFiles(""+dir+list[i]); 
        else 
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           print((count++) + ": " +dir + list[i]); 
     } 
  } 
</macro> 
<button> 
label=<html><font color=blue size=+1>HELP</font></html> 
icon=_Kwiatuszek/Pies-1.png 
arg= run("URL...", "url=file:///E:/PZFociEZSite/index.html"); 
<button> 
label=<html><font color=blue size=+1>Hide IJ</font></html> 
icon=_Kwiatuszek/Horseman.png 
arg=<hide> 
</line> 
<codeLibrary> 
</codeLibrary> 
<startupAction> 
</startupAction> 
//<main> 
//<DnD> 
 
A.7.2. MaskEZ.txt 
 
//Action Bar description file : MaskEZ 
run("Action Bar","/plugins/PZFociEZ/MaskEZ.txt"); 
exit(); 
</noGrid> 
<sticky> 
<line> 
<button> 
label=<html><font color=magenta size=2>OpenImage</font></html> 
icon=noicon 
arg=<macro> 
open(); 
t=getTitle(); 
print(t); 
</macro> 
<line> 
<line> 
<button> 
label=<html><font color=magenta size=2>OpenNext</font></html> 
icon=noicon 
arg=<macro> 
dir=getInfo("image.directory"); 
nam=getInfo("image.filename"); 
run("Open Next", "/"+".tif"); 
</macro> 
</line> 
<line> 
<button> 
label=<html><font color=red size=2>MakeMask</font></html> 
icon=noicon 
arg=<macro> 
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run("Run...", "run=plugins/PZFociEZ/SuperMaska.txt"); 
</macro> 
<line> 
<line> 
<button> 
label=<html><font color=red size=2>MakeAgain</font></html> 
icon=noicon 
arg=<macro> 
run("Analyze Particles...", "size=500-Infinity circularity=0.01-1.00 show=Masks 
exclude clear include record add in_situ"); 
</macro> 
</line> 
<line> 
<button> 
label=<html><font color=blue size=2>Multply</font></html> 
icon=noicon 
arg=<macro> 
run("Multiply..."); 
</macro> 
<line> 
<line> 
<button> 
label=<html><font color=blue size=2>Subst</font></html> 
icon=noicon 
arg=<macro> 
run("Subtract..."); 
</macro> 
</line> 
<line> 
<button> 
label=<html><font color=blue size=2>SubsBg</font></html> 
icon=noicon 
arg=<macro> 
run("Subtract Background..."); 
</macro> 
<line> 
<line> 
<button> 
label=<html><font color=blue size=2>Smooth</font></html> 
icon=noicon 
arg=<macro> 
run("Gaussian Blur...", "sigma=2"); 
</macro> 
</line> 
<line> 
<button> 
label=<html><font color=blue size=2>Binary</font></html> 
icon=noicon 
arg=<macro> 
run("Make Binary"); 
</macro> 
<line> 
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<line> 
<button> 
label=<html><font color=blue size=2>Watershed</font></html> 
icon=noicon 
arg=<macro> 
run("Watershed"); 
</macro> 
</line> 
<line> 
<button> 
label=<html><font color=blue size=2>Invert</font></html> 
icon=noicon 
arg=<macro> 
run("Invert"); 
</macro> 
<line> 
<line> 
<button> 
label=<html><font color=black size=2>FillHol</font></html> 
icon=noicon 
arg=<macro> 
run("Fill Holes"); 
</macro> 
</line> 
<line> 
<button> 
label=<html><font color=magenta size=2>Erode</font></html> 
icon=noicon 
arg=<macro> 
run("Erode"); 
</macro> 
<line> 
<line> 
<button> 
label=<html><font color=magenta size=2>Dilate</font></html> 
icon=noicon 
arg=<macro> 
run("Dilate"); 
</macro> 
</line> 
<line> 
<button> 
label=<html><font color=magenta size=2>Open-</font></html> 
icon=noicon 
arg=<macro> 
run("Open"); 
</macro> 
<line> 
<line> 
<button> 
label=<html><font color=magenta size=2>Close-</font></html> 
icon=noicon 
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arg=<macro> 
run("Close-"); 
</macro> 
</line> 
<line> 
<button> 
label=<html><font color=black size=2>CloseImage</font></html> 
icon=noicon 
arg=<macro> 
close(); 
</macro> 
<line> 
<line> 
<button> 
label=<html><font color=magenta size=2>CloseBar</font></html> 
icon=noicon 
arg=<close> 
</line> 
<line> 
<button> 
label=<html><font color=green size=2>ShowAll</font></html> 
icon=noicon 
arg=<macro> 
roiManager("Show All"); 
</macro> 
<line> 
<line> 
<button> 
label=<html><font color=green size=2>ShowNone</font></html> 
icon=noicon 
arg=<macro> 
roiManager("Show None"); 
</macro> 
</line> 
<line> 
<button> 
label=<html><font color=blue size=2>SaveRoi/n-Dapi</font></html> 
icon=noicon 
arg=<macro> 
t=getTitle(); 
f = getInfo("image.filename"); 
d=getInfo("image.directory") ; 
run("Duplicate...", "title=temp"); 
rename(""+ t +""); 
t1=getTitle(); 
File.makeDirectory(d+"Dapi"); 
roiManager("Save", d+"Dapi/"+"D-"+ t1+".zip"); 
saveAs("tif", d+"Dapi/"+"D-"+t1); 
close(); 
</macro> 
</line> 
<line> 
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<button> 
label=<html><font color=blue size=2>EditMask</font></html> 
icon=noicon 
arg=<macro> 
run("Edit...", "open=plugins/PZFociEZ/SuperMaska.txt"); 
</macro> 
<line> 
<line> 
<button> 
label=<html><font color=blue size=2>EditBar</font></html> 
icon=noicon 
arg=<macro> 
run("Edit...", "open=plugins/PZFociEZ/MaskEZ.txt"); 
</macro> 
</line> 
<line> 
<button> 
label=<html><font color=magenta size=2>Enlarge [f]</font></html> 
icon=noicon 
arg=<macro> 
macro "enlarge [f]" { 
run("Enlarge...", "enlarge=1"); 
} 
</macro> 
<line> 
<line> 
<button> 
label=<html><font color=magenta size=2>Shrink  [s] 
icon=noicon 
arg=<macro> 
macro "shrink [s]" {  
 pixels = 1; 
  saveSettings(); 
  rectOrOval = selectionType==0 || selectionType==1; 
  getPixelSize(unit, pixelWidth, pixelHeight); 
  n =1; 
  decimalPlaces = 0; 
  if (floor(n)!=n) decimalPlaces = 2; 
  pixels = round(n/pixelWidth); 
  if (rectOrOval) 
      shrinkRectOrOval(pixels); 
  else 
      shrink(pixels); 
  restoreSettings(); 
   function shrinkRectOrOval(n) { 
       getBoundingRect(x, y, width, height); 
       x += n; 
       y += n; 
       width = width - 2*n; 
       height = height - 2*n; 
       if (width>0 && height>0) { 
           if (selectionType==0) 
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               makeRectangle(x, y, width, height); 
           else 
               makeOval(x, y, width, height); 
       } 
   } 
   function shrink(n) {  
       if (pixels>255)  
           exit("Cannot shrink by more than 255 pixels");  
       id = getImageID(); 
       setBatchMode(true);  
       width = getWidth(); 
       height = getHeight(); 
       run("Options...", "iterations=1 count=1");  
       run("Create Mask"); 
       run("Distance Map"); 
       setThreshold(n+1, 255); 
       run("Create Selection"); 
       close();  
       selectImage(id);  
       run("Restore Selection");  
   }  
} 
</macro> 
</line> 
<line> 
<button> 
label=<html><font color=magenta size=2>DelateROI [a]</font></html> 
icon=noicon 
arg=<macro> 
macro "DelateROI [a]" { 
roiManager("Delete"); 
} 
</macro> 
<line> 
<line> 
<button> 
label=<html><font color=magenta size=2>AddROI [t]</font></html> 
icon=noicon 
arg=<macro> 
roiManager("Add"); 
</macro> 
</line> 
<line> 
<button> 
label=<html><font color=magenta size=2>UpdateROI [d]</font></html> 
icon=noicon 
arg=<macro> 
macro "update [d]" { 
roiManager("Update"); 
} 
</macro> 
<line> 
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<line> 
<button> 
label=<html><font color=magenta size=2>CombineROI</font></html> 
icon=noicon 
arg=<macro> 
macro "Combine" { 
roiManager("Select All"); 
roiManager("Combine"); 
} 
</macro> 
</line> 
<line> 
<button> 
label=<html><font color=red size=2>SaveRoi-Foci</font></html> 
icon=noicon 
arg=<macro> 
t=getTitle(); 
f = getInfo("image.filename"); 
d=getInfo("image.directory") ; 
run("Duplicate...", "title=temp"); 
rename(""+ t +""); 
t1=getTitle(); 
File.makeDirectory(d+"Foci"); 
roiManager("Save", d+"Foci/"+"F-"+ t1+".zip"); 
saveAs("tif", d+"Foci/"+"F-"+t1); 
close(); 
</macro> 
</line> 
<line> 
<button> 
label=<html><font color=purple size=2>OpenWRoi</font></html> 
icon=noicon 
arg=<macro> 
run("Open Next"); 
d = getInfo("image.directory"); 
f = getInfo("image.filename"); 
roiManager("reset"); 
roiManager("Open" d+""+f+".zip"); 
roiManager("Show All"); 
</macro> 
</line> 
<line> 
<button> 
label=<html><font color=purple size=2>SaveRoi</font></html> 
icon=noicon 
arg=<macro> 
d = getDirectory("current"); 
f = getInfo("image.filename"); 
roiManager("Save", d+""+f+".zip"); 
</macro></line> 
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A.7.3. FociEZ.txt 
// Action Bar description file :FociEZ 
run("Action Bar","/plugins/PZFociEZ/FociEZ.txt"); 
exit(); 
//<sticky> 
<Grid> 
<line> 
<button> 
label=<html><font color=purple size=+1>Open Image</font></html> 
icon=_Kwiatuszek/g-9.png 
arg=<macro> 
run("Open..."); 
</macro> 
<line> 
<line> 
<button> 
label=<html><font color=red size=+1>Surface Plot</font></html> 
icon=_Kwiatuszek/g-6.png 
arg=<macro> 
run("Surface Plot...", "polygon=100 shade draw_axis smooth"); 
</macro> 
</line> 
<line> 
<button> 
label=<html><font color=purple size=+1>Substract Background</font></html> 
icon=_Kwiatuszek/g-4.png 
arg=<macro> 
run("Subtract Background..."); 
</macro> 
<line> 
<line> 
<button> 
label=<html><font color=green size=+1>MeasureAndDraw</font></html> 
icon=_Kwiatuszek/g-8.png 
arg=<macro> 
macro "FociDraw" { 
open(); 
t=getTitle(); 
 t2= t +' ROI.tif';  
setFont("SansSerif", 14); 
 run("Out"); 
run("Brightness/Contrast...");  
run("Enhance Contrast", "saturated=0.5");  
rename("dapi"); 
run("Out"); 
 run("Duplicate...", "title=dapicopy");  
open(); 
run("Out"); 
rename("FITC"); 
selectWindow("dapi"); 
run("Subtract Background...", "rolling=60"); 
run("Gaussian Blur...", "radius=4"); 
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selectWindow("dapi");  
setThreshold(10, 200); 
run("Threshold", "thresholded remaining black");  
run("Watershed"); 
selectWindow("dapi"); 
run("Colors...", "foreground=black background=white selection=yellow");  
run("Analyze Particles...", "minimum=300 maximum=15000 show=Nothing record 
exclude");  
o = nResults; 
 for (i=0; i<o; i++) { 
 x = getResult('XStart', i);  
y = getResult('YStart', i);  
doWand(x,y); 
roiManager("add");  
}  
selectWindow('FITC'); 
run("Set Measurements...", "area mean limit display redirect=None decimal=4");  
n = roiManager("count"); 
run("Colors...", "foreground=white background=black selection=yellow"); 
roiManager("deselect"); 
for (i=0; i<n; i++) { 
if (i==1) { 
write(" " +t);  
write("found " +n);  
} 
run("Set Measurements...", "area mean centroid limit display redirect=None 
decimal=4");  
setThreshold(0, 40); 
roiManager("select", i);  
write("foci for nucleus "+i);  
run("Analyze Particles...", "minimum=3 maximum=999999 show=Nothing display "); 
run("Colors...", "foreground=white background=black selection=yellow");  
write("FITC intensity for nucleus: " +i);  
resetThreshold(); 
run("Set Measurements...", "area mean centroid display redirect=None decimal=4"); 
run("Measure"); 
 x = getResult('X'); 
 y = getResult('Y'); 
 L = toString(i); 
getVoxelSize(width, height, depth, unit);  
drawString(L, x/width, y/height);  
roiManager("draw"); 
roiManager("deselect"); 
 }  
selectWindow("dapicopy"); 
write("integrated DAPI intensity per nucleus ");  
setThreshold(30, 255); 
for (i=0; i<n; i++) {  
roiManager("select", i); 
run("Analyze Particles...", "minimum=30 maximum=15000 bins=20 show=Nothing 
display"); 
roiManager("deselect"); 
204 
} 
resetThreshold(); 
selectWindow("ROI Manager"); 
run("Close");  
selectWindow("dapi");  
run("Close");  
run("RGB Merge...", "green=*None* red=FITC blue=dapicopy"); 
rename(t2);  
selectWindow("Results"); 
} 
</macro> 
</line> 
<line> 
<button> 
label=<html><font color=red size=+1>FindMaxima</font></html> 
icon=_Kwiatuszek/g-2.png 
arg=<macro> 
run("Find Maxima..."); 
</macro> 
<line> 
<line> 
<button> 
label=<html><font color=red size=+1>Check settings for FociRB</font></html> 
icon=_Kwiatuszek/g-5.png 
arg=<macro> 
macro "SettingsFinder" { 
open();  
getRawStatistics(area, mean, min, max, std, h);      
    label = getTitle(); 
    radius= 1;  
    background = 10; 
    substract = 10; 
    noise = 10; 
    Dialog.create('FociRB Settings Finder');   
   Dialog.addMessage('Optimize settings for FociRB macro');  
    Dialog.addString('Label', label);    
    Dialog.addNumber('MaximumRadius', radius); 
    Dialog.addNumber('CreateBackground', background); 
    Dialog.addNumber('SubstractValue', substract); 
    Dialog.addNumber('MaximaNoiseTolerance', noise); 
    Dialog.show();     
    label1 = Dialog.getString(); 
    radius = Dialog.getNumber(); 
    background1 = Dialog.getNumber(); 
    substract1 = Dialog.getNumber(); 
    noise1 = Dialog.getNumber();  
       print(label);    
       a = 0 + mean;    
       b = 0 + std;    
       print("Image mean"); 
       print(a); 
       print("Image StdDev");  
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       print(b);    
      rename("OrginalImage-"+label1+""); 
       t1=getTitle(); 
       selectWindow(""+t1+""); 
      run("Duplicate...", "title=CreatedBG"); 
      run("Maximum...", "radius="+ radius +"");
  run("Subtract Background...", "rolling="+ background1 +" create"); 
   print("Background" +background1); 
   print(background1); 
   imageCalculator("Subtract create", ""+t1+"","CreatedBG"); 
     t2=getTitle();    
     run("Duplicate...", "title=BeforeSubstraction"); 
     selectWindow(""+t2+""); 
     run("Subtract...", "value="+ substract1 +""); 
        print("Substract"); 
        print(substract1); 
  
        selectWindow(""+t2+""); 
        rename("Final-"+label1+" 
CreatBG-"+ background1 +" Sub-"+ substract1 +" Noise--"+ noise1 +"");   
        t3=getTitle(); 
        run("Tile"); 
   open(); 
   selectWindow(t3); 
   n = roiManager("count");     
   for (i=0; i<n; i++) {    
   roiManager("select", i);  
   run("Find Maxima...", "noise="+ noise1 +" output=Count"); 
   roiManager("Measure");  
     }  
       print("Noise"); 
       print(noise1); 
     print("********************************"); 
} 
</macro> 
</line> 
<line> 
<button> 
label=<html><font color=blue size=+1>FociRB</font></html> 
icon=_Kwiatuszek/g-7.png 
arg=<macro> 
macro "CountFoci" { 
run("ROI Manager..."); 
open(); 
t=getTitle(); 
roiManager("reset");  
open(t+".zip"); 
foci = getInfo("image.filename"); 
curr=getDirectory("current"); 
default= " "; 
 macro "Get Time" { 
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     MonthNames = 
newArray("Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec"
); 
     DayNames = newArray("Sun", "Mon","Tue","Wed","Thu","Fri","Sat"); 
     getDateAndTime(year, month, dayOfWeek, dayOfMonth, hour, minute, second, 
msec); 
     TimeString ="Date: "+DayNames[dayOfWeek]+" "; 
     if (dayOfMonth<10) {TimeString = TimeString+"0";} 
     TimeString = TimeString+dayOfMonth+"-"+MonthNames[month]+"-
"+year+"\nTime: "; 
     if (hour<10) {TimeString = TimeString+"0";} 
     TimeString = TimeString+hour+":"; 
     if (minute<10) {TimeString = TimeString+"0";} 
     TimeString = TimeString+minute+":"; 
     if (second<10) {TimeString = TimeString+"0";} 
     TimeString = TimeString+second; 
     print(TimeString);          
 getRawStatistics(area, mean, min, max, std, h);     
 print("File Path"); 
 print(curr);     
 print("ImageName");       
 print(foci);     
 print("Image mean"); 
 print(mean); 
 print("Image StDev"); 
 print(std);      
 print("Minimum Pixel Value"); 
 print(min); 
 print("Maximum Pixel Value"); 
 print(max);          
  Dialog.create("Select Settings");  
  title = ""+default+"";        
  label1 = ""+foci+"";        
  Dialog.addString("ResultsName:", title);     
  Dialog.addString("Label:", label1);      
  Dialog.addNumber("RollBallRadius:", 50); 
  Dialog.addNumber("MaximumRadius:", 1);     
  Dialog.addNumber("CreateBgRadius:", 10);     
  Dialog.addNumber("SubstractValue:", 10);     
  Dialog.addNumber("NoiseTolertance:", 1);     
  Dialog.addCheckbox('SaveResults',false);     
  Dialog.show();    
  title = Dialog.getString();       
  label1 = Dialog.getString(); 
  rollingb = Dialog.getNumber();  
  maximum = Dialog.getNumber();      
  background = Dialog.getNumber();      
  substract = Dialog.getNumber();      
  noise = Dialog.getNumber();  
  res=Dialog.getCheckbox();     
  rename("copy");  
   run("Subtract Background...", "rolling="+ rollingb +""); 
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  run("Duplicate...", "title=BG"); 
  selectWindow("BG");       
  run("Maximum...", "radius="+ maximum +""); 
  run("Subtract Background...", "rolling="+ background +" create"); 
  imageCalculator("Subtract create", "copy","BG");    
     selectWindow("BG");    
     close();      
     selectWindow("copy");    
     close();     
  
     selectWindow("Result of copy");  
  
  rename(""+title+""+label1+""); 
  run("Subtract...", "value="+ substract +"");    
sum=0; 
coun=0; 
s = roiManager("count");  
for (l=0;l<s; l++) { 
  roiManager("Select", l); 
  getSelectionCoordinates(x,y);  
for (i=0;i<x.length;i++) { 
        if (i<x.length-1) { 
            dx=x[i+1]-x[i]; 
            dy=y[i+1]-y[i]; 
        } else { 
            dx=x[0]-x[i]; 
            dy=y[0]-y[i]; 
        } 
        n=round(sqrt(dx*dx+dy*dy)); 
        xinc=dx/n; 
        yinc=dy/n; 
        xx=x[i]; 
        yy=y[i]; 
        for (j=0;j<n;j++) { 
            sum+=calibrate(getPixel(round(xx),round(yy))); 
            xx+=xinc; 
            yy+=yinc; 
            coun++; 
        } 
} 
    roiManager("Measure"); 
    background=sum/coun; 
    area=getResult('Area',nResults-1); 
    mean=getResult('Mean',nResults-1); 
    if (isNaN(area)||isNaN(mean)) 
        exit("Area and Mean must be be selected in Analyze>Set Measurements"); 
        cormean=mean-background; 
        corden=area*cormean; 
setResult('Background',nResults-1,background); 
setResult('CorMean',nResults-1,cormean); 
setResult('CorDen',nResults-1,corden); 
run("Find Maxima...", "noise="+ noise +" output=Count"); 
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focii=getResult('Count', nResults-1); 
setResult('Count',nResults-2,focii);  
updateResults(); 
} 
   print("Number of Cells"); 
   print(s); 
   print("********************************");  
   print("                                        ");     
       selectWindow("Results"); 
       if (res==true) { 
      saveAs("txt", 
curr+"FociRB"+label1+title); 
       run("Close"); 
       } 
      if (res==false);   
      selectWindow(""+title+""+label1+""); 
       close(); 
          selectWindow("ROI Manager"); 
       run("Close");    
}      
</macro> 
<line> 
<line> 
<button> 
label=<html><font color=blue size=+1>Integrated Density</font></html> 
icon=_Kwiatuszek/g-3.png 
arg=<macro> 
macro "BackgroundCorrected" { 
run("ROI Manager..."); 
open(); 
t = getTitle(); 
curr=getDirectory("current"); 
roiManager("reset");  
open(t+".zip"); 
foci = getInfo("image.filename"); 
default = " "; 
 macro "Get Time" { 
     MonthNames = 
newArray("Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec"
); 
     DayNames = newArray("Sun", "Mon","Tue","Wed","Thu","Fri","Sat"); 
     getDateAndTime(year, month, dayOfWeek, dayOfMonth, hour, minute, second, 
msec); 
     TimeString ="Date: "+DayNames[dayOfWeek]+" "; 
     if (dayOfMonth<10) {TimeString = TimeString+"0";} 
     TimeString = TimeString+dayOfMonth+"-"+MonthNames[month]+"-
"+year+"\nTime: "; 
     if (hour<10) {TimeString = TimeString+"0";} 
     TimeString = TimeString+hour+":"; 
     if (minute<10) {TimeString = TimeString+"0";} 
     TimeString = TimeString+minute+":"; 
     if (second<10) {TimeString = TimeString+"0";} 
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     TimeString = TimeString+second; 
     print(TimeString); 
 getRawStatistics(area, mean, min, max, std, h);     
 print("File Path"); 
 print(curr);     
 print("ImageName");       
 print(foci);     
 print("Image mean"); 
 print(mean); 
 print("Image StDev"); 
 print(std);      
 print("Minimum Pixel Value"); 
 print(min); 
 print("Maximum Pixel Value"); 
 print(max); 
  Dialog.create("Select Settings");  
  title = ""+default+"";        
  label1 = ""+foci+""; 
  rb= " ";       
  Dialog.addString("ResultsName:", title);     
  Dialog.addString("Label:", label1);      
  Dialog.addNumber("SubstractBackground:", 255);    
  Dialog.addCheckbox('SaveResults',false);     
  Dialog.show();    
  title = Dialog.getString();       
  label1 = Dialog.getString(); 
  rollingb = Dialog.getNumber();      
  res=Dialog.getCheckbox(); 
selectWindow(""+ label1 +""); 
rename(""+title+""+label1+""); 
run("Subtract Background...", "rolling="+ rollingb +""); 
sum=0; 
coun=0; 
s = roiManager("count");  
for (l=0;l<s; l++) { 
  roiManager("Select", l); 
  getSelectionCoordinates(x,y); 
for (i=0;i<x.length;i++) { 
 setBatchMode(true); 
        if (i<x.length-1) { 
            dx=x[i+1]-x[i]; 
            dy=y[i+1]-y[i]; 
        } else { 
            dx=x[0]-x[i]; 
            dy=y[0]-y[i]; 
        } 
        n=round(sqrt(dx*dx+dy*dy)); 
        xinc=dx/n; 
        yinc=dy/n; 
        xx=x[i]; 
        yy=y[i]; 
        for (j=0;j<n;j++) { 
210 
            sum+=calibrate(getPixel(round(xx),round(yy))); 
            xx+=xinc; 
            yy+=yinc; 
            coun++; 
        } 
} 
    roiManager("Measure"); 
    background=sum/coun; 
    area=getResult('Area',nResults-1); 
    mean=getResult('Mean',nResults-1); 
    if (isNaN(area)||isNaN(mean)) 
        exit("Area and Mean must be be selected in Analyze>Set Measurements"); 
        cormean=mean-background; 
        corden=area*cormean; 
setResult('Background',nResults-1,background); 
setResult('CorMean',nResults-1,cormean); 
setResult('CorDen',nResults-1,corden); 
updateResults(); 
} 
   print("Number of Cells"); 
   print(s); 
   print("********************************");  
   print("                                        ");  
selectWindow("Results"); 
if (res==true) { 
saveAs("txt", curr+"IntDen-"+label1+title); 
run("Close"); 
} 
if (res==false);  
selectWindow(""+title+""+label1+"");    
close(); 
selectWindow("ROI Manager"); 
roiManager("Delete");   
run("Close"); 
} 
</macro> 
</line> 
<line> 
<button> 
label=<html><font color=blue size=+1>Integrated Density with 
Counting</font></html> 
icon=_Kwiatuszek/Pies-3.png 
arg=<macro> 
macro "BackgroundCorrectedVmaxima" { 
run("ROI Manager..."); 
open(); 
t = getTitle(); 
curr=getDirectory("current"); 
roiManager("reset");  
open(t+".zip"); 
foci = getInfo("image.filename"); 
default = " "; 
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 macro "Get Time" { 
     MonthNames = 
newArray("Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec"
); 
     DayNames = newArray("Sun", "Mon","Tue","Wed","Thu","Fri","Sat"); 
     getDateAndTime(year, month, dayOfWeek, dayOfMonth, hour, minute, second, 
msec); 
     TimeString ="Date: "+DayNames[dayOfWeek]+" "; 
     if (dayOfMonth<10) {TimeString = TimeString+"0";} 
     TimeString = TimeString+dayOfMonth+"-"+MonthNames[month]+"-
"+year+"\nTime: "; 
     if (hour<10) {TimeString = TimeString+"0";} 
     TimeString = TimeString+hour+":"; 
     if (minute<10) {TimeString = TimeString+"0";} 
     TimeString = TimeString+minute+":"; 
     if (second<10) {TimeString = TimeString+"0";} 
     TimeString = TimeString+second; 
     print(TimeString); 
 getRawStatistics(area, mean, min, max, std, h);     
 print("File Path"); 
 print(curr);     
 print("ImageName");       
 print(foci);     
 print("Image mean"); 
 print(mean); 
 print("Image StDev"); 
 print(std);      
 print("Minimum Pixel Value"); 
 print(min); 
 print("Maximum Pixel Value"); 
 print(max); 
  Dialog.create("Select Settings");  
  title = ""+default+"";        
  label1 = ""+foci+""; 
  rb= " ";       
  Dialog.addString("ResultsName:", title);     
  Dialog.addString("Label:", label1);      
  Dialog.addNumber("SubstractBackground:", 666);    
  Dialog.addNumber("FociNoiseTolertance:", 10);    
  Dialog.addCheckbox('SaveResults',false);     
  Dialog.show();    
  title = Dialog.getString();       
  label1 = Dialog.getString(); 
  rollingb = Dialog.getNumber();      
  noise = Dialog.getNumber();  
  res=Dialog.getCheckbox(); 
selectWindow(""+ label1 +""); 
rename(""+title+""+label1+""); 
run("Subtract Background...", "rolling="+ rollingb +""); 
sum=0; 
coun=0; 
s = roiManager("count");  
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for (l=0;l<s; l++) { 
  roiManager("Select", l); 
  getSelectionCoordinates(x,y); 
for (i=0;i<x.length;i++) { 
        if (i<x.length-1) { 
            dx=x[i+1]-x[i]; 
            dy=y[i+1]-y[i]; 
        } else { 
            dx=x[0]-x[i]; 
            dy=y[0]-y[i]; 
        } 
        n=round(sqrt(dx*dx+dy*dy)); 
        xinc=dx/n; 
        yinc=dy/n; 
        xx=x[i]; 
        yy=y[i]; 
        for (j=0;j<n;j++) { 
            sum+=calibrate(getPixel(round(xx),round(yy))); 
            xx+=xinc; 
            yy+=yinc; 
            coun++; 
        } 
} 
    roiManager("Measure"); 
    background=sum/coun; 
    area=getResult('Area',nResults-1); 
    mean=getResult('Mean',nResults-1); 
    if (isNaN(area)||isNaN(mean)) 
        exit("Area and Mean must be be selected in Analyze>Set Measurements"); 
        cormean=mean-background; 
        corden=area*cormean; 
setResult('Background',nResults-1,background); 
setResult('CorMean',nResults-1,cormean); 
setResult('CorDen',nResults-1,corden); 
run("Find Maxima...", "noise="+ noise +" output=Count"); 
foci=getResult('Count', nResults-1); 
setResult('Count',nResults-2,foci);  
updateResults(); 
} 
   print("Number of Cells"); 
   print(s); 
   print("********************************");  
   print("                                                "); 
selectWindow("Results"); 
if (res==true) { 
saveAs("txt", curr+"IntCnt-"+label1+title); 
run("Close"); 
} 
if (res==false) 
selectWindow(""+title+""+label1+"");    
close(); 
selectWindow("ROI Manager"); 
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roiManager("Delete");   
run("Close"); 
}  
</macro> 
<line> 
<line> 
<button> 
label=<html><font color=black size=+1>Batch Devil</font></html> 
icon=_Kwiatuszek/D-2.png 
arg=<macro> 
macro "batch" { 
default=" "; 
 Dialog.create('Batch'); 
 Dialog.addMessage('Select Settings'); 
Dialog.addString("Label:", default); 
Dialog.addNumber("SubstractBackground:", 666); 
Dialog.addNumber("CreateBackground:", 10);      
Dialog.addNumber("SubstractValue:", 10); 
 Dialog.addNumber("MaximaNoiseTolerance:", 10); 
 Dialog.addCheckbox('FociCountingRB',false); 
 Dialog.addCheckbox('IntDensity',false); 
 Dialog.addCheckbox('IntDensityWithCounting',false); 
Dialog.show(); 
default=Dialog.getString(); 
subbackground = Dialog.getNumber(); 
background = Dialog.getNumber();        
substract = Dialog.getNumber();        
noise = Dialog.getNumber();   
a=Dialog.getCheckbox(); 
b=Dialog.getCheckbox(); 
c=Dialog.getCheckbox(); 
setBatchMode(true); 
 if (a==0 && b==0 && c==0)  
     exit("Select a Method You must"); 
 if (a==1 && b==1 && c==1) 
     exit("An Idiot You are"); 
if (a==0 && b==1 && c==1) 
 exit("HWDP"); 
if (a==1 && b==0 && c==1) 
 exit("Tempy Chuj??"); 
if (a==1 && b==1 && c==0) 
exit("A stupid choise You made"); 
if (a==1 && b==0 && c==0) { 
start = getTime; 
dir = getDirectory("current"); 
list = getFileList(dir); 
h=list.length; 
g=(h/2); 
k=1; 
for (r=0; k<=list.length; r++) { 
if (endsWith(list[r], ".tif")) { 
w=File.getName(list[r]); 
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print(w); 
selectWindow("ROI Manager"); 
roiManager("reset"); 
open(list[r]+".zip"); 
setBatchMode(true); 
open(w);  
  selectWindow(w); 
  rename("copy"); 
   run("Subtract Background...", "rolling="+ subbackground +""); 
  run("Duplicate...", "title=BG");      
  run("Maximum...", "radius=1");  
  run("Subtract Background...", "rolling="+ background +" create"); 
  imageCalculator("Subtract create", "copy","BG");  
     selectWindow("BG");    
     close();      
     selectWindow("copy");    
     close();     
  
     selectWindow("Result of copy");  
  
  rename(""+default+""+w+""); 
  run("Subtract...", "value="+ substract +""); 
sum=0; 
coun=0; 
s = roiManager("count");  
for (l=0;l<s; l++) { 
  roiManager("Select", l); 
  getSelectionCoordinates(x,y);  
for (i=0;i<x.length;i++) { 
        if (i<x.length-1) { 
 dx=x[i+1]-x[i]; 
            dy=y[i+1]-y[i]; 
        } else { 
            dx=x[0]-x[i]; 
            dy=y[0]-y[i]; 
        } 
        n=round(sqrt(dx*dx+dy*dy)); 
        xinc=dx/n; 
        yinc=dy/n; 
        xx=x[i]; 
        yy=y[i]; 
        for (j=0;j<n;j++) { 
            sum+=calibrate(getPixel(round(xx),round(yy))); 
            xx+=xinc; 
            yy+=yinc; 
            coun++; 
        } 
} 
    roiManager("Measure"); 
    backgroun=sum/coun; 
    area=getResult('Area',nResults-1); 
    mean=getResult('Mean',nResults-1); 
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    if (isNaN(area)||isNaN(mean)) 
        exit("Area and Mean must be be selected in Analyze>Set Measurements"); 
        cormean=mean-backgroun; 
        corden=area*cormean; 
setResult('Background',nResults-1,backgroun); 
setResult('CorMean',nResults-1,cormean); 
setResult('CorDen',nResults-1,corden); 
run("Find Maxima...", "noise="+ noise +" output=Count"); 
focii=getResult('Count', nResults-1); 
setResult('Count',nResults-2,focii);  
updateResults(); 
} 
selectWindow(""+default+""+w+""); 
close(); 
setBatchMode(false); 
end=getTime; 
e=(end - start)/1000; 
} 
if (r==h-1)  
exit("Congratulations! With the speed of "+ e++/g +"sec/Image "+ g +" pictures were 
successfuly analysed. ImageJ wish you  breaktrough results. Have a Nice Day -:)"); 
} 
} 
if (a==0 && b==1 && c==0) { 
start=getTime; 
dir=getDirectory("current"); 
list = getFileList(dir); 
h=list.length; 
g=(h/2); 
k=1; 
for (r=0; k<=list.length; r++) { 
if (endsWith(list[r], ".tif")) { 
w=File.getName(list[r]); 
selectWindow("ROI Manager"); 
roiManager("reset"); 
open(list[r]+".zip"); 
setBatchMode(true); 
open(w); 
rename(""+default+""+w+""); 
run("Run...", "run=plugins/PZFociEZ/BackgroundCorrectedBatch"); 
selectWindow(""+default+""+w+""); 
close(); 
setBatchMode(false); 
end=getTime; 
e1=(end - start)/1000; 
} 
if (r==h-1)  
exit("Congratulations! With the speed of "+ e1++/g +"sec/Image "+ g +" pictures were 
successfuly analysed. ImageJ wish you  breaktrough results. Have a Nice Day -:)"); 
} 
} 
if (a==0 && b==0 && c==1) { 
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start = getTime; 
dir = getDirectory("current"); 
list = getFileList(dir); 
h=list.length; 
g=(h/2); 
k=1; 
for (r=0; k<=list.length; r++) { 
if (endsWith(list[r], ".tif")) { 
w=File.getName(list[r]); 
selectWindow("ROI Manager"); 
roiManager("reset"); 
open(list[r]+".zip"); 
print(w); 
setBatchMode(true); 
open(w); 
rename(""+default+""+w+""); 
run("Subtract Background...", "rolling="+ subbackground +""); 
sum=0; 
coun=0; 
s = roiManager("count");  
for (l=0;l<s; l++) { 
  roiManager("Select", l); 
  getSelectionCoordinates(x,y);   
for (i=0;i<x.length;i++) { 
        if (i<x.length-1) { 
            dx=x[i+1]-x[i]; 
            dy=y[i+1]-y[i]; 
        } else { 
            dx=x[0]-x[i]; 
            dy=y[0]-y[i]; 
        } 
        n=round(sqrt(dx*dx+dy*dy)); 
        xinc=dx/n; 
        yinc=dy/n; 
        xx=x[i]; 
        yy=y[i]; 
        for (j=0;j<n;j++) { 
            sum+=calibrate(getPixel(round(xx),round(yy))); 
            xx+=xinc; 
            yy+=yinc; 
            coun++; 
        } 
} 
    roiManager("Measure"); 
    backgroun=sum/coun; 
    area=getResult('Area',nResults-1); 
    mean=getResult('Mean',nResults-1); 
    if (isNaN(area)||isNaN(mean)) 
        exit("Area and Mean must be be selected in Analyze>Set Measurements"); 
        cormean=mean-backgroun; 
        corden=area*cormean; 
setResult('Background',nResults-1,backgroun); 
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setResult('CorMean',nResults-1,cormean); 
setResult('CorDen',nResults-1,corden); 
run("Find Maxima...", "noise="+ noise +" output=Count"); 
foci=getResult('Count', nResults-1); 
setResult('Count',nResults-2,foci);  
updateResults(); 
} 
selectWindow(""+default+""+w+""); 
close(); 
setBatchMode(false); 
end=getTime; 
z=(end - start)/1000; 
} 
if (r==h-1) 
exit("Congratulations! With the speed of "+ z++/g +"sec/Image "+ g +" pictures were 
successfuly analysed. ImageJ wish you  breaktrough results. Have a Nice Day -:)"); 
} 
setBatchMode(false); 
</macro> 
</line> 
<line> 
<button> 
label=<html><font color=purple size=+1>Edit FociEZ</font></html> 
icon=_Kwiatuszek/g-13.png 
arg=<macro> 
run("Edit...", "open=plugins/PZFociEZ/FociEZ.txt"); 
</macro> 
</line> 
 
A.7.4. StartMacros.txt 
 
macro "DelateROI [a]" { 
roiManager("Delete"); 
} 
macro "update [d]" { 
roiManager("Update"); 
} 
macro "enlarge [f]" { 
run("Enlarge...", "enlarge=1"); 
} 
macro "Zoom [z]" { 
setTool("zoom"); z 
} 
macro "FreeHandRoi [c]" { 
setTool("freehand");  
} 
macro "OvalRoi [x]" { 
setTool("oval");  
} 
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A.7.5. SuperMaska.txt 
 
macro "SuperMaska [l]" { 
//open(); 
t = getTitle(); 
f = getInfo("image.filename"); 
dir=getInfo("image.directory"); 
print(t); 
//print(dir); 
run("Subtract Background...", "rolling=50"); 
run("Enhance Contrast", "saturated=0.35"); 
currwa = getDirectory("current"); 
run("Gaussian Blur...", "sigma=10"); 
run("Smooth"); 
run("Smooth"); 
//run("Smooth"); 
run("Subtract...", "value=5"); 
//run("Subtract Background...", "rolling=10 create"); 
run("Multiply...", "value=3.000"); 
//run("Subtract...", "value=11"); 
//run("Gaussian Blur...", "sigma=4"); 
//run("Multiply...", "value=4.000");                      
//run("Minimum...", "radius=1")  
//run("Subtract Background...", "rolling=60");                                                        
//run("Smooth");  
run("Make Binary"); 
run("Dilate");                                              
run("Watershed");  
run("Analyze Particles...", "size=20-Infinity circularity=0.01-1.00 show=Masks clear 
include record add in_situ");      
run("Analyze Particles...", "size=30-Infinity circularity=0.01-1.00 show=Masks exclude 
clear add in_situ");   
run("Analyze Particles...", "size=40-Infinity circularity=0.01-1.00 show=Masks exclude 
include add in_situ");  
run("Analyze Particles...", "size=50-Infinity circularity=0.01-1.00 show=Masks exclude 
include add in_situ"); 
run("Analyze Particles...", "size=500-Infinity circularity=0.01-1.00 show=Masks 
exclude clear include record add in_situ"); 
id=getImageID(); 
d=0-id; 
print("******************"); 
t=getTitle(); 
selectWindow(t); 
close(); 
open(dir+f); 
id1=getImageID; 
rename(f); 
roiManager("Show All"); 
} 
 
A.7.6. BackgroundCorrectedBatch.txt 
macro "BackgroundCorrectedBatch" { 
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sum=0; 
coun=0; 
s = roiManager("count");  
for (l=0;l<s; l++) { 
  roiManager("Select", l); 
  getSelectionCoordinates(x,y); 
for (i=0;i<x.length;i++) { 
 setBatchMode(true); 
        if (i<x.length-1) { 
            dx=x[i+1]-x[i]; 
            dy=y[i+1]-y[i]; 
        } else { 
            dx=x[0]-x[i]; 
            dy=y[0]-y[i]; 
        } 
        n=round(sqrt(dx*dx+dy*dy)); 
        xinc=dx/n; 
        yinc=dy/n; 
        xx=x[i]; 
        yy=y[i]; 
        for (j=0;j<n;j++) { 
            sum+=calibrate(getPixel(round(xx),round(yy))); 
            xx+=xinc; 
            yy+=yinc; 
            coun++; 
        } 
} 
    roiManager("Measure"); 
    background=sum/coun; 
    area=getResult('Area',nResults-1); 
    mean=getResult('Mean',nResults-1); 
    if (isNaN(area)||isNaN(mean)) 
        exit("Area and Mean must be be selected in Analyze>Set Measurements"); 
        cormean=mean-background; 
        corden=area*cormean; 
setResult('Background',nResults-1,background); 
setResult('CorMean',nResults-1,cormean); 
setResult('CorDen',nResults-1,corden); 
updateResults(); 
} 
} 
 
A.7.7. color_and_merge.txt 
// Action Bar description file :color_and_merge 
run("Action Bar","/plugins/PZFociEZ/color_and_merge.txt"); 
exit(); 
<sticky> 
<line> 
<button> 
label=<html><font color=black size=+1>X</font></html> 
icon=noicon 
arg=<close> 
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</line> 
<line> 
<button> 
label=Blk 
icon=noicon 
arg=<macro> 
run("Grays"); 
</macro> 
</line> 
<line> 
<button> 
label=<html><font color=red size=+1>R</font></html> 
icon=noicon 
arg=<macro> 
run("Red"); 
</macro> 
</line> 
<line> 
<button> 
label=<html><font color=green size=+1>G</font></html> 
icon=noicon 
arg=<macro> 
run("Green"); 
</macro> 
</line> 
<line> 
<button> 
label=<html><font color=blue size=+1>B</font></html> 
icon=noicon 
arg=<macro> 
run("Blue"); 
</macro> 
</line> 
<line> 
<button> 
label=<html><font color=black size=+1>1</font></html> 
icon=noicon 
arg=<macro> 
id = getImageID(); 
set("image1",id); 
</macro> 
</line> 
<line> 
<button> 
label=<html><font color=black size=+1>2</font></html> 
icon=noicon 
arg=<macro> 
id = getImageID(); 
set("image2",id); 
</macro> 
</line> 
<line> 
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<button> 
label=<html><font color=black size=+1>M</font></html> 
icon=noicon 
arg=<macro> 
id1 = parseInt(get("image1")); 
id2 = parseInt(get("image2")); 
setBatchMode(true); 
selectImage(id1); 
run("Duplicate...", "title=temp"); 
run("RGB Color"); 
id1 = getImageID(); 
selectImage(id2); 
run("Duplicate...", "title=temp"); 
run("RGB Color"); 
id2 = getImageID(); 
imageCalculator("Add create", id1,id2); 
rename("Merge"); 
setBatchMode(false); 
</macro> 
</line> 
<codeLibrary> 
function get(s) (return parseInt(call("ij.Prefs.get","JMAB."+s,0));)    
function set(s,v) (call("ij.Prefs.set","JMAB."+s,v); return;)</codeLibrary>  
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